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Traditional anti-doping assays target known banned drugs and endogenous 
molecules. A discovery platform such as metabolomics can be employed to find 
small molecule biomarkers that are related to the function of drugs of misuse. 
Biomarkers can be endogenous surrogate metabolites which have the potential to 
facilitate the discovery of new doping agents with biological activities similar to 
related named prohibited substances, as well as improving the sensitivity and 
prolonging the detection time window. Working towards this end, the focus of this 
thesis was to apply metabolomics to the anti-doping field in order to enhance 
detection of drug misuse in sport, in particular focusing in methodology that would 
help discover endogenous biomarkers, namely: sample information, quality, 
storage, transport, and multivariate/univariate statistics to mine significant 
biomarkers from metabolic data. 
The first part of the thesis explored analytical method-development in 
metabolomics, overall assessing the amount and quality of the metabolic 
information acquired in small sample volumes using paper spots. Methods for high 
resolution and high mass accuracy instrument were also studied to aid with the 
identification of molecules. After this, paper spots were also assessed for storage 
stability and compared with the conventional sampling method. From these 
analyses it was concluded that paper spots are a good option when limited sample 
is available, due to reproducibility, storage and transport advantages, however there 





accuracy did help with identification although the method was not tested in 
fragmentation mode.  
Then the application of multivariate statistics to mine biomarkers from “doping 
fingerprints” was studied in detail.  Firstly, a small clinical trial with longitudinal 
samples containing one (endogenous and exogenous) metabolite in urine, GHB, 
was “fingerprinted”. The aim was to find biomarkers that could be identified for a 
longer detection window than GHB in urine. A battery of multivariate tools was 
used to mine the data. Several metabolic features, albeit partly unidentified, 
showed interesting results, however it was concluded that a new study design with 
diet control and a placebo group, was needed to validate these features.   
Lastly, samples from athletes were analysed and were grouped as salbutamol 
detectable and non-detectable specimens. Since this study was based upon the 
shortcomings of the previous GHB study, a strategy to diminish false positive 
biomarker discovery was included by adding a salbutamol spiked group in the 
experimental design. Results revealed a potential endogenous biomarker of 
salbutamol, hypoxanthine, with a ROC of 79 % prediction. These promising results 
need further validation with a subsequent clinical trial. 
Overall these preliminary studies show the potential of metabolic fingerprinting in 
anti-doping.  The findings have shown that metabolomics is a valuable tool in the 
discovery of surrogate biomarkers in doping. 
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Chapter 1 Introduction 
  




1.1 Development and challenges of anti-doping tests in sport 
The development of sports has always been accompanied by attempts to use 
prohibited substances and methods, i.e. doping. According to historians, the idea of 
doping dates back to the ancient Olympic Games more than 2000 years ago, when 
some athletes drank potions made from plant extracts, and even ate raw animal 
testicles, in order to enhance their sports performance (Kelland 2012). Athletes in 
the modern Olympics era have continued this practice, but with new doping 
strategies. This may be the result of advances in scientific research, which have led 
to the discovery and use of performance-enhancing substances.  
The International Association of Athletics Federations (IAAF) was the first 
international sports federation (IF) to formally ban doping in 1928 (Bowers 2012), 
but it was not until the 1960s that the fight against doping in humans using 
analytical methods commenced following the amphetamine-related death of a 
Danish cyclist during the Olympic Games in Rome, and another fatal incident in 
the Tour de France in 1967 (Beckett 1981). Since then various actions and 
measures have been initiated to control the misuse of performance-enhancing 
substances in sport, and a brief history of some remarkable movements is shown in 
Table 1-1.  
  




Table 1-1 Brief history of doping control in human sport 
Year Event 
1928 The IAAF becomes the first federation to ban doping 
1966 
The IAAF, the Union Cycliste Internationale (UCI), and the Fédération 
Internationale de Football Association (FIFA) introduce urine drug tests in their 
respective championships 
1967 
The International Olympic Committee (IOC) institutes its Medical Commission 
and sets up the first list of prohibited substances 
1968 Drug tests introduced at the Olympic Games 
1970s 
Marked increase in the number of doping-related disqualifications after the 
introduction by the IOC of anabolic steroids to its list of prohibited substances 
1980s Introduction of out-of-competition testing 
1986 Blood transfusion banned by IOC 
1990 rhEPO included in the IOC’s list of prohibited substances 
1990s Introduction of blood tests 
1999 WADA is established succeeding Medical Commission of IOC 
2004 The World Anti-Doping Code is adopted worldwide 
2005 
United Nations Educational, Scientific and Cultural Organization (UNESCO) 
adopts the International Convention against Doping in Sport 
2008 
The UCI is the first federation to introduce the haematology module of Athlete 
Biological Passport (ABP) 
2012 
Introduction of indirect biomarker test of growth hormone using IGF-1 and P-
III-NP 
2014 Introduction of steroids module of ABP 
IFFA: the International Association of Athletics Federations; rhEPO: recombinant human 
erythropoietin; WADA: World Anti-doping Agency; IGF-I: insulin-like growth factor-I; P-
III-NP: procollagen type III amino-terminal propeptide.  
Table adapted from (Sottas, Robinson et al. 2011) with supplements 




The techniques and coverage of compounds in anti-doping tests have vastly 
improved in the past 50 years. Immunological methods and gas chromatography 
(GC) –based techniques were initially used as preferential screening methods to 
detect prohibited substances, although they were limited to non-endogenous 
stimulants and narcotics (Botrè, de la Torre et al. 2016). This was followed by the 
rapid and revolutionary development of gas chromatography-mass spectrometry 
(GC–MS), which held a dominant position in routine doping controls from the 
1980s until almost the end of the 20th century (Thevis, Thomas et al. 2011). It 
overcame some major challenges using sophisticated derivatization strategies, such 
as analysing heavy volatile or polar compounds. 
The list of banned substances has grown significantly during the past two decades, 
and the incapability of GC–MS to identify high molecular weight, thermolabile, 
non-volatile analytes and peptide hormones has driven anti-doping scientists to 
develop techniques based on liquid chromatography–(tandem) mass spectrometry 
[LC–MS(/MS)]. Moreover, the consideration of time and manpower, as well as the 
necessity to use hazardous derivatizing reagents in GC, has further reinforced the 
leading role of LC–MS (/MS) in sport anti-doping testing (Thevis and Schänzer 
2007, Hemmersbach 2008). 
In today’s anti-doping laboratories, rapid and high-throughput technologies are 
utilised to routinely screen for and quantify hundreds of endogenous and 
exogenous compounds prohibited by the World Anti-Doping Agency (WADA) 
(Table 1-2). LC–MS(/MS) and particularly ultra-high performance liquid 
chromatography (UHPLC–MS(/MS) ) have become the instruments of choice in 
the comprehensive identification of prohibited drugs in doping control specimens, 




due to their imperative capabilities compared to the inherent limitations of other 
commonly-used strategies, such as immunology and GC–MS(/MS) based detection 
methods (Thevis, Thomas et al. 2013).  
Table 1-2  World Anti-Doping Agency Prohibited List - January 2016  
 Information obtained from (WADA 2016)  
 
Despite the continual improvement in analytical techniques, there is no sign of 
doping trend coming to an end. As soon as a detection method is proven to be 
successful, the dopers move on to even more sophisticated compounds and 
methods. The list of doping substances and methods has continued to grow since 
the first anti-doping test in the 1960s, and today’s anti-doping laboratories tend to 
focus on using sophisticated analytical methods in an attempt to identify prohibited 
substances (or methods) or the corresponding metabolites in athletes’ samples. 
However, the ever-changing improvements have always been matched by the 




increasingly sophisticated methods or drugs available to cheat due to the advances 
in science and medicine, which means that the test methods are constantly 
responding to new threats. This is often described as a race against cheaters who 
are always one step ahead.  
Another major issue facing doping test is the doping using biological therapeutic 
agents or technologies, including protein therapeutics such as insulins, recombinant 
human growth hormone (rhGH), insulin-like growth factors (IGFs), recombinant 
human erythropoietin (rhEPO) and blood doping, which highly resemble their 
endogenous counterparts, making the detection and proof of doping much more 
complicated. The potential abuse of gene therapy has also become a serious 
concern as recently reviewed Brzeziańska et al., pointing out the lack of credible 
and effective tests to detect gene doping (Brzezianska, Domanska et al. 2014).  
Facing these new threats, the sports authorities and testing laboratories have 
increasingly recognised that to counter doping in sports, targeted screening for 
ever-increasing number of compounds cannot remain the method of choice and, 
radically different approaches are in demand (Teale, Barton et al. 2009).  
Anti-doping laboratories in recent years have started modifying their screening 
approach from targeted data acquisition to total data capture using high resolution 
mass spectrometry instruments (Virus, Sobolevsky et al. 2008, Peters, Oosterink et 
al. 2010, Vonaparti, Lyris et al. 2010, Musenga and Cowan 2013, Thevis, 
Kuuranne et al. 2014). This permits total data capture and eliminates the 
requirement for a priori selection of the compounds to be targeted. Though this 
adds tremendous flexibility to the methods and enables retrospective analysis of 




samples, the data processing step still depends on a targeted approach, where 
“targeted” extracted ion chromatograms are generated from the “untargeted” 
acquired data. Rather, a new paradigm shift in sports anti-doping tests has come to 
view, from the direct identification of banned substances in the biofluids of athletes 
to the detection of abnormalities in biomarkers that potentially indicate doping, 
which is considered one of the most promising strategies that could aid for the 
emerging threats, leading to significant coordinate funding by WADA (WADA 
2016). 
1.2 Biomarker and its discovery approach 
1.2.1 Definition of a biomarker and its potential to control doping  
A biomarker is defined as “a molecule that indicates an alteration of the 
physiological state of an individual in relation to health or disease state, drug 
treatment, toxins, and other challenges of the environment” (Zolg and Langen 
2004). However, it can be extended to any measurable parameter that has 
significantly changed in a living system in response to a challenge. Another 
definition of biomarker recently by NIH-FDA biomarker working group is “a 
defined characteristic that is measured as an indicator of normal biological 
processes, pathogenic processes, or responses to an exposure or intervention, 
including therapeutic interventions. Molecular, histologic, radiographic, or 
physiologic characteristics are types of biomarkers. A biomarker is not an 
assessment of how an individual feels, functions, or survives.” (FDA-NIH 2016) 
The application of biomarkers as surrogate indicators of the a bodily state is a well-
developed field, especially in diagnosing diseases such as cancer (Zhang, Li et al. 




2007) and Alzheimer’s (Whiley and Legido-Quigley 2011). In the same way that 
disease-related biomarkers can assist the diagnosis of disease pathology, the 
physiological changes caused by doping agents or technologies are also invaluable 
tools to mirror the misuse by utilising specifically selected biomarkers. Since the 
effect of the doping agent generally remains detectable in the body in a longer time 
scale than the substance itself, biomarkers are essential if the drug or method has a 
very short detection window.  
The biomarker method is the first indirect test that has been developed to detect 
misuse of an endogenous substance. The discrimination principle is not based on a 
distinction between the exogenous substance and its endogenous counterpart, but 
rather on the physiological effect induced by the intake of the exogenous substance 
on some selected biological markers. In fact, this is not a new concept because the 
sports authorities have used a concentration of testosterone/epitestosterone (T/E) to 
detect the administration of anabolic steroids since the 1980s, which will be 
discussed later in section 1.3.1. 
The potential of the biomarker method to indicate the use of a certain category of 
drugs is also particularly attractive. Today’s anti-doping analytical methods need to 
be continuously modified to address every new agent that is added to the prohibited 
list, which makes the detection methods more and more complex, as well as time-
consuming and expensive. Furthermore, so-called “designer drugs” from 
underground laboratories could circulate for quite a while among athletes and their 
trainers before fully coming to the public’s attention. However, most of these 
emerging threats are analogues of known banned substances, with which they share 
the same functional group, causing similar biological reactions in the body. Thus, 




monitoring one/several biomarker(s) that are indicative of a certain biological 
process caused by the corresponding drug category could potentially be a rapid 
screening method for targeting athletes with a suspicious profile, followed by an 
established confirmatory method (Riedmaier, Becker et al. 2009). 
However, it is somewhat difficult to utilise biomarkers to confirm Anti-Doping 
Rule Violations (ADRV) because these methods must be proven to be totally 
reliable in view of all the heterogeneous and confounding factors, with a very high 
specificity. This is an extremely complex and time-consuming process, which is 
still difficult to achieve. Nonetheless, some biomarker methods have already been 
successfully applied to confirm ADRVs, such as the biomarker approach to detect 
the human growth hormone (hGH) and the Athlete Biological Passport (ABP) to 
detect autologous blood transfusion (ABT) and gene doping, which will be 
discussed later in section 1.5. 
1.2.2 Large-scale “omics” approaches to discovery novel biomarkers 
The discovery of novel biomarkers in doping mainly entails the use of large-scale 
“omics” technologies, including genomics, transcriptomics, proteomics and 
metabolomics (Figure 1-1), as directed and supported by WADA. The “omics” 
approaches rely on high-throughput technologies to simultaneously detect, 
characterise and quantify thousands of molecules in biosystems. A simplified 
overview of the “omics” cascade can be found in Figure 1-1. In summary, a single 
gene coding for a protein, for example an enzyme, can be transcribed to mRNA 
multiple times. In turn, each strand of mRNA can be translated many times into the 
relevant proteins. Finally, each resultant enzyme molecule could potentially lead to 




the catalysis of a large number of metabolic reactions, resulting in the perturbation 
of small molecule metabolites. At the same time, feedback, crosstalk, and other 
complex interactions of those stages can occur. 
 
Figure 1-1 A simplified overview of the “omics” cascade. Feedforward, feedback, 
crosstalk, and other complex interactions of those stages can occur. 
 
 
The “omics” approaches are widely used in disease diagnostics as well as for 
monitoring disease progression and therapies. In terms of doping control, since 
changes in the level of molecules are assumed to be signs of doping, a number of 
studies have been conducted on the application of an “omics” strategy. C. Reichel 
summarised research using “omics” strategies before 2011 and demonstrated the 
potential of “omics”-sciences in the anti-doping field (Reichel 2011).  
While the ultimate goal is the biomarker discovery of substancs or methods that are 
difficult to detect (e.g. hGH and autologous blood transfusion), the longitudinal 
monitoring of changes in “omics-patterns” can provide a new horizon for anti-




doping control within the frame work of ABP, details of which will be provided in 
section 1.5.5. 
 
1.2.2.1 Genomics and transcriptomics 
Genomics deals with the exploration of genome, which are organised in genes. The 
information for the synthesis of proteins carried by genes need to be first 
transcribed into RNA, especially messenger RNA (mRNA). The entire set of 
expressed RNA in specific cells, tissues, or the whole organism, is called 
transcriptome (Reichel 2011). The term “transcriptomics” generally refers to the 
science dealing with characterization and quantification of transcriptome. Since 
doping substances have been shown to influence mRNA expression, it has been 
suggested that these changes can be detected by transcriptional profiling 
(Friedmann, Rabin et al. 2010), using expression profiling technologies such as 
DNA microarrays, serial analysis of gene expression (SAGE) and next generation 
sequencing (NGS), followed by targeted quantitation tool of quantitative real-time 
polymerase chain reaction (qRT-PCR). Genomics/transcriptomics approaches have 
been largely applied in the anti-doping research, such as the indirect detection of 
hGH (Thakkar, Butt et al. 2008, Mitchell, Nelson et al. 2009), rhEPO (Varlet-
Marie, Audran et al. 2009, Bailly-Chouriberry, Noguier et al. 2010), autologous 
blood transfusion (Pottgiesser, Schumacher et al. 2009) and gene doping (Baoutina, 
Coldham et al. 2010, Beiter, Zimmermann et al. 2011, Perez, Le Guiner et al. 
2013). It is worth to mention that recently several groups have suggested that the 
small, non-coding circulating microRNAs (miRNAs), which enable post-
transcription regulation of gene expression by the suppression of specific target 




mRNAs, have great potential to be a new generation of anti-doping biomarkers 
(Leuenberger, Jan et al. 2011, Leuenberger, Robinson et al. 2013, Kelly, 
Haverstick et al. 2014, Leuenberger and Saugy 2015). 
1.2.2.2 Proteomics  
The science of proteomics generally deals with the large-scale determination of 
gene and cellular function directly at the protein level (Aebersold and Mann 2003). 
The huge potential of protein biomarkers to revolutionize clinical practice and thus 
improve patient care through molecular based diagnostics has been thoroughly 
described. Protein profiling provides a powerful method for characterizing the 
complete set of proteins expressed in a biological system (Kohn, Azad et al. 2007), 
as well as detecting individual isoforms of each protein, thus in anti-doping 
research, it can improve the specificity and possibly the detection window. The key 
techniques employed are mainly two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) for protein separation followed by MS(/MS) for 
identification (Aebersold and Mann 2003, Kay and Creaser 2010), other analytical 
techniques such as two-dimensional fluorescence difference gel electrophoresis 
(2D-DIGE), high performance liquid chromatography (HPLC) and stable isotopes 
labelling are also widely used (Reichel 2011). The doping-related proteomics 
research so far have been largely dedicated to the biomarker discovery for the 
misuse of recombinant human growth hormone (Ding, List et al. 2009, Kay, Barton 
et al. 2009, Baumann 2012). Other topics such as blood transfusion(Salamin, De 
Angelis et al. 2016), erythropoietin (Christensen, Sackmann-Sala et al. 2011, 
Christensen, Ludvigsen et al. 2015), anabolic steroids (Imperlini, Mancini et al. 




2010, McGrath, van Meeuwen et al. 2013), proteases (Kohler, Thomas et al. 2009), 
and endurance exercise (Kohler, Walpurgis et al. 2010) have also been described. 
1.2.2.3 Metabolomics 
Metabolomics originated from the idea that changes in tissues and biological fluids 
are indicative of disease which dates back at least as far as ancient Greece 
(Nicholson and Lindon 2008). Nowadays, metabolomics, and the related field of 
metabonomics, metabolic profiling, metabolic phenotyping uses modern techniques 
focusing on a large-scale and high-throughput measurement of small molecules in 
samples (< 1,500 Da, the intermediates and products of metabolism); in other 
words, the metabolome. These terminologies employed can become confusing due 
to the large number of definitions found in the literature, with the most common of 
these being metabolomics and metabonomics. Metabolomics refers to the study of 
the global, dynamic endogenous metabolic profiles in a living system (cell, tissue, 
or organism) under a given set of conditions, such as diseases (e.g., cancer and 
diabetes), pathophysiological stimuli (e.g., xenobiotics) or genetic modifications 
(Goodacre, Vaidyanathan et al. 2004). Metabonomics has been described as the 
“quantitative measurement over time of the metabolic responses of an individual or 
population to drug treatment or other intervention (Holmes, Wilson et al. 2008).”  
The focus of metabonomics is on understanding systemic change through time in 
complex multicellular systems, while metabolomics seeks an analytical description 
of complex biological samples. The difference is rather philosophical than 
technical, and the two terms are often used interchangeably in practice, with the 
same analytical and data treatment procedures (Nicholson and Lindon 2008). 




The metabolic phenotype provides a readout of the metabolic state of an individual 
and is the product of genetic and environmental contributions under a particular set 
of conditions (Nicholson 2006). It has certain benefits such as integrating the 
different levels of genome, proteome and metabolomes, regardless of the 
remarkably difference in timescale. In addition, environmental factors and lifestyle 
have great impact on individual and population that it is far from enough to 
interpret their effects using gene-related data (Nicholson and Lindon 2008).  
Metabolic phenotyping or metabolomics can monitor the global outcome of all the 
influencing factors such as the variation and expression of gene (genomics), the 
expression and modification of protein (proteomics), and exposure to the 
environment, without making assumptions about the effect of any single 
contribution to that outcome.  
Metabolomics is now establishing itself as an integral part of research efforts in the 
life sciences (Nicholson, Holmes et al. 2012, Patti, Yanes et al. 2012), providing us 
an enhanced understanding in a variety of fields including disease mechanisms, the 
discovery of diagnostic biomarkers, the mechanisms for drug action, drug 
discovery and an increased ability to predict individual variation in drug response 
phenotypes (Soga, Baran et al. 2006, Sreekumar, Poisson et al. 2009). It is of 
particular interest in areas like doping control where the metabolomics application 
is just emerging. Shifts in metabolomic signatures occur when drugs are 
administered and although these are largely unknown, once they are identified, a 
more sensitive and/or longer detection than the administered compound(s) can 
potentially be achieved. Some pilot studies concerning drug abuse in equine sports 
(Kieken, Pinel et al. 2011, Chan, Ho et al. 2016) and livestock production (Regal, 




Anizan et al. 2011, Anizan, Bichon et al. 2012, Dervilly-Pinel, Courant et al. 2012) 
have demonstrated the possibility of applying metabolomics in the fight against 
doping.  
The discovery of the metabolomic biomarker can be divided into two approaches, 
namely, targeted and non-targeted. Riedmaier et al. (Riedmaier, Becker et al. 2009) 
reviewed the potential applications of metabolomics to test steroid hormone and  
beta-agonist agents, and proposed the analysis of some small molecules such as 
glucose, fatty acid, lactate and creatinine. Many research groups have been devoted 
to endogenous steroid profiling using metabolomics, i.e. steroidomics (Boccard, 
Badoud et al. 2011, Kiss, Jacquet et al. 2011, Van Renterghem, Van Eenoo et al. 
2011, Ponzetto, Mehl et al. 2016). Most of these studies are targeted metabolomics 
(hypothesis driven), based on the hypothesis that certain compounds or metabolic 
pathways may be affected by the doping substances or methods. Thus, they utilised 
specific methodology to match the research target. 
Nonetheless, a non-targeted or “top-down” strategy is useful for finding novel 
biomarkers and possibly identifying new perturbed metabolism, with the aim of 
analysing a biofluid non-discriminately and ascertaining any differences in the 
concentration of the detected molecules. Non-targeted approaches are becoming 
more popular, with an increase in demand for hypothesis generating results. 
However, it is still a relatively new technique and there are certain disadvantages. 
Firstly, “non-target” means it tries to extract and analyse as many molecules as 
possible, which inevitably encounters numerous interferences. For instance, the 
extraction of highly abundant molecules may require a dilution step for accurate 
analysis, but those molecules at a low concentration will be diluted to below the 




limit of detection. Other examples can be matrix effect and ion suppression during 
LC-MS analysis in non-targeted manner, due to the intrinsic complexity of bio-
samples. Secondly, the time and economic cost can be elevated as vast quantities of 
information gained  compared to targeted approaches. It requires comprehensive 
data treatment and statistical modelling to refine the information, which will be 
further discussed in section 1.4.1. Additional time cost includes the identification 
of any features of interest. Moreover, due to the limited capacity of the database, it 
is very difficult to confirm the molecules in many occasions.  
Despite these drawbacks, non-targeted metabolomics is gaining increasing interest. 
It treats the biological process as a whole without a specific focus; thus, in anti-
doping field it has the potential to identify novel biomarkers and possibly unknown 
mechanisms or the metabolic pathways of doping agents. So far, the application of 
non-targeted metabolomics in anti-doping research has been rather limited (hardly 
any before this PhD project). Using untargeted metabolomics, Raro et al. recently 
found that 1-cyclopentenoylglycine was a potential marker for testosterone ester 
misuse (Raro, Ibanez et al. 2015); Kiss et al. found increased pantothenic acid 
(vitamin B5) in a salbutamol positive group (Kiss, Lucio et al. 2013). Although 
these findings were preliminary, they demonstrated the potential usefulness of 
untargeted metabolomics for doping control purposes. The M. Thevis group has 
been working on the application of untargeted metabolomics in doping control to 
investigate alternative markers for testosterone and growth hormone abuse (Thevis 
and Thomas 2015). Another on-going project funded by WADA has found three 
blood (plasma and serum) metabolites associated with red blood cells, which could 
be potential markers for rhEPO misuse (Pitsiladis, Gmeiner et al. 2016). 




1.3 Analytical techniques for metabolomics 
For large-scale metabolomics experiments, nuclear magnetic resonance (NMR) and 
mass spectrometry (MS) are the main techniques used, others such as Fourier 
transform-infrared (Harrigan, LaPlante et al. 2004, Derenne, Verdonck et al. 2012) 
HPLC-UV (Chen, Duran et al. 2003, Yang, Xu et al. 2004) approaches have also 
been successfully applied, though some article suggested that those approaches 
provide less information content in the spectrum obtained (Lenz and Wilson 2006).  
1.3.1 Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectroscopy is the primary technique for global profiling as all compounds 
with NMR-measurable nuclei can be detected. It is a robust and reliable technique 
allowing the detection of a wide range of structurally diverse metabolites 
simultaneously (Beckonert, Keun et al. 2007). Based on atom-centred nuclear 
interactions and properties, NMR spectroscopy can provide detailed structural 
information of small organic molecules, therefore has enabled a large number of 
biofluid constituents to be identified and catalogued (Nicholson, Foxall et al. 1995, 
Lenz and Wilson 2006). Furthermore, NMR is non-invasive and non-reliance on 
separation prior to analysis, which enables the sample for further analysis such as 
GC/LC-MS. In addition, sample preparation for NMR analysis is relatively simple 
with little or no physical or chemical treatment required prior to analysis. As such, 
it is suitable for the metabolomics profiling of complex biofluid samples.  
Despite being such a powerful, cost-effective and easy-applied approach, the main 
weakness of NMR is lack of sensitivity. This means small molecules in low 
abundance may not be adequately detected, thus NMR falls behind the highly 




sensitive technology of mass spectrometry. However, the use of labelled 
compounds can compensate this aspect, leading to significant improvements in 
sensitivity (Putri, Yamamoto et al. 2013). 
1.3.2 Mass spectrometry (MS) 
Mass spectrometry (MS) is a pivotal tool in analytical chemistry, providing the 
structural characterization of biological molecules, especially those present in 
minute quantities in complex biological samples. MS offers qualitative and 
quantitative analysis of compounds with high sensitivity and selectivity (Xiao, 
Zhou et al. 2012). The recent growth of metabolomics has greatly depended on the 
development of mass spectrometry. The main advantages of mass spectrometry in 
biological analysis lie in 1) wide variety of sample type, including biofuilds and 
tissues, containing compounds ranging from non-polar to polar, and from low 
molecular weight to high molecular weight. 2) High sensitivity with tiny amount of 
sample used. Currently the absolute sensitivity can be up to 10-11g, i.e. micro-liter 
sample used can achieve satisfactory results. 3) High speed of analysis as fast as 
1/1000s, which is ideal for chromatograph-mass coupling technique. However, 
many compounds in complex mixtures give variable responses in MS experiments, 
which can be highly misleading (Nicholson and Lindon 2008). 
Mass spectrometry can be effectively coupled to chromatographic technologies, 
such as LC-MS, GC-MS, CE-MS (Capillary electrophoresis–mass spectrometry) 
etc., thus conducting identification and quantify analysis in complex bio-samples. 
One advantage of LC/GC/CE-MS methods is that metabolites can be separated 
based on their physicochemical characteristics prior to detection and analysis, 




reducing the number of molecules that enter the MS at a given time. Multiple 
components entering the MS at the same time can impact ionization and cause ion 
suppression, especially when using electrospray ionization (ESI), hence better 
separation tends to improve measurement sensitivity and accuracy.   
In metabolomics research, LC-MS (Want, Wilson et al. 2010, Want, Masson et al. 
2013) methods are predominantly used, followed by GC-MS (Chan, Pasikanti et al. 
2011) and CE-MS (Garcia-Perez, Angulo et al. 2010) approaches, other techniques 
such as direct infusion MS (Southam, Lange et al. 2014), comprehensive GC×GC–
MS (Mohler, Dombek et al. 2007), supercritical fluid chromatography (SFC)-MS 
have also been used (Jones, Rainville et al. 2014). HPLC-MS combines the 
advantage of both HPLC and MS, allowing separation of metabolites of a wide 
range of molecular weight and polarity with high throughput and high sensitivity. 
LC-MS for global metabolic profiling has been increasingly used (reviewed in 
(Theodoridis, Gika et al. 2008) (Becker, Kortz et al. 2012) (Fang and Gonzalez 
2014) ), especially those employing reverse phase (RP) separations, coupled to 
electrospray ionization (ESI) in both positive and negative modes of ionization, 
such as the profiling based on urine or plasma. Urine samples can be injected 
directly into the LC-MS system (Theodoridis, Gika et al. 2008), or more often, 
diluted with water before the injection onto the column (Werner, Croixmarie et al. 
2008, Wang, Reijmers et al. 2009). Other protein-rich biofluids such as plasma or 
cerebrospinal fluids can also be analysed with minimal sample pre-treatment 
mainly using organic solvents to precipitate proteins (Want, O'Maille et al. 2006, 
Bruce, Tavazzi et al. 2009). 




LC-MS was once considered unsatisfactory for the analysis of hydrophilic 
metabolites; however, the emergence of hydrophilic interaction chromatography 
(HILIC) column in recent years has successfully achieved the analysis of 
hydrophilic metabolites such as amino acids, organic acids, nucleic acids, sugar, 
sugar alcohols, sugar phosphates etc. without any derivatization (Antonio, Larson 
et al. 2008, Buszewski and Noga 2012). 
Ultra-high performance liquid chromatography (UHPLC) uses even smaller 
particle sizes (sub-2µm) in column, and a pump with a maximum pressure of 100 
MPa. It requires the solvent delivery systems capable of operating at higher 
pressures in the 6000–15000 psi range (Plumb, Castro-Perez et al. 2004). As a 
result, resolution, sensitivity and even speed of analysis are dramatically increased. 
The key chromatographic principles are as follows: 
N = L/H 
H = A + B/u + Cu  (Van Deemter Equation) 
A = 2ldp 
Where 
• N is the number of theoretical plates, a measure of the resolving power of 
the column  
• L is column length 
• H is plate height  
• A is Eddy-diffusion parameter 
• B is diffusion coefficient  
• C is resistance to mass transfer coefficient  
• u is linear velocity 
• λ  is particle shape  
• dp is particle diameter 
When particle size (dp) decreases, H decreases, and N increases, leading to 
improved analytical performance. 





The high chromatographic resolution, which leads to narrow peak widths and an 
increased S/N (signal/noise) compared to conventional HPLC, is advantageous in 
metabolic phenotyping to detect a greater number of metabolites at physiological 
concentrations (Dunn, Broadhurst et al. 2008) 
The value of UHPLC-MS for metabolomics has been demonstrated in a number of 
studies. In a study employing rodent urine, analysis of the same set of samples by 
both conventional LC-MS and UHPLC-MS revealed much improved 
chromatographic efficiency and a higher peak count for the latter (Wilson, 
Nicholson et al. 2005). Another subsequent application showed that UHPLC with a 
short, 1.5 min reversed-phase gradient for a range of rodent-derived samples, gave 
similar performance to that was obtained using conventional HPLC-MS with a 10 
min separation (Plumb, Granger et al. 2005). 
 High resolution mass spectrometry (HRMS) is a widely practiced technique in 
analytical and bioanalytical sciences. HRMS offers exceptionally high resolution 
and accurate mass measurements with sub-ppm errors, improving the sensitivity 
and information content of global approaches. It is thus possible to detect 
metabolites having the same nominal mass but distinct exact masses in complex 
biological matrix. It can also give the highest degree of structure confirmation, 
which facilitates database inquiries for identification purposes. All of these 
advantages make HRMS an extremely suitable tool for MS-based untargeted 
metabolomic experiments. HRMS has been successful applied in many 
metabolomic studies over the past decade, which have been reviewed in detail 
recently (Junot, Fenaille et al. 2014, Ghaste, Mistrik et al. 2016). Time-of-flight 




mass spectrometry (TOF-MS) is a representative HRMS technique that has been 
widely used in metabolomic studies to obtain accurate and precise MS data (Dan, 
Su et al. 2008). TOF-MS provides high sensitivity and resolution to profile intact 
precursor ions which are generated from metabolites through ESI and represents 
the most appropriate MS instrument to apply LC separations for this objective 
(Mao, Yang et al. 2012, Qian, Wang et al. 2013). Fourier transform mass 
spectrometers (FTMS) or Fourier transform ion cyclotron resonance mass 
spectrometers (FT-ICR-MS) are the most advanced mass analysers in terms of high 
accuracy and resolving power with sub-parts-per-million mass accuracy. The main 
disadvantage of FT-ICR-MS instruments, nevertheless, is their relatively slow 
acquisition rates (e.g. scan rate of 1 Hz with mass resolution of 100,000 at m/z 
4000), which limits the application of FT-ICR-MS in metabolomics (Ghaste, 
Mistrik et al. 2016). Another MS technique that has been increasing used in 
metabolomics recent years is Orbitrap. The Orbitrap analyser provides a higher 
mass resolution and mass accuracy over a wider dynamic range allowing the 
potential detection of a greater number of metabolites of similar accurate mass, 
with a high level of confidence for metabolite identification (Makarov, Denisov et 
al. 2006). Similar to MSe technology of  TOF (Plumb, Johnson et al. 2006), 
Orbtirap allows the accurate mass full scan and single/multiple or full mass 
fragmentation spectra to be acquired simultaneously (Dunn, Broadhurst et al. 
2008). 
Generally, TOF based instruments can achieve mass resolution up to 60,000 (at m/z 
200), while Orbitrap based instruments can achieve much higher mass resolution—
up to 240,000, and over 1,000,000 for FT-ICR (at m/z 400) (Junot, Fenaille et al. 




2014). However, the resolving power of TOF-MS instruments is independent of the 
acquisition rate, which could be considered a key feature especially when fast 
chromatographic separations are to be used (Hopfgartner 2011). The mass 
resolution of the Orbitrap is correlated to scan rate with longer acquisition time 
providing higher mass resolution. However, fast scan speed is preferred in 
metabolomics, thus the most appropriate parameters need to be chosen considering 
the balance between resolution and scan rate, which is studied and discussed in 
Chapter 3 of this thesis. 
By coupling UHPLC with HRMS, various types of metabolites in a wide-ranging 
concentration in a complex bio-matrix can be identified effectively and efficiently. 
Thus UHPLC-HRMS including both TOF and Orbitrap technologies are applied in 
this thesis to develop a sensitive metabolomic approach to the discovery of doping 
biomarkers.  
One drawback of these highly developed MS coupled with pre-separation 
techniques is the loss of information on the spatial localization of the metabolites in 
tissue samples. Yet recently, MS imaging (MSI) combined with soft ionization 
methods (e.g. MALDI, NIMS, DESI)  has emerged as a technology that makes it 
possible to resolve the distribution of biological molecules present in tissue 
sections by direct ionization and detection (Miura, Fujimura et al. 2012), and 
several studies have suggested the importance of in situ metabolite imaging in 
metabolomic studies and other biomedical applications (Benabdellah, Touboul et 
al. 2009, Eberlin, Ifa et al. 2010, Miura, Fujimura et al. 2010, Greving, Patti et al. 
2011). 




Although some sophisticated analytical technologies for metabolomics with high 
throughput, high selectivity and sensitivity have been developed and applied for 
decades, a method capable of analysing all metabolites simultaneously is still 
currently unavailable due to the complexity and the dynamic nature of the 
metabolome. Therefore, researchers need to select the most appropriate approach 
for their work, taking account of factors such as sensitivity, resolution, throughput 
and cost, and ultimately multiple analytical platforms may be needed to cover the 
full spectrum of metabolites (Xiao, Zhou et al. 2012, SastiaPrama, Fumio et al. 
2014). 
1.4 Metabolomics data treatment 
Metabolomics can be classified as targeted and non-targeted metabolomics as 
stated above, however in data treatment stage, non-targeted metabolomics are 
frequently followed by targeted approach focusing on specific metabolites of 










Figure 1-2 Typical workflow of metabolomics. Sample cohorts can be subjected 
to targeted and non-targeted metabolomics analyses. However it is also a common 
strategy that non-targeted metabolomics can be followed by targeted analysis once 
relevant metabolites are identified from multivariate analysis. 
  
 
1.4.1 Non-targeted approach 
Typically, a non-targeted metabolomic experiment includes a comprehensive 
metabolite fingerprinting step, either by NMR or LC-MS methods. The primary 
challenges of such untargeted experiments include detecting intact small molecules 
(<1500Da) over a wide concentration range, as well as ensuring sufficient 
metabolite coverage to shed light on the metabolic problem being investigated. 
Hence, non-targeted metabolomics studies often use multiple analytical 
technologies to study the same samples, and metabolomic protocols are now 
available for a variety of biofluid and tissue types. In the data pre-treatment stage, 
there are numerous software available for the non-targeted approach (e.g., XCMS 
and MZmine for LC-MS, TagFinder and metab for GC-MS and JDAMP for CE-
MS etc.).  




Since the data set of non-targeted metabolomics is extremely large, researchers 
need to focus on the metabolites relevant with the alternation of the condition. The 
using of multivariable analysis can help to extract the metabolites of interest from 
such a big data matrix. Principal component analysis (PCA) is a non-supervised 
chemometric method and is most widely used in metabolomic studies, visualizing 
the relationship among groups. The non-supervised method is to simply classify, 
given that sample identity is unknown. On the contrary, the supervised 
multivariable analysis technique such as Partial Least Squares (PLS), Partial Least 
Squares-Discriminant Analysis (PLS-DA), Orthogonal Partial Least Squares 
(OPLS), use the prior information about sample class, giving better information in 
biomarkers discovery (Jonsson, Bruce et al. 2005). Meanwhile, when searching for 
significant metabolites, researchers can not only use the loading matrix, but also 
the ‘variable importance in the projection'(VIP) (Perez-Enciso and Tenenhaus 
2003) and the ‘coefficient variables’. Finally, the selected and calculated features 
(potential markers), can be subjected to database search, such as HMDB (Human 
Metabolome Database), Metlin, MassBank and MMCD (Madison Metabolomics 
Consortium Database) or more general chemical databases (e.g., PubChem or 
ChemSpider). The use of tandem MS (MS/MS), by acquiring MS/MS spectra of 
these ions, in combination of precursor m/z and retention time, can derive the 
molecular structural information, thus the results from mass-based identification 
can be further refined. Reference standards are normally used for the final 
confirmation. 
An informative table describing the various forms of data treatment and 
chemometric approaches available in metabolomic studies was compiled in a 




review by Madsen et al. (Madsen, Lundstedt et al. 2010) and can be found in 
Table 1-3. 
Table 1-3 Frequently used data analysis methods in metabolomics.  
Technique Typical use Description and comments 
Univariate testing 





Univariate analysis where the 
corresponding p-values are the standard 
scientific measure of significance. Multiple 
testing is prone to false positives unless 





Standard multivariate analysis method to 
provide an overview of a large dataset. 
Useful for identifying outliers, clusters and 
trends in the data. Is not a classification 
method 
Partial least squares 
discriminant analysis 
(PLS-DA) (Wold, 




Classification variant of PLS. Works best 
with homogeneous classes. Biomarker 
identification possible, but not as straight 
forward as with OPLS-DA. 
Orthogonal projection 
to latent structures 
discriminant analysis 
(OPLS-DA) (Bylesjö, 





Classification variant of OPLS method. 
Ability to separate between-class from 
within-class variability. Straight forward 
interpretation and identification of potential 
biomarkers 
Self organizing maps 




A neural network based method for 
identifying trends and clusters in the data. 
Can account for non-linearities in the data. - 
not there in the other descriptions. 
Support vector 
machines 
(SVM) (Sitter, Bathen 
et al. 2009) 
Classification 
(non-linear) 
High flexibility in modeling non-linearities. 
Careful model selection reduces possibility 
of overfitting. Potential biomarker 
identification more complex compared to 
linear methods, 
except when linear variant is used (LS-SVM) 











1.4.2 Targeted approach  
After identifying the metabolites of interest by means of non-targeted statistical 
analysis, it comes to the step of targeted approach aiming at validation of the 
hypothesis or the statistical model, focusing on the objective metabolites, i.e., 
biomarkers. The researchers need to confer the significance and reliability of these 
markers. Furthermore, a highly reproducible data matrix for comparison with the 
previous experiments should be conducted, thus, the development of a quantifiation 
method is important. Normalization, by means of internal standards, external 
standards and total signal, should also be optimized for each research purpose. In 
addition, researchers can determine the optimal ion for targeted metabolite 
quantification to acquire highly sensitive and reproducible data. 
Model construction using PLS, PLS-DA, OPLS or OPLS-DA plays an 
indispensable role in metabolomics research, and if the reliable and reproducible 
data can be obtained with the targeted approach, the robustness of the prediction 
model then should also be validated. Cross validation (K-fold validation) is a 
frequently used method for validation of the constructed model (Wold 1976, 
Geisser 1993, Jumtee, Bamba et al. 2009), with the root mean square error of 
evaluation (RMSEE) determined for robustness and  the root mean square error of 
prediction (RMSEP) for reliability. Receiver operating characteristic (ROC) curve 
is also a commenly used strategy in the validation study of biomarkers. It 
investigates the accuracy of a model’s ability to separate positive from negative 
cases (such as predicting the presence or absence of doping practice) (Lasko, 
Bhagwat et al. 2005). It is especially useful in evaluating the predictivtiy of our 




models or selected biomarkers with output values over a continuous range, since it 
captures the trade-off between sensitivity and specificity over that range. 
Based on the background mentioned above, metabolomics approaches will be 
applied in the field of drug control in this thesis, in order to detect surrogate 
markers of doping substances, and build a systematic model that can be applied in 
doping control.  
1.5 Current biomarker research and applications in doping control 
1.5.1 Anabolic-androgenic steroids 
One of the first approaches used on the biomarker concept was using the ratio of 
testosterone (T) to epitestosterone (E) to detect the misuse of anabolic steroids in 
early 1980s (Catlin, Fitch et al. 2008). Anabolic-androgenic steroids (AAS) are 
synthetic derivatives of testosterone, modified to enhance its anabolic actions to 
promote protein synthesis and muscle growth (Saudan, Baume et al. 2006). AAS 
are the most frequently detected doping substances in sports for years. According 
to 2014 WADA report, anabolic agent accounted 50 % of total positive findings 
(adverse analytical findings (AAF) and atypical findings (ATF)) (Table 1-4), and 
among the 1812 positive cases of anabolic agents, 84 % are anabolic-androgenic 
steroids (WADA 2015). The abuse of AAS was first witnessed in 1960s, but there 
was not any detection method until the implement of immunoassy (IA) in mid-
1970s. However, as IA lacks of specificity, shortly GC-MS or LC-MS was required 
by IOC as the gold standard to test AAS. Unfortunately, GC-MS and LC-MS can 
only comfirm the exist of sythetic AAS, and neither of them are capable of 
distinguish the AAS natrully occurred in human body (such as T) from the ones 




that are administrated. In 1980 Summer Olympic Games in Moscow, no positive 
case of AAS was reported, however rumours said the use of endogenous steroids 
were circulating (Catlin, Fitch et al. 2008). Thus intensive efforts were made by 
anti-doping laboratories in the following years to study the urine steroid profile. It 
was soon found that there is a T isomer without known biological function in 
human urine, namely, epitestosterone (E). The natural median ratio of urinary T to 
E (T/E ratio) is approximately 1:1 and the administration of T does not increase the 
concentration of E, thus it upsets the balance of the two steriods and increases the 
ratio (Donike, Barwald et al. 1983, Donike, Zimmermann et al. 1984, Catlin, 
Hatton et al. 1997). Currently a T/E ratio of greater than 4 is used as a screening 
indicator for possible T misuse and followed by the confirmation using isotope 
ratio mass sepctrometry (IRMS), which is a direct method differentiating natural 
and synthetic endogenous steroids by means of the ratios of stable carbon isotopes 
13C and 12C (Becchi, Aguilera et al. 1994, Piper, Emery et al. 2011). The detection 
of other endogenous steroid hormones have also applied this concept such as the 
ratio of androsterone to etiocholanolone (Andro/Etio ratio) and Andro/T ratio 
(Donike, Geyer et al. 1992, Van Renterghem, Van Eenoo et al. 2010). 
  




Table 1-4 Summary: Substances Identified as AAFs and ATFs in Each Drug 
Class in ADAMS (All Sports). Table obtained from (WADA 2015) 
Table 1-4A Substances Identified as AAFs in Each Drug Class 
  
Table 1-4B Substances Identified as ATFs in Each Drug Class 
  
ADAMS: Anti-Doping Administration and Management System. * The Adverse 
Analytical Findings (AAFs) and Atypical Findings (ATFs) in this report are not to 
be confused with adjudicated or sanctioned Anti-Doping Rule Violations 
(ADRVs), as the figures given in this report may contain findings that underwent 
the Therapeutic Use Exemption (TUE) approval process or multiple findings on the 
same Athlete. In addition, Atypical Findings may correspond to multiple 
measurements performed on the same Athlete, such as in the case of longitudinal 
studies on testosterone. For the more detailed definetions of AAFs and ATFs, refer 
to (WADA 2015). 
 
 
These ratios, which are the start of the process to determine if an athelte has used 
AAS, however, are not always reliable as they can be influenced by a number of 




factors due to existing intra- and inter- individual variabilities standing. For 
instance, the T/E ratio can return to baseline when the user discontinues taking T. 
In extreme rare cases, the athletes have naturally elevated T/E ratio. Moreover, 
some athletes even administrate E to lower it. Therefore, monitoring other steroid 
metabolites and evaluation of additional steroid ratios as potential biomarkers can 
possibly increase the efficiency of detecting T misuse among athletes. Numerous 
studies of human urinary sterioid profiles are still being carried out and the effects 
of envorimental and physiological factors have also been included. 
Among those studies, the “-omics” strategy has been largely applied. Boccard et al. 
reported an untargeted steroidomic approach to analyse urine samples from a 
human clinical trial and discovered several metabolites relevant to the detection of  
T intake (Boccard, Badoud et al. 2011); Raro et al. used an untargeted 
metabolomic strategy and found 1-cyclopentenoylglycine as a potential marker for 
T ester misuse (Raro, Ibanez et al. 2015).  
However, both the T/E ratio and the studies mentioned above are population based 
strategy. Monitoring of individual steroid profiles over time allows switching from 
population-based towards subject-based reference ranges for improved detection. 
Van Renterghem et al. suggested 3 ratio markers for dihydrotestosterone (DHT) 
and 4 ratio markers for dehydroepiandrosterone (DHEA) based on a pilot 
comprehensive steroid profiling on 6 subjects and reported the usefulness of 
subject-based referencing for the selected markers (Van Renterghem, Van Eenoo et 
al. 2010), and a similar study conducted by the same authors found 4 novel urinary 
steroid ratios in addition to the T/E ratio (Van Renterghem, Van Eenoo et al. 2011). 
An individual based paradiam as such can drastically increase the overall 




sensitivity, and the use of multiple markers as formalized in Athlete Biological 
Passport (ABP) can provide firm evidence of doping with endogenous steroids, 
which will be reviewed in detail in section 1.5.5. 
1.5.2 Growth hormone  
The abuse of growth hormone (GH) is favoured by athletes due to its anabolic, 
lipolytic and post-trauma healing properties, and it is a major concern of WADA 
and the sports regulators. It has been rumored for a long time to be used largely 
among athletes but for a long time there was no proper detection method (Holt and 
Sonksen 2008, Meinhardt, Nelson et al. 2010), until the direct ‘isoform’ approach 
approved by WADA from 2004 Summer Olympic Games in Athens (Barroso, 
Schamasch et al. 2009). 
GH produced in the anterior pituitary is a mixture of different isoforms, of which 
the most abundant one is a 22 kDa protein (approx. 70%), following by the second 
isoform has a mass of 20 kDa (approx. 5%-10%) (Baumann 1999). GH extracted 
from human was previously used to treat infant growth deficiency and it is still 
available in black market but with the risk of transmission of Creutzfeld-jcob 
disease (Holt and Sonksen 2008). The recombinant human growth hormone (rhGH) 
was introduced in 1981, and it is composed only the 22 kDa isoform (Bidlingmaier, 
Wu et al. 2003). Thus it leads to the well-known “isoform” approach: during the 
administration of rhGH, the 22 kDa isoform will be abundant, whereas other 
pituitary isoforms will be suppressed (Wu, Bidlingmaier et al. 1999) (Figure 1-3, 
A). Thus, specific IA targeting these different isoforms was used based on this 
background. However, the specificity and the standardization of these assays 




remain problematic. In addition, this approach has a limited detection window (~24 
h) due to the short plasma half-life of GH (Cunha and Mayo 2002, Bidlingmaier, 
Suhr et al. 2009). Furthermore, instead of being constitutively secreted, GH is 
produced in a pulsatile manner and can be affected by exercise and other 
environmental and circumstantial challenges, which will further complicate the 
direct detection of rhGH misuse (Armanini, Faggian et al. 2002, Velloso 2008). 
Another shortcoming of IA approach is that it cannot identify the doping with 
pituitary GH and GH promotors.  
All of these issues have led to the development of an indirect biomarker approach, 
and one approach of combined detection of insulin-like growth factor-I (IGF-I) and 
procollagen type III amino-terminal propeptide (P-III-NP) for testing growth 
hormone (GH) misuse has been approved. This strategy lies on the fact that GH 
action is mediated via GH-dependent growth factors such as IGF-1, IGF-binding 
protein3 (IGFB3) and the subunits of IFG1/IGFB3 complexes (ALS), which 
increase upon the GH administration. Other bone and collagen turnover markers 
such as P-III-NP and collagen-I telopeptides (ICTP) have also shown to increase 
significantly with GH administration (Figure 1-3, B). Intensive studies have been 
carried out on these markers with different designs and statistical models and 
finally the combination detection of IGF-I and P-III-NP was established as they 
have small intra-individual variability and yield the best predictive scores (Powrie, 
Bassett et al. 2007, Holt 2009, Erotokritou-Mulligan, Guha et al. 2012). Notably 
this biomarker approach can prolong the detection window up to 2-4 weeks after 
discounting treatment. Just before the 2012 Summer Olympics in London, this 
approach was approved and introduced by the WADA and has led to the detection 




of a number of athletes misusing GH (Powrie, Bassett et al. 2007, Holt 2013), and 
further refinement studies are still being carried out (Holt, Böhning et al. 2015).  
 
Figure 1-3 Principles of isoform and biomarker approaches to detect 
recombinant human growth hormone (rhGH) misuse. A, the isoform approach: 
under normal circumstances, GH is secreted from the pituitary under the control of 
the hypothalamic hormones, growth hormone–releasing hormone (GHRH), 
somatostatin and ghrelin. Pituitary GH appears as different isoforms, although 22 
kDa represents the majority (represented in the figure as a circle). IGF-I is secreted 
in the liver and acts in a classical negative endocrine feedback mechanism to 
reduce GH secretion. The detection is based on measuring the abundance of 
different GH isoforms due to the suppression of natural pituitary GH caused by 
exogenous GH negative feedback. Consequently the proportion of total 22 kDa GH 
increases. B, the biomarker approach: the detection is based on measuring the GH-
dependant biomarkers of IGF-1 and P-III-NP. Growth hormone acts on the liver to 
increase circulating IGF-I and on soft tissue to increase P-III-P. Figure adapted 
from (Holt 2009) 
A 
B 




This biomarker approach still have some limitations such as the lack of pure 
recombinant IGF-I standard and differences in antibody specificity in different 
assays (Duntas and Popovic 2013). Despite these, there have been a number of 
studies focusing on finding novel biomarkers of GH. 
The studies applied “omics” approaches for discovery of novel biomarkers of GH 
misuse are rather limited in number, mainly using genomics, transcriptomics and 
proteomics approaches, including applying microarray technology to detect 
differential gene expression profiles induce by GH (Mitchell, Nelson et al. 2009), 
quantification of circulating mRNAs for GH and growth hormone–releasing 
hormone (GHRH) with real-time PCR (Thakkar, Butt et al. 2008, Kelly, Haverstick 
et al. 2014), and proteomics-based 2-dimensional electrophoresis (2-DE) for the 
discovery of new GH induced serum biomarkers (Ding, List et al. 2009). In 
metabolomics field, hardly any research has been published. An LC-MS based 
metabolomics study assessed the metabolic perturbations caused by recombinant 
equine growth hormone administration in horses, and tens of ions were highlighted 
responsible for the modification of metabolic profile observed in treated animal, 
(Boyard- Kieken, Dervilly- Pinel et al. 2011) and this approach can possibly be 
extend to humans. 
1.5.3 Enhancement of oxygen carriage (blood doping)  
1.5.3.1 Erythropoietin  
Erythropoietin is a glycoprotein produced primarily in the kidneys that acts on the 
bone marrow to increase erythrocyte proliferation. Recombinant human 
erythropoietin (rhEPO) was first produced in late 1980s to treat patient suffering 




from diseases such as anaemia, a common complication of chronic kidney disease 
caused principally by a deficiency in the synthesis of endogenous erythropoietin. 
Not long after that, it was said that rhEPO were largely abused by athletes, 
particularly in endurance sports where increased circulating erythrocyte would 
enhance the oxygen carriage and consequently sports performance. It was soon 
banned by IOC in 1990, although no detection method was readily available at that 
time. In addition to that, the easy access to the substance and the enormous impact 
on performance resulted in widespread abuse of rhEPO during the 1990s/2000s, 
including the notorious case of the seven-time Tour de France winner Lance 
Armstrong, who subsequently admitted the use of both rhEPO and blood 
transfusions throughout his career. 
The first direct method of isoelectric focusing (IEF) for detecting rhEPO has been 
available since the beginning of the 21st century. It relies on a difference in 
glycosylation between the endogenous and the exogenous EPO molecules, 
resulting in different migration characteristics during IEF. Another improved 
method emerged later applying SDS/SAR-PAGE (sodium dodecyl sulphate/ 
sarcosyl polyacrylamide gel electrophoresis). Endogenous EPO and rhEPO (and 
their variants) can be distinguished by SDS-PAGE as they are slightly different in 
their molecular mass. Other direct methods such as 2-DE, enzyme-linked 
immunosorbent assay (ELISA)-based methods, membrane-assisted isoform 
immunoassay (MAIIA) and MS methods have also been proposed as reviewed by 
Reichel and Pottgiesser et al. (Reichel 2011, Pottgiesser and Schumacher 2013). 
However not all rhEPO cases are detectable, because the detection window for 
rhEPO is known to be relatively short and, dosage and administration method 




dependent (Ashenden, Gough et al. 2011). Furthermore, different types of rhEPO 
variants which are continuously produced by underground laboratories with 
slightly modifications from batch to batch, often do not meet the WADA positivity 
criteria (Pottgiesser and Schumacher 2013). 
Prior to the implementation of IEF method, the indirect biomarker method had 
been explored for many years. In late 1990s, the so-called ‘no-start’ rules was 
introduced with the official objective to protect the health of the athletes, 
specifying several blood markers such as hematocrit (HCT) and hemoglobin 
(HGB) cannot exceed certain limits before sports (UCI 1997). These earlier 
markers with upper limits of definite blood values may result in athletes who would 
titrate or micro-dosing rhEPO to approach the HGB and HCT thresholds without 
exceeding them (Cazzola 2000). Another limitation is that those markers are likely 
to be affected by plasma volume fluctuations, which can by caused by posture, 
exercise, and training (Sharpe, Hopkins et al. 2002), altitude exposure (Ashenden, 
Gore et al. 2003, Ashenden, Sharpe et al. 2004), etc. To make it worse, some 
athletes can cover up the elevated HGB and HCT concentrations by hemodilution 
with intravenous infusion of saline.  
Therefore, the exploration of novel biomarker of EPO has never stopped and a so-
called ‘ON and OFF models’ strategy has been proposed (Parisotto, Gore et al. 
2000, Parisotto, Wu et al. 2001). Five different serum hematopoietic parameters: 
[EPO concentration, soluble transferrin receptor concentration (sTFr), HCT, 
percentage of reticulocytes (RET %) and percentage of macrocytes] were chosen as 
the most clearly affected markers by the administration of rhEPO, and then 
multivariate models were built during current treatment (ON-models) and weeks 




after withdraw (OFF-models). The sensitivity and specificity were improved by 
further refinement with a larger number of subjects, leading to a ‘second 
generation’ blood test (Gore, Parisotto et al. 2003), of which the OFF-hr model, a 
score combining HGB and RET %, is recommend by current ABP operating 
guidelines (WADA 2014). The use of indirect biomarkers of doping has 
culminated in the introduction of the ABP, which will be described later in section 
1.5.5. 
On the other side, the “omics” strategies for identifying EPO abuse are still in their 
infancy, and mainly focusing on genomics and transcriptomics by analysing gene 
expression profile following erythropoiesis-stimulating agents (ESAs) 
administration, which have the similar functions of EPO to stimulate red blood cell 
production (erythropoeisis).  Varlet-Marie et al identified 33 genes that could be 
significant markers of high dose ESA administration, and five genes showed as 
significant markers both in high and micro dose of rhEPO (Varlet-Marie, Audran et 
al. 2009). Further biomarkers could be derived from ‘circulating miRNAs' 
suggested by Leuenberger et al. for the detection of ESAs (Leuenberger, Jan et al. 
2011). In this context, the application of newer diagnostic tools related to the 
“omics” technologies including metabolomics will nurture this area in near future.  
1.5.3.2 Blood transfusion 
There are two types of direct blood doping, homologous blood transfusion (HBT, 
infusion of blood or red cell concentrates from a donor) and autologous blood 
transfusion (ABT, withdrawal and reinfusion of one’s own blood or red cell 
concentrates), with the aim to directly increase red blood cells in circulation to 




improve the oxygen delivery capacity. Since the IEF method for rhEPO was 
developed, there has been a growth in the use of blood transfusion in athletes 
(Soule and Lestrelin 2011).  
HBT can be detected using flow cytometry, based on the fact that there are a large 
number of cell antigens differing from individual to individual (Nelson, Popp et al. 
2003). While this method for the detection of HBT has been established for many 
years, no comparable methods currently exist for the direct detection of ABT, 
making it the most challenging doping method to detect. 
It is worth to mention that the OFF-hr model stated above was originally developed 
for the detection of rhEPO, it is also sensitive to other forms of blood doping such 
as blood transfusion nevertheless (Mørkeberg, Sharpe et al. 2011, Pottgiesser, 
Sottas et al. 2011). As such, ABT is currently monitored using indirect method of 
markers in a longitudinal profile included in haematological module of ABP (see 
section 1.5.5). However micro-dosing still remains undetectable (Ashenden, Gough 
et al. 2011), and suspicious profiles in athletes often result from altitude, heat stress 
or illness (Salamin, De Angelis et al. 2016). Therefore additional biomarkers are 
needed. 
Salamin et al. recently reviewed the emerging biomarkers for ABT, which are 
developed based on “omics” approaches as well as plasticizers in urine (Salamin, 
De Angelis et al. 2016). Reliant on transcriptomics, ABT altered gene expressions 
were identified using digital multiplexed gene expression, and it was found that 
those genes are related to red blood cell metabolism (Salamin, De Angelis et al. 
2016). Also, blood reinfusion can cause a distinct change in the pattern of 




circulating miRNA, which is detectable up to 3 days post-transfusion. Ironomics 
found ferritin and hepcidin (a hepatic peptide that regulate the availably of iron to 
erythropoiesis) can serve as potential biomarkers of ABT (Leuenberger, Barras et 
al. 2016). The changes of red blood cells in protein level during the storage can be 
identified by proteomics approach, for instance Peroxiredoxin 2 was preliminary 
identified as potential markers of blood transfusion (Rinalducci, D'Amici et al. 
2011, Marrocco, Pallotta et al. 2012). It is concluded that the “omics” technologies 
can provide a variety of promising markers which could be tested in an individual 
based model, with the potential to largely improve the ABP approach (see section 
1.5.5).  
In 2010, a stratgy of di-(2-ethyhexyl) phthalate (DEHP) and its metabolites as 
indirect markers of ABT was proposed (Monfort, Ventura et al. 2010). DEHP is a 
plasticizer contained in blood bags acting as a protective role on erythrocytes 
survival and, can infuse into blood duing long-term storage. When the blood is 
reinfused into the body, DEHP will circulate in the body and its metabolites can be 
detected in urine by LC-MS/MS (Monfort, Ventura et al. 2012). Notably the 
phthalates method is the only approach proposed so far to detect blood transfusion 
using urine as analysis matrix, which could be easily collected in anti-doping 
controls.  
Figure 1-4 summrizes the current and potential detection methods for the 
enhancement of oxygen carriage (blooding doping), including rhEPO, HBT and 
ABT. 
 





Figure 1-4 Summary of established and potential detection methods for blood 
doping, grouped by direct detetion and biomarker detection. Established 
methods are printed in black (solid line), potentail or experimental methods are 
printed in gray (dashed line). rhEPOs, recombinant erythropoietins; IEF, isoelectric 
focusing; SDS/SAR-PAGE, sodium dodecyl sulphate polyacrylamide/ sarcosyl 
polyacrylamide gel electrophoresis; MAIIA, membrane-assisted isoform 
immunoassay. Data obtained from (Reichel 2011, Pottgiesser and Schumacher 
2013, WADA 2014) 
 
 
1.5.4 Gene doping 
Gene therapy has made great progress in the last decade. It attempts to treat 
patients by direct introduction of genetic material into the body or by up-/down-
regulation of the activity of some genes. In-vitro and animal studies have proved 
the possibility of gene doping via the improved production of human recombinant 
proteins, such as GH, IGF-1 and EPO, and a few therapeutic clinical trials have 
showed encouraging results (Lee, Barton et al. 2004, Khan, Brown et al. 2005, 
Haisma and de Hon 2006, Hojman, Gissel et al. 2007, Brzezianska, Domanska et 
al. 2014). Unfortunately, this technique is inevitably pursued to be misused in 
sports with the attempt to create a “super althlete”.  




By its nature gene doping cannot be controlled by the application of technologies 
currently in use in anti-doping laboratories, thus there is still no completed work on 
the standardization of reliable tests to detect gene doping and scientists are making 
a lot of efforts to develop novel detection methods. 
Direct methods development are mainly focusing on detecting the gene carrier 
(usually a vector) and the transgenes using PCR-based assays, as reviewed by 
Perez et al (Perez, Le Guiner et al. 2013). The methodology for detecting EPO 
gene doping, involving the PCR assays targeting intronless complementary DNA 
(cDNA) sequences that are present in doping genes but absent in intron-containing 
endogenous genes, is under implementation in WADA accredited laboratories 
(WADA 2016). 
Observing the host immune response to the viral vectors via measuring the 
parameters such as antibodies to the viral in blood can be used as an indirect 
method to identify gene doping. However this method is often unable to 
discriminate between natural infection and artificial introduction of the virus and, 
with genetically engineered viral vectors which are less immunogenic, the immune 
response could be minimized (Baoutina, Alexander et al. 2008, Brzezianska, 
Domanska et al. 2014). 
Apart from monitoring the immune response, indirect evaluation of changes of 
markers in gene, protein and metabolite patterns using genomics/ transcriptomics, 
proteomics and metabolomics is trending in gene doping control research, as 
reflected from a number of WADA funded projects (WADA 2016).  




Transcriptomics/ genomics, which is capable to identify subtle changes in 
thousands of genes using microarray technology, can assess the expression profile 
of endogenous genes that may be modified following the expression of the 
introduced genes (Baoutina, Alexander et al. 2008). Proteomic profiling for 
detection of gene doping is based on the structural difference between the 
recombinant proteins produced by the transgenes and the endogenous counterparts, 
which can be identified using SELDI-TOF (surface enhanced laser 
desorption/ionization time-of-flight mass spectrometry) (Issaq, Veenstra et al. 
2002). Metabolomics, while analysing small molecule metabolites, could provide 
evidence for suspicious metabolic responses to these artificial stimuli, however no 
study has been reported so far applying metabolomics strategy to identify gene 
doping. 
Alternatively, ABP has the potential to address the gene doping of different gene 
targets, which will be discussed in the following section.  
1.5.5 The Athlete Biological Passport (ABP) 
The introduction of the Athlete Biological Passport (ABP) is considered a 
milestone in the anti-doping movement over the years. On top of historically 
directly detecting an administered prohibited substance or its metabolites, 
authorities now can longitudinally monitor selected biomarkers that would 
indirectly reveal the effects of doping in individual athlete through the 
implementation of the ABP programme. In addition to population-based 
parameters, this paradigm focus more on the subject-based fluctuations compared 
with their own historical, intra-individual data (Saugy, Lundby et al. 2014). The 




ABP intends to establish that an athlete is manipulating his/her physiological 
variables, without necessarily relying on the detection of a particular prohibited 
substance or method using traditional targeted analytical approaches. The ABP 
does not replace traditional testing methods, but rather a complementary strategy to 
further refine and strengthen overall anti-doping programmes. The intelligent, 
timely interpretation of ABP data can be used to identify athletes for specific 
targeted testing, and may also be used to pursue an ADRV in the absence of a 
positive analytical test (Adverse Analytical Finding, or AAF) in accordance with 
World Anti-Doping Code (WADA 2014). The ABP introduces a new form of 
doping evidence and, as such, paves the way for a more global and integrated fight 
against doping. At present, ABP includes a haematological module and a steroidal 
module, which use statistical algorithms and in-depth expert analysis to determine 
the likelihood that a fluctuation in an individual athlete's passport is indicative of 
hematologic or steroid doping (Sottas, Robinson et al. 2011).   
The haematological module has been in place in some federations since 2008, with 
the intention to gather the information on the potential markers for blood doping, 
such as rhEPO doping, blood transfusion and gene doping. The module was 
developed based on the model previously mentioned in section 1.5.3.1, and has 
been continuously appraised, leading to subsequent markers and measurements 
added in. Currently in this module, ten markers affected by blood doping have to 
be measured and longitudinally recorded: HCT, HGB, red blood cells count (RBC), 
RET %, reticulocytes count (RET#), mean corpuscular volume (MCV), mean 
corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration 
(MCHC), red cell distribution width (standard deviation) (RDW-SD) and immature 




reticulocyte fraction (IRF) (WADA 2014). Further calculated markers specific to 
the haematological module include the aforementioned stimulation index OFF-hr 
Score (OFFS), which is a combination of HGB and RET % (Gore, Parisotto et al. 
2003), and Abnormal Blood Profile Score (ABPS), which is a combination of 
HCT, HGB, RBC, RET %, MCV, MCH, and MCHC (Sottas, Robinson et al. 
2006). The intra-individual variabilities of these blood markers are lower than their 
corresponding inter-individual variabilities (Sharpe, Ashenden et al. 2006, Sottas, 
Robinson et al. 2008), and each athlete has his/ her own reference values of the 
markers. The Union Cycliste Internationale is the first organization to implement 
the haematological module of the ABP in 2008, to identify blood doping in elite 
cycling (Figure 1-5), and subsequently several riders have been prosecuted and 
sanctioned on the sole basis of their abnormal haematological profiles (Sottas, 
Robinson et al. 2011). 
 
Figure 1-5 Example haematological passport of an elite rider. The figure 
included tests on 9 occasions for 4 markers of blood doping: haemoglobin (HGB), 
the stimulation index OFF-hr Score (OFFS), the Abnormal Blood Profile Score 




(ABPS), and the percentage of reticulocytes (RET %). Blue lines represent actual 
test results. Red lines indicate limits at which the test result is considered abnormal. 
Initial limits (e.g., 124–172 g/L for HGB) are based on population epidemiology 
and are adapted in the course of individual data acquisition to produce individual 
final limits (121–150 g/L for HGB). Colour bars indicate sequence (seq) 
abnormality (Sottas, Robinson et al. 2010); prob, probability. The numerous 
abnormalities suggest that it is very unlikely that such a blood profile would not be 
obtained under normal physiological conditions. The rider was subsequently 
convicted of doping with the ESA known as CERA (continuous erythropoiesis 
receptor activator). Figure obtained from (Sottas, Robinson et al. 2011) 
  
The steroidal module took effective in January 2014, aiming to identify 
endogenous anabolic androgenic steroids (EAAS) when administered exogenously 
and other anabolic agents, such as selective androgen receptor modulators 
(SARMS). The steroidal marker in urine includes T, E, T/E ratio and four 
testosterone metabolites, androsterone (A), etiocholanolone (Etio), 5α-androstane-
3α,17β-diol (5αAdiol) and 5β-androstane-3α,17β-diol (5βAdiol). Further urinary 
ratios of steroid metabolites to be considered include A/T, A/Etio, 5αAdiol/5βAdiol 
and 5αAdiol/E (WADA 2014).  
The indirect markers in the ABP can be affected by the heterogeneous and 
confounding factors (Sottas, Robinson et al. 2010), thus additional individual 
athlete information for the ABP is also required to provide as precisely as possible 
for a better interpretation of the markers, which includes (but not limited to) sex, 
location of testing, type of sports, whereabouts information, recent blood loss or 
gain, recent training and competition schedules, exposure to extreme heat 
conditions, usage of hypoxic devices, and altitude information (Lippi and Franchini 
2010, Lundby, Millet et al. 2012, WADA 2014). Among those, training at high 
altitude is considered one of the factors that can cause the highest variability of the 
model in the haematological module, as a result it is generally accepted that 




exposure to high altitude during the two weeks preceding the sample collection 
must be taken into account in establishing individual limits (Sottas, Robinson et al. 
2010). The steroidal ratios are robust and do not change due to circadian rhythm or 
physiological conditions such as exercise workload, but they can be largely 
affected by heterogeneous factors such as sex and age (Mareck, Geyer et al. 2008, 
Saugy, Lundby et al. 2014). 
Although at the moment longitudinal monitoring exists only for hematologic and 
steroidal variables, the third module of ABP, namely endocrinological module is 
currently underway to be finally structured and validated (Saugy, Lundby et al. 
2014, Holt, Böhning et al. 2015), aiming to detect GH axis misuse such as GH, 
IGF-1 and GHRH, based on the aforementioned GH dependant biomarkers, IGF-1 
and P-III-NP. With the longitudinal sequence of those markers, the implementation 
of the endocrine module in the ABP can undoubtedly provide more selective 
evidence to prove manipulations of growth promoters. 
ABP still need further refinement as the sensitivity of the ABP to detect doping is 
limited if the physiological result of a low level of doping remains within the 
individual’s own reference range, for instance it cannot flag the EPO micro-dosing 
at this time (Ashenden, Gough et al. 2011). Thanks to the recent development of 
high-throughput “omics” technologies, they can provide new opportunities to 
discover biomarkers for the ABT. Each doping violation has its own pattern in 
proteomic or metabolomic profile, therefore a high specificity will be achieved by 
the recognition of a unique signature in high-multidimensional profiles derived 
from “longitudinal–omics”, instead of a single biomarker with supposedly high 
specificity to doping (Figure 1-6) (Sottas and Vernec 2012). Transcriptomics, 




proteomics and especially metabolomics have the potential to significantly 
strengthen the ABP approach and contribute to other traditional anti-doping tests, 
by providing a single proteomic or metabolomic profile, allowing the detection of 
large cohorts of substances. The identified specific fingerprints in this way could be 
integrated in the ABP following due validation and assessment of confounding 
factors (Vernec 2014).  
 
Figure 1-6 Possible “longitudinal-omics” collated in an Athlete Biological 
Passport to detect doping “fingerprints”. Each colour map represents the 
athletes’ “omics” data at a particular time. Each small coloured square within a 
map represents a feature measured in the “omics” field (e.g., a metabolite in 
metabolomics or a protein in proteomics) with the colour indicating the measured 
level in a biological fluid. Red represents a high value for this particular subject, 
blue a low value for this subject. In a non-targeted approach, the detection method 




is based on the recognition of “omics” patterns specific to the doping substance: the 
wider the profile, the more likely the tests would detect a specific doping pattern.  
Figure obtained from (Sottas and Vernec 2012) 
 
 
1.5.6 Limitations of the biomarker approach 
The main advantages and disadvantages of direct and biomarker approaches are 
outlined comparatively in Table 1-5: 
Table 1-5 The main advantages/disadvantages of direct vs. biomarker 
approaches 
 
Since the biomarker approach is an indirect method to screen for agents based on 
their physiological effects rather than their structure, validation is still the major 
challenge in terms of assuring an accreditation body of its effectiveness, and this 
limits the use of this biomarker approach to confirm the misuse of an agent or 








• Not able to address the 
emerging threat (e.g. designer 
drug) 
• Difficult to detect 
endogenous substance or 
biological technologies 
• Time consuming 




• Able to detect endogenous 
doping substance 
• Downstream biomarkers 
rather than the agent itself 




for fast screening 
• Difficult to validate and can 
get challenged  
• Can be affected by 
confounding factors 
• Variabilities exist, not always 
reliable 
• Need direct method as final 
confirmation method in most 
cases 




method. Moreover, biomarkers applied to sports testing need to be highly 
discriminatory to meet the forensic standards compared to clinical diagnose. To 
this end, large-scale validation studies are needed to consider various 
circumstances and provide sufficient evidence for a legally binding indirect test. 
The diversity of the population has always been an issue when applying a 
biomarker, making it difficult to determine of the abnormal limits. The ABP 
programme with the longitudinal monitoring of individual subjects can overcome 
this problem and encouragingly, this has been fully accepted by the Court of 
Arbitration for Sport (CAS) in recent hearings (Saugy, Lundby et al. 2014). 
However, this promising tool reaches its limit when confounding factors are used 
to justify the abnormal values of the markers, such as the effect of recent training at 
a high altitude in ABP haematological module. Indeed, the huge intra-individual 
biological variation caused by exercise, diet, or environmental factors could lead to 
physiological changes in the levels of RNA, protein and metabolites. These various 
confounding factors and their effect should be addressed by studying sufficiently 
large and heterogeneous populations in different confounding circumstances during 
the development phase of the biomarker method in order to ensure the specificity 
of a biomarker test. However it is still very difficult to assess the impact of 
environmental factors such as seasonal and temperature effects because of the high 
frequency of travel of athletes across different continents, despite the use of the 
“Whereabouts” system (Delanghe, Maenhout et al. 2014). Another hurdle is that 
ordinary members of the population cannot totally replace élite athletes in studies 
because of their physiological differences and this may lead to legal and ethical 




concerns that could constrain the latitude of the experimental design (Teale, Barton 
et al. 2009). 
Large scale “omics” approaches can respond to the need for more and more novel 
biomarkers to enhance the sensitivity when confronted with sophisticated low-dose 
doping schemes, such as the failure to detect multi-level micro-dosing, as discussed 
in section 1.5.5. Nonetheless, although “omics” approaches have been used in the 
discovery of indirect biomarkers for doping for the last decade, the results have not 
yet led to any routine application in anti-doping control. This is mainly due to the 
biological complexity and inter-individual variation, as well as the intricate 
validation procedures mentioned above. 
The practical limits of these methods include the frequent and regular profiling of a 
single athlete, with consequential practical and laboratory limitations. Other 
factors, including various sample collecting strategies and inter-laboratory 
variations can reduce the efficiency of the biomarker approach, especially the ABP; 
thus, the standardisation is mandatory from sampling conditions to analysis 
(Delanghe, Maenhout et al. 2014, WADA 2014). 
  




1.6 Dried biofluid spots (DBS) 
1.6.1 DBS and their practical applications 
Dried biofluid spots (DBS) are obtained by spotting small volumes (typically less 
than 20 μL) of biofluids, such as blood, urine, cerebrospinal fluid (CSF) and bile 
specimens onto different types of absorbent paper. DBfdaS have been used in 
preclinical drug development, disease diagnostics and treatment since the 1960s 
(Naylor and Chace 1999, Wilcken, Wiley et al. 2003, Barfield, Spooner et al. 2008, 
Turpin, Burnett et al. 2010, la Marca, Giocaliere et al. 2012, la Marca, Malvagia et 
al. 2012, Demirev 2013, Jiang, Sidhu et al. 2016), and DBS studies are also 
becoming increasingly popular in drug analysis (Barfield, Spooner et al. 2008, la 
Marca, Malvagia et al. 2008, Abu-Rabie and Spooner 2009, Spooner, Lad et al. 
2009, Van Berkel and Kertesz 2009). 
DBS, especially dried blood spots have begun to attract increasing interest recently 
for their potential in anti-doping analyses. Compared to a conventional sampling 
collection technique, DBS offer benefits that include minimal invasiveness and 
easier storage and transport. Further advantages are longer stability, the possibility 
for automation, and robustness against manipulation, thereby constituting a 
promising matrix for anti-doping purposes (Ganz, Singrasa et al. 2012, Martin and 
Cooper 2014, Sadones, Capiau et al. 2014, Wagner, Tonoli et al. 2016). The 
detection of growth hormone, IGF-1, rhEPO and blood transfusion as well as the 
hematological module of ABP currently rely solely on blood specimens. However, 
despite an increase in recent years, there are much fewer blood samples than urine 
samples being collected, mainly because of the strict blood collection protocols 




(e.g. the necessity of the presence of a licensed phlebotomist supervised by a 
doping control officer and the need to dispatch samples in a refrigerated state as 
soon as possible after collection, ideally arriving at the accredited laboratory on the 
same day and preferably within 36 h of collection (WADA 2016)). Therefore, the 
substantial expenditure and logistical difficulties that limit the time and location of 
the sample collection could be alleviated by using DBS. Although DBS have not 
been implemented in routine doping control analyses, some inspirational 
applications have demonstrated the suitability for using DBS in anti-doping tests 
(Peng, Segura et al. 2000, Cox, Rampton et al. 2013, Tretzel, Thomas et al. 2014, 
Reverter-Branchat, Bosch et al. 2016, Thevis, Geyer et al. 2016, Tretzel, Gorgens 
et al. 2016). 
The small sample volume of typically 20 μL of blood requires high sensitivity of 
the detection instruments, thus the mass spectrometer are mostly used, nonetheless, 
other analytical methods such as immunoassays for GH have also been developed 
(Reverter-Branchat, Bosch et al. 2016).	
1.6.2 DBS in metabolomics 
The use of diverse analytical approaches in large-scale metabolomics studies 
emphasises the need for standardised and robust sample storage methods. At the 
discovery stage of metabolomics, the use of small amounts of biofluids also confers 
several advantages and is the ethically-preferred route (particularly when dealing 
with infants and small animals).  In addition to the small sampling volume, DBS 
have a number of other practical benefits, as mentioned above; thus, it is an 
appealing sampling matrix for large-scale metabolic profiling. Therefore, spot 




profiling can result in a more economical experimental design, particularly when 
considering the cost of animals, sampling, storage and shipment. Moreover, if DBS 
can be implemented in doping control, the DBS collected from routine tests would 
be very attractive samples for metabolomics and proteomics research in the 
discovery of novel doping biomarkers. 
Pioneering metabolomics studies have shown the utility of DBS fingerprinting with 
1H NMR spectroscopy, UHPLC–MS and GC–MS-based methods (Constantinou, 
Papakonstantinou et al. 2004, Michopoulos, Theodoridis et al. 2010, Kong, Lin et 
al. 2011). The cited UHPLC–MS investigation was not limited to blood, but also 
showed that urine and serum spotting are viable alternatives when directly 
compared with classic metabolite profiling and data treatment. In their study, 
Michopoulos et al. proved that best results are achieved when spots are stored 
frozen on additive-free collection cards, since additives can interfere with the 
quality of the raw data (Michopoulos, Theodoridis et al. 2010, Michopoulos, 
Theodoridis et al. 2011). Another study validated a novel lipid profiling method 
based on HRMS using dried blood spots and concluded that, although spotting and 
drying had notable effects on some of the lipids, it was still possible to obtain 
information on changes in the global lipid metabolism. They also pointed out that 
the results from DBS were no less reproducible than other lipid profiling methods 
that required comparatively larger samples (Koulman, Prentice et al. 2014).  
Hence an in-vial spot extraction and UHPLC-MS analysis method for 
metabolomics was first developed and validated in this thesis (see Chapter 2). This 
work combines the benefits of a spot analysis with the metabolic coverage and 
analytical reproducibility of the in-vial extraction (IVDE) method for 




metabolomics. Further assessments include a comparison of the novel method and 
the conventional method, as well as the short-term storage stability of urine 
specimens (see Chapter 4).  
The overall hypothesis of this thesis is that LC-MS based metabolomics have the 
potential to discover the surrogate biomarkers in doping. To test this hypothesis, 6 
following chapters will be conducted. In short, Chapter 2 will explore the analytical 
method-development in metabolomics, overall assessing the amount and quality of 
the metabolic information acquired in small sample volumes using paper spots. 
Chapter 3 will develop methods for high resolution and high mass accuracy 
instrument to aid with the identification of molecules. Chapter 4 will bring the 
work performed in chapters 2 and 3 together, by evaluating dried urine spot 
metabolomics using high-resolution mass spectrometry. In chapter 5 and 6, the 
metabolomics strategy will be applied to actual doping samples to validate the 
hypothesis.  Finally, Chapter 7 will summarize all the findings and evaluate how 
the evidence supports the hypothesis. A schematic flow and interaction of the 
chapters is described in Figure 1-7: 





Figure 1-7 The schematic flow and interaction of the chapters. 
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Chapter 2  The feasibility of paper spots for 
metabolomics: Metabolic phenotyping of the 
healthy rodent model using in-vial extraction of 






Metabolomics-based studies have already contributed to major advances in 
biomedical knowledge: e.g. the correlation of diet and gut microbial activities with 
high blood-pressure using NMR metabolomics (Holmes, Loo et al. 2008), and the 
association of gut flora metabolism with cardiovascular disease through LC-MS 
based metabolomics (Wang, Klipfell et al. 2011). However, as an “omics” 
approach it is not as established as other methods such as proteomics and 
genomics, in particular since it deals with the small-molecule fingerprinting of 
complex biological samples and aims to identify metabolites in samples containing 
a multitude of similar molecules. 
Typically, an untargeted metabolomics experiment includes a comprehensive 
metabolite fingerprinting step, either by NMR or LC-MS methods. The primary 
challenges of such untargeted experiments include detecting intact small molecules 
(<1500 Da) over a wide concentration range, as well as ensuring sufficient 
metabolite coverage to shed light on the metabolic problem being investigated. 
Hence, untargeted metabolomics studies often use multiple analytical technologies 
to study the same samples, and metabolomics protocols are now available for a 
variety of biofluid and tissue types. For large-scale metabolomics experiments, LC-
MS (Want, Wilson et al. 2010, Want, Masson et al. 2013) and NMR (Beckonert, 
Keun et al. 2007) methods are predominantly used, followed by GC-MS (Chan, 
Pasikanti et al. 2011) and CE-MS (Garcia-Perez, Angulo et al. 2010) approaches.  
The diversity of analytical approaches used in large-scale metabolomics studies 





discovery stage of metabolomics, the use of small amounts of biofluids also confers 
several advantages, and is the ethically preferred route (particularly when dealing 
with animal models) (Burnett 2011) One small-volume sampling approach involves 
profiling dried blood spots (DBS), blood samples which have been collected onto 
different types of absorbent paper. Such spots have a number of practical benefits, 
including the added ease of storage and transportation at ambient conditions.  As 
stated in the section 1.6.1, dried spots have been widely used in many fields such as 
preclinical drug development, diagnostics, treatment and drug analysis for more 
than 50 years. Pioneering metabolomics studies have shown the utility of DBS 
fingerprinting with 1H NMR spectroscopy, UHPLC–MS and GC–MS based 
methods (Constantinou, Papakonstantinou et al. 2004, Michopoulos, Theodoridis et 
al. 2010, Kong, Lin et al. 2011). The UHPLC–MS investigation cited was not 
limited to blood, but also showed that urine and serum spotting are viable 
alternatives when compared directly with classic metabolite profiling and data 
treatment. Another study by Michopoulos et al. proved that best results were 
achieved when spots are stored frozen on collection cards which are additive-free, 
as the latter could interfere with the quality of the raw data (Michopoulos, 
Theodoridis et al. 2010, Michopoulos, Theodoridis et al. 2011). Spot profiling can 
thus result in a more economical experimental design, particularly when 
considering the cost of animals, sampling, storage and shipment. 
Whilst our laboratory have previously succeeded in devising a small volume (20 
µL) plasma fingerprinting method that yields comprehensive metabolite coverage 
(Whiley, Godzien et al. 2012), optimising coverage per volume or mass unit of 





sample preparation, in-vial and in-vial dual extraction (IVDE), and UHPLC-MS 
analysis for use in metabolic fingerprinting is described. We have investigated the 
robustness and capabilities of this method for metabolite phenotyping by testing it 
on rat serum and RPMI cell nutrient broth analysis and have applied the method to 
the study of serum, urine, and CSF from two separate rodent (rat and mouse) 
models. As previously demonstrated, the IVDE method yields reproducible data 
with low analytical variation, and requires very small amounts of biofluid for 
successful implementation. The aim of the study described herein thus is to 
combine the benefits of spot analysis with the analytical reproducibility of the in-
vial extraction (IVDE) method for metabolomics, which can give a viable 
alternative for anti-doping metabolomics.  
2.2 Methods 
2.2.1 Chemicals reagents and materials 
LC-MS grade water and methanol, analytical-grade formic acid and methyl tert.-
butyl ether (MTBE), as well as rat serum used for validation experiments, were 
purchased from Sigma-Aldrich (UK). Samples were spotted onto Whatman FTA® 
DMPK-C Cards from GE Healthcare Bio-Sciences (NJ, USA). All sample 
extractions were performed in amber glass HPLC vials with fixed 0.3 mL inserts 
(from Chromacol: Welwyn Garden City, UK). RPMI-1640 cell nutrient broth was 
purchased from Invitrogen. 





Three adult male and three adult female Sprague–Dawley (SD) rats (250–280 g), 
and three normal c57 mice (25 g) were obtained from the Laboratory Animal Unit 
of the LKS Faculty of medicine in the University of Hong Kong, and were 
maintained in a temperature-controlled room with a 12 h light/dark cycle. The 
animals were handled according to protocols approved by the Committee on the 
Use of Live Animals in Teaching and Research of the University of Hong Kong. 
The rats were anesthetized with an intra-peritoneal injection of a ketamine/xylazine 
mixture (ketamine 80 mg/kg and xylazine 8 mg/kg; from Alfasan: Woerden, 
Holland). The skin at the back of the neck, on the chest and the lower abdomen was 
shaved, and alcohol pads were used to clean the skin. A horizontal incision opened 
the lower abdominal wall and a 1 mL syringe was used to withdraw urine directly 
from the bladder. A longitudinal incision in the back of the neck skin was then 
made, through which the foramen magnum was found. A 1 mL syringe was used to 
puncture through the dura and withdraw CSF. Finally, through an incision in the 
chest, blood was withdrawn from the right atrium using a heparinized 5 mL 
syringe. The blood samples were centrifuged at 4000 r.c.f. for 20 min at 4 ˚C and 
plasma was collected. 
Spots were prepared by dropping 15 µL of each biofluid onto sample spots on 
Whatman FTA® DMPK-C cards, with the exception of murine CSF, which was 
diluted 10x in MilliQ water before spotting. Between 2 and 4 replicates were 
prepared for each biofluid type per animal. Spots were air-dried for two hours at 
room temperature and then placed in PE plastic packaging for shipment. Samples 
were shipped in the absence of desiccant, at ambient temperature. A total of 30 





bearing rat biofluids (urine = 12, serum = 22, CSF = 13) were extracted and 
analysed. Samples for validation were prepared by creating spots with 10 µL 
commercially obtained rat serum (x10) and 10 µL RPMI1640 (cell nutrient fluid) 
(x10). Validation samples were prepared to investigate analytical reproducibility of 
the spot-IVDE methodolog at 10 µL volumes. Mice and rat biofluids were 15 µL in 
keeping with conventional blood collection volumes (max 0.6 ml/kg/day).  
2.2.3 Sample spot extraction 
The extraction methods were adapted from a procedure previously used for the 
analysis of plasma by Whiley et al.(Whiley, Godzien et al. 2012) Spots with a 
diameter of 6 mm were punched out of the Whatman cards and then introduced 
into a Chromacol HPLC vial (with a 300 µL insert). All subsequent extraction steps 
were performed in the same vial, allowing analytical samples to be withdrawn from 
the extract with minimal sample loss. Extraction protocols for different biofluids 
are described below. 
2.2.3.1 Serum IVDE 
Figure 2-1 illustrates the use of the IVDE method for the extraction of serum spots. 
10 µL water was added to each vial containing a sera spot, followed by 40 µL 
methanol for protein precipitation. Samples were vortex-mixed for 2 min, after 
which 200 µL of MTBE was added to each sample. Samples were vortexed at room 
temperature for 60 min. Following addition of 50 µL water per vial, the samples 
were centrifuged at 3000 r.c.f. for 10 min. This resulted in a clear separation of 
MTBE (upper) and aqueous (lower) phases, with protein precipitate aggregated at 





the LC-MS system in two separate runs, by adjustment of injection needle height 
(15 mm for upper phase, 5 mm for lower).  
2.2.3.2 In-vial extraction (IVE) of urine, CSF and cell nutrient fluid (RPMI)  
Water (50µL) was added to each vial containing urine, CSF or cell nutrient fluid 
spots. Proteins were precipitated with 150 µL methanol and vortex-mixed for 2 
min, followed by centrifugation at 3000 r.c.f. for 10 min. The sample was then 
injected into the LC-MS system directly from the vial. 
 
 
Figure 2-1 In-vial dual extraction (IVDE) of serum spot samples. Top left is a 
Whatman FTA DMPK-C sample card, with each circled area bearing 10-15 µL of 
biofluid. A 6mm (diameter) spot (bottom left) is punched out from the card and 
inserted into a Chromacol vial with a 300 µL glass insert (right). Extraction 
solvents are added in the manner described in the Methods section, and the 
resultant solvent bilayer serves for non-targeted general extraction of polar and 
non-polar analytes. 
 





LC-MS analysis was completed using a Waters ACQUITY UPLC® coupled to a 
Waters Xevo® G1 QTOF (Waters: Milford, USA). Sample extract (5 µL) was 
injected onto a reversed-phase C18 column (Supelco Discovery HS C18, 150 mm × 
2.1 mm i.d., 3 µm particle size). Separation was performed at 25 °C with a flow-
rate of 0.2 mL/min, solvent A composed of 0.1% formic acid in water, and solvent 
B composed of 0.1% formic acid in methanol. Metabolites were eluted using the 
following gradient elution method: from 0% B at 0 min to 100% B in 10 min, 
returning to initial conditions in 1 min and holding for 4 min. Blank extractions 
were inserted in every 10 samples throughout the LC-MS run to avoid any carry-
over effect.  A feature is any m/z signal maximising at an individual retention time. 
Figure 2-2 shows an example of a chromatogram from rat urine that clearly 
illustrates the density of molecular features obtained using this gradient elution 
method. 
MS analysis was completed in separate positive and negative mode experiments. In 
both modes, all analyses were acquired in LockSpray mode to ensure accuracy and 
reproducibility; leucine-enkephalin was used as a lock mass (m/z 556.2771) at a 
concentration of 500 ng/mL and a flow rate of 10 µL/min. Data was collected in the 
centroid mode over the m/z range 100–1000 with an acquisition time of 0.1 seconds 
a scan. In positive ion mode, the XEVO QTOF was operated with a capillary 
voltage of 3.2 kV and a cone voltage of 35 V. The extraction cone was set to 2.0 V. 
The desolvation gas flow was 400 L/hour and maintained at 400 °C. The source 
temperature was 120 °C and cone gas was set to 50 L/hour. In negative ionization 
mode, the XEVO QTOF was operated with a capillary voltage of -2.6 kV and a 





flow was 800 L/hour and maintained at 350 °C. The source temperature was 120 
°C. 
All data was collected using Waters MSe technology, at two constantly 
interchanging energies. This enables data collection at two “levels”. Level one is 
traditional MS raw data with parent molecular ionisation. Level two initiates high 
collision energies within the MS source, which has the effect of causing molecular 
fragmentation, meaning accurate mass fragmentation data can be collected 
simultaneously with accurate mass precursor ion data. In this instance, data was 
acquired at level one with a low collision energy of 5 V, whereas level two 
acquired the data at collision energy of 50 V. 
2.2.5 Data processing and analysis 
All data was processed within the Masslynx application manager 4.1 (Waters: 
Milford, USA), and exported into SIMCA version 13 (MKS Umetrics AB, 
Sweden) for multivariate analysis. Data files collected in MassLynx were imported 
into MarkerLynx (a module within MassLynx) for data pre-treatment, including 
peak alignment and normalization to total peak area (per chromatogram). Processed 
data was subsequently filtered using an in-house algorithm, which allowed the 
selection of normalized features present in > 50% of samples within each biofluid 
group (e.g. within the rat CSF group, within the mouse urine group, etc.). Filtered 
data was then pareto-scaled and subjected to principal component analysis (PCA) 
in SIMCA. Note that data is mean-centered as a matter of course during PCA 
modelling in SIMCA software. Graphical outputs were prepared in SIMCA, as well 





Benton, Want et al. 2010) and VennDiagram (Chen and Boutros 2011) packages in 
R (R-Core-Team 2013).  
2.3 Results and discussion 
The use of dried biofluid spots for the acquisition of semi-quantitative 
metabolomics data is advantageous for a number of reasons. Firstly, there are the 
practical benefits associated with easier storage and safer transport alternatives 
available to spot samples. Secondly, there are important ethical and experimental 
reasons for pursuing the use of viable small-volume sample spot methods. Burnett 
(Burnett 2011) summarises the ethical benefits of spot analysis, which include a 
reduction in the number of animals or participants needed (such as the use of single 
animals for TK studies), as well as method refinement via the use of less invasive 
collection procedures. The latter is possible as 10-20 µL samples can be acquired 
using anticoagulant-coated glass capillaries, which is infeasible for conventionally 
collected 0.3-0.5 mL blood volumes. It is worth noting that the long-term stability 
of components in spots has not been thoroughly investigated, even though spot 
freezing upon acquisition has been recommended for metabolomics 
applications.(Michopoulos, Theodoridis et al. 2011) However, the aforementioned 
practical and ethical advantages associated with spot analysis, when combined with 
the concomitant decrease in man-hours needed for sample collection and 
processing, could lead to broad adoption of the spot methodology in the near 
future. 
Here, we applied the in-vial extraction protocol to the analysis of dried biofluid 





coverage IVDE method yields reproducible results in a validation set of samples, 
with low inter-sample variability.  
 
Figure 2-2 Example base peak intensity ion chromatogram of mouse urine 
extract (positive ionization mode). 
 
2.3.1 Spot-IVDE reproducibility study  
To test the reproducibility of the extraction and analysis protocols when applied to 
the spot samples, 10 spots bearing 10 µL rat serum and 10 spots bearing 10 µL cell 
nutrient medium were studied. Spots that were 6 mm in diameter were punched out 
of the Whatman cards and extracted using either a modification of the previously 
published IVDE method (Whiley, Godzien et al. 2012) (rat serum) or a methanol: 
water extraction solvent (RPMI cell nutrient medium). The combination of aqueous 
and organic phases in the IVDE method permits the extraction of both polar and 
non-polar metabolites without transfer-associated sample loss.  
The 10 replicates from each method were analysed using identical LC-MS 
protocols and fingerprints with > 4000 distinct features per chromatogram were 





six features from each type of extract (i.e. organic and aqueous extracts for serum, 
aqueous extract for RMPI), representing a range of retention times and masses, 
were chosen for the analysis of reproducibility. In order to select peaks for 
reproducibility analysis, the raw data was inspected for m/z-retention time features 
that were present in every sample of the groups in Table 2-1. The raw data was 
then processed using the Waters QuanLynx application’s ApexTrack algorithm, 
which performed mean peak smoothing and baseline correction prior to peak 
detection and integration for selected masses. Output integrated peak areas were 
then used for the analysis of variation within the validation groups. Relative 
standard deviation (RSD) for the peak areas of these metabolites ranged from 1.4-
9.4% RSD for these metabolites, an acceptable level of variation (see Table 2-1). 
Processed data from both positive and negative modes was further parsed using an 
unsupervised multivariate analysis (MVA) principal component analysis (PCA) 
model. A PCA model best explains the variability in the data, and to quantify this 
variability, the distance between the two principal vectors was measured for the 
different types of extract. This vector distance was obtained from the difference 
between the maximum and minimum vector scores for each group of replicates. In 
Figure 2-3, the PCA scores can be observed for the data collected in positive 
ionization mode. The variability within the swarm of replicates for each group 
(calculated as the maximum and minimum vector distance in both PC1 and PC2 
directions) corresponds to the serum ether extracts (averaged RSD of 15.1%), 
followed by aqueous serum extracts (8.1%) and RPMI extracts (5.7%) respectively. 
The PCA analysis shows that the cumulative fingerprint of the ether group was less 
reproducible (i.e. showed more spread) than the other sample extracts. However the 





serum ether extracts was similar to that of the metabolites from the other extracts 
(see Table 2-2). This higher variability in the lipophilic extracts and fingerprint 
could be attributed to increased peak overlapping at the higher organic gradient 
conditions. In our previous work injection of the ether layer was highly 
reproducible for single features, showing 821 with variation RSD < 5 % when 





Table 2-1 Peak area variation for six selected analytes from each extract type 
in the test set. 
(a) serum-upper layer 
M/Z RT Average Peak Area RSD(%) RSD(%) for ratioa 
178.12 5.11 458.79 5.48 3.70 
647.25 5.87 48.69 5.98 - 
491.18 5.92 52.45 3.83 3.36 
205.04 6.18 887.27 9.41 9.97 
674.51 11.93 449.04 6.61 7.26 
765.49 12.23 527.25 6.96 7.78 
(b) serum-lower layer 
M/Z RT Average Peak Area RSD(%) RSD(%) for ratioa 
378.90 1.79 224.35 1.39 3.38 
182.08 5.82 1271.42 3.50 - 
250.04 7.01 117.34 3.59 3.81 
188.07 7.79 6860.07 4.46 1.83 
801.03 9.73 130.01 2.50 3.13 
550.63 12.66 66.56 6.44 6.83 
(c) RPMI1640 
M/Z RT Average Peak Area RSD(%) RSD(%) for ratioa 
242.93 1.75 304.85 4.74 7.20 
497.06 2.05 62.80 3.47 5.31 
188.07 8.04 294.01 3.59 - 
349.18 8.34 30.56 5.92 5.86 
171.10 9.16 1179.99 8.90 8.52 
413.27 14.58 3264.73 5.18 6.89 
     
a calculated ratio = Peak Area of feature/ peak area of bolded features in a, b and c 







Figure 2-3 PCA plot depicting the variation of spots for rat serum (both 
organic and aqueous extracts) and for the aqueous (methanolic) extract of the 
RPMI cell nutrient fluid. 
 
Table 2-2 Variation for each extract type in the test(validation) set as 
calculated from the PCA scores plot, where variation is calculated per group of 
10 replicates as dispersion observed for the two first PC vector scores (t[1] and 
t[2]). 
 (a) serum-upper layer  
(b) serum-lower 
layer  (c) RPMI1640 




2450.87 379.16  -642.67 -2015.97  -2065.26 830.42 
Δ* 504.69 284.91  241.63 160.24  211.39 255.70 
RSD(%) 6.55 23.75  13.60 2.70  2.85 8.55 







Since small changes in metabolite concentrations can indicate important 
abnormalities in metabolic pathways, analytically robust methods for metabolomics 
fingerprinting are essential in order to extract meaningful biomarker data. However 
analytical variation of some magnitude will always be a factor when assessing 
potential markers in metabolic fingerprint data. LC-MS as a tool for quantitative 
analysis can generally show inaccuracies of 10% to 15% RSD, depending on 
factors such as the type of molecule being detected, absolute concentrations, and 
matrix effects (Ellison SLR 2012), and this variability depends upon the 
relationship between these factors and molecular ionization behaviours (e.g. ion 
suppression or enhancement phenomena) (Xu, Ji et al. 2013). In recent studies with 
UHPLC-MS/MS (Fortuna, Ragazzoni et al. 2013), 13% RSD variation was 
accounted for in a conventional drug pharmacokinetic assay in plasma. While a 
small sample analysis where sensitivity is compromised, such as in hair analysis, 
variation of 11.5% was recorded in another validated method.(Roth, Moosmann et 
al. 2013) In addition, the recoveries of tacrolimus from blood spots can have a 
wider 135% allowed bracket in validation studies.(Li, Cao et al. 2013) 
2.3.2 Inter-animal and intra-animal fingerprinting comparison 
As a proof of concept the method described above was applied to spots bearing 
three different biofluids (CSF, urine and serum) from healthy rats and mice. After a 
systematic process of data cut-off and mining which consisted of recording features 
that were present in at least 50% of the group (per biofluid and per animal), a total 





Figure 2-4 illustrates the overlap in molecular features acquired per animal and per 
biofluid in the form of Venn diagrams. Feature selection was performed on data 
processed in the Waters MarkerLynx application, using a mass tolerance of 0.05 
Da and a retention time window of 0.2 min as threshold values for peak detection 
and grouping. There is no carry-over found in blanks and they were excluded prior 
to the feature detection. Features were considered matched if they had the same m/z 
and retention time values after processing, and the Venn Diagrams were produced 
based on these matched features. From Figure 2-4 B, C, E and F, it is evident that 
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Figure 2-4  Venn diagrams depicting the distribution of molecular features 
extracted from rodent biofluids. A total of 1,182 and 2,625 distinct features were 
observed. A, Overlap between features found in mice and rats (positive ionization 
mode). B, Overlap between features found in all three murine biofluids (positive 
mode). C, Overlap between features found in all three rat biofluids (positive mode). 
D, Overlap between features found in mice and rats (negative mode). E, Overlap 
between features found in the three murine biofluids (negative mode). F, Overlap 
between features found in the three rat biofluids (negative mode). Figures were 
prepared using the VennDiagram package (Chen and Boutros 2011) in R (Smith, 
Want et al. 2006, Tautenhahn, Bottcher et al. 2008, Benton, Want et al. 2010). 
 
Numbers of features in serum were decreased when compared to previous work in 





(Whiley, Godzien et al. 2012). It must be noted that the 15 min gradient used for 
spot analysis in this study is much shorter than the 60 min gradient used for the 
previous analysis of plasma by IVDE. This reduction in gradient length is a factor 
worth considering since the number of distinguishable features diminishes greatly 
as the run length decreases. Such a diminishment can mean an inability to detect 
small changes in metabolite profiles, such as those associated with lower dose 
treatments or with changes in low-concentration metabolites. For spots to be a 
viable alternative for metabolomics studies in animal models, extensive additional 
work with validation steps will need to cover all aspects of sample handling, 
shipment, storage, processing (e.g. biofluid temperature and viscosity, punch size, 
etc.) which have not been considered in the experimental procedure presented here. 
However, the presented combination of faster screening methods with low sample 
volumes is likely to be preferred when hundreds or thousands of samples are being 
investigated in a single experimental design. 
2.4 Conclusions 
An analytical method for dried biofluid spot metabolomics was designed and tested 
using samples from rat serum and RPMI cell nutrient medium. 10 µL serum and 10 
µL cell medium spot samples were extracted using in-vial extraction protocols, and 
selected metabolites of varying lipophilicity and mass were chosen for evaluation 
of method reproducibility. Peak area variations for these selected metabolites were 
found to be 1.4-9.4% RSD, an acceptable range for conventional LC-MS 
procedures. When cumulative fingerprints were subjected to standard multivariate 
statistical data treatment, fingerprints from the serum ether extracts had the highest 





nutrient liquid aqueous extracts accounted for 8.1% and 5.7% variation 
respectively. To test the utility of the method in an animal model, the spot-IVDE 
method was used in the analysis of 86 spots of three different biofluids, which were 
obtained from healthy rats and mice. A total of 1182 features were recorded in 
positive ionization mode and 2625 in negative and from those, 610 and 1078 
respectively were found to be shared in mice and rats. Furthermore, a higher 
overlap of molecular features was observed between urine and CSF spots for both 
animals. With this work we have clearly shown that the application of the IVDE 
method to dried biofluid spots results in reproducible metabolic fingerprints, with 
sufficient feature coverage for high-throughput metabolomics experiments. The 
small sample sizes (10-15 µL) required for the spots, and the low transfer losses 
associated with the IVDE method, suggest that the spot-IVDE procedure should be 
widely adopted, in particular for large-scale metabolomic studies.   
Paper spots will be compared with the conventional sampling method and further 
assessed for storage stability in Chapter 4, utilising the analytical and data-
treatment protocol designed in Chapter 3. The protocol will be tailored for high 
resolution and high mass accuracy instruments in order to aid with the 
identification of molecules, and can be applied to the discovery of doping 
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Chapter 3  Development of an analytical and data-








An entire metabolomics experimental workflow includes sample preparation, 
instrumental analysis, data treatment and biological interpretation. Among these, 
instrumental analysis and the following data treatment are considered crucial steps, 
as metabolomics is highly dependent on robust methodology. Various techniques 
can be applied in metabolomics and protocols that give increased metabolic 
information while maintaining the cost of the analysis are preferred. It is beneficial 
for a metabolomics research laboratory to know how to make the best use of the 
analytical instrument and to develop a standard instrumental and data-treatment 
protocol.  
In sample analysis, liquid chromatography (LC) combined with mass spectrometry 
(MS) is  the most used instrument for metabolomics showing high metabolic 
coverage (Want, Wilson et al. 2010). High mass resolution is particularly important 
for all types of experiments involving complex mixtures (e.g. biological, 
environmental, food), since these contain a significant number of background 
(matrix) ions in addition to the possible analytes of interest. Metabolomics usually 
focuses on such complex samples, thus, high-resolution accurate-mass (HRAM) 
mass spectrometry is more and more preferred in metabolomics field due to its 
capacities of analysis of unknowns, confirmation of analyte structure, retrospective 
search for new compounds and addressing sensitivity requirements. 
However, a challenge associated with metabolomics, as well as other “omics” 
studies is that huge and complex datasets are generated and those need to be 





combination format of chromatogram and spectrum, and data pre-processing need 
to be first applied to reduce the dimension of the data to 2-D format (Figure 3-1). 
Markerlynx is a software provided by Waters Corporation and specifically 
processes the fingerprinting data from Waters Quadrupole Time-of-flight Mass 
Spectrometry (QTOF-MS). Our laboratory has previously developed a 
metabolomics workflow using Markerlynx (Whiley, Sen et al. 2014), and Chapter 2 
was based on the established data pre-processing procedures. However, Markerlynx 
works only for Waters instruments and processes relatively small data sets (e.g. up 
to 200 samples), thus new data pre-processing techniques are urgently needed. 
XCMS has emerged as a powerful metabolomics data processing method. It is 
available from the free-access programming software R, and highly adaptable to 
almost all types of LC-MS and GC-MS data sets with the help of format 
conversion tools (Smith, Want et al. 2006, Tautenhahn, Bottcher et al. 2008).  
Even after pre-processing, datasets still comprise large number of metabolic 
features (1K-40K) that are difficult to summarize and visualize. Multivariate 
analysis is usually employed for the analysis and modelling of complex data. 
Models can be non-supervised chemometrics method, e.g. principal component 
analysis (PCA), where outliers and overall data distribution will be assessed, or 
supervised, such as partial least-squares (PLS), partial least-squares discriminate 
analysis (PLS-DA) and orthogonal partial least-squares discriminate analysis 
(OPLS-DA), where grouping of samples is possible to select their descriptive 






Figure 3-1 Schematic diagram of dimension reduction of LC-MS profiling 
through data pre-processing. A, visualized combination of LC-MS 
chromatogram and spectrum. B, an example output table after data pre-processing. 
At each retention time there are various ions detected. Data pre-processing will 
give an output of peak area (or intensity) of distinct features with different Mass-to-
Charge Ratio (m/z) and retention time (RT) in each sample. 
 
The aim of this chapter is to give an optimised methodology to best practice the 
general hypothesis of this thesis, by developing a metabolomic protocol for the 
laboratory using UHPLC-HRMS (Q-ExactiveTM Orbitrap-MS). Firstly the 
analysis conditions will be optimized and various resolutions will be tested for 
metabolic profiling. The addition of quality control samples can aid the accuracy 





namely, data pre-processing in XCMS, normalization and multivariate analysis in 
SIMCA. The ability of dealing with complex large matrix and stability of this 
protocol will then be tested by profiling 101 urine and QC samples. This workflow 
developed for UHPLC-Q-ExactiveTM Orbitrap-MS is shown in Figure 3-2: 
 
Figure 3-2 General steps of proposed metabolomics data treatment workflow 









3.2.1 Chemicals and materials 
All solvents used were HPLC grade. Acetonitrile and methanol were obtained from 
Fisher Scientific (Loughborough, UK). Formic acid (99–100 %) was purchased 
from VWR (Leicestershire, UK). Ultrapure water (18 MΩ · cm) was obtained from 
an ultra-pure water system (Elga, UK).  
3.2.2 Urine samples  
The samples from anti-doping tests were acquired after professional sport 
competition and came from diverse demographics at random times of the day. A 
total of 91 urine samples were obtained from 91 different athletes, who had 
indicated their consent for research on their samples. For resolution suitability test, 
two experiments were carried out: 1) One single salbutamol detectable sample 
(DET) was used and repeated injection for 3 times in different resolutions. 2) Three 
DET samples and two salbutamol non-detectable samples (NON-DET) were 
randomly chosen and analysed under different resolutions in MS. A pooled sample 
from 20 urine samples was used as a quality control (QC). For intra-batch 
reproducibility test, all the 91 samples were injected into LC-MS and quality 
controls (QC) were inserted after every 10 samples throughout the whole run. The 
specific gravity was measured by a calibrated DM40 densitometer (Mettler-Toledo 
International, Switzerland).  All urine samples were aliquoted and stored in 
polypropylene tubes at -20 °C for at least three months and anonymized prior to 





3.2.3 Sample preparation 
 All the urine samples were centrifuged at 6,000 r.c.f for 15 minutes to remove any 
particles. An aliquot of 50 µL of supernatant was diluted with 200 µL ultrapure 
water. The solution obtained was pipetted into amber HPLC vials with inserts. 
Then a volume of 10 µL sample in each vial was injected into LC-MS system.  
3.2.4 UHPLC–HRMS analysis 
 For chromatographic separation, a Dionex™ Ultimate® 3000 UHPLC system 
(Dionex™, Sunnyvale, USA) was used. Separation was carried out on a reversed-
phase C18 column (Supelco Discovery HS C18, 150 mm × 2.1 mm i.d., 3 µm 
particle size). The column was thermostatted at 25 °C and a flow-rate of 
0.2 mL/min was used. Solvent A was composed of 0.3 % formic acid in water, and 
solvent B composed of 0.3 % formic acid in acetonitrile. Metabolites were eluted 
using the following gradient elution method: from 0 % B at 0 min to 100 % B in 10 
min, returning to initial conditions in 0.5 min and held for 2 min.  
Detection was performed by means of a Q-ExactiveTM Quadrupole-Orbitrap mass 
spectrometer (Thermo Fisher Scientific, San Jose, USA) equipped with a heated 
electrospray (HESI-II) ion source, operated in polarity switching mode. The 
instrument was calibrated before each batch of samples. Source conditions were as 
follows: sheath gas flow rate, auxiliary gas flow rate and sweep gas flow rate: 70, 
10 and 0 arbitrary units respectively; capillary temperature: 320 °C; heater 
temperature: 350 °C; spray voltage: +3.75 kV (positive ionization mode) and 
−3.00 kV (negative ionization mode); lock mass: off. Nitrogen was used as both the 





of 17,500, 35,000, 70,000 and 140,000 FWHM at m/z 200. Each acquisition cycle 
included a full-scan acquisition in positive ionization mode and a full-scan 
acquisition in negative ionization mode (polarity switching mode). The AGC target 
was set to 1e6 and the scan range was m/z 100–1000 for all acquisition events.  
3.2.5 Data processing and analysis 
All raw data were collected using Thermo Xcalibur software, before being 
processed within XCMS in R and XCMS online (https://xcmsonline.scripps.edu) 
and exported into SIMCA version 13 (MKS Umetrics AB, Sweden) for 
multivariate analysis. Data files (.RAW) collected in Xcalibur were converted by 
Proteomic Wizard (http://proteowizard.sourceforge.net/) to .mzXML format, before 
importing into freely available XCMS package in R and XCMS online. For peak 
picking the following parameters were used: method = 'centWave', ppm = 4, 
peakwidth = c (6, 30), prefilter = c (10, 5000). For peak grouping, bw = 5, mzwid = 
0.05 were used. After peak alignment to allow minor retention time variation and 
filling missing peaks, an output table of time-aligned detected features was 
exported with their retention time, m/z ratio, and intensity in each sample. A feature 
is any m/z signal maximizing at a specific retention time. The resulting tables were 
readily exported to Microsoft Excel and feature numbers were obtained in the 
Excel output tables. Then the data collected were normalized by the specific 
gravity (SG) of each sample and ready for multivariate analysis. Levine-Fahy 
equation was used for SG-normalization: 
Concentration SG normalized = Concentration specimen • (SG reference - 1)/ (SG 





SG reference is a population reference value for specific gravity representing 
“normal” or “non-diluted urine” and SG specimen is the specific gravity of the test 
urine specimen. The SG reference utilized in all corrections was 1.0200 (WADA 
2014). 
3.2.6 Statistical analysis and data interpretation 
The data from both positive and negative ionization mode were then normalized by 
the specific gravity of each sample, before importing into SIMCA (UMetrics, 
Umeå, Sweden), where they were subjected to multivariate data modelling, 
including pareto-scaled principal component analysis (PCA). The cloud plots were 
prepared in XCMS online. For intra-batch reproducibility test, QCs were inspected 
for clustering in PCA and a technical variation smaller than 15% of total inter-
sample variation (calculated as the maximum and minimum vector distance in both 
t[1] and t[2] directions) was deemed acceptable for metabolomics data. 
3.3 Results and discussion 
3.3.1 HRMS resolution selection 
Resolution selection is a crucial step for untargeted metabolomics analysis. High-
Resolution Mass Spectrometry (HRMS) provides accurate mass measurement, for 
Q-Exactive the resolution can go up to 140,000 FWHM (at m/z 200), with a mass 
accuracy < 1ppm with internal calibration. However  as the resolution increases, 
the scan speed drops, leading to reduced sensitivity. While the maximum scan 
speed can reach 12 Hz at the resolution setting of 17,500 in single polarity and full 





less than 1/10 of that amount. Studies using Orbitrap instruments to analyse 
complex matrix have chosen different resolution settings: Vanhaecke et al. used 
Fourier Transform (FT) Orbitrap MS at 50,000 FWHM for full MS scan in search 
for growth-promoting agents in meat (Vanhaecke, Van Meulebroek et al. 2013).  
Xu et al. used three Orbitrap MS instruments for targeting of 137 chemical 
compounds: 30,000 FWHM for the LTQ-Orbitrap Discovery and 100,000 FWHM 
for the LTQ-Orbitrap XL and the Exactive, which is the top resolution both 
instruments can reach (Xu, Heilier et al. 2010). Raro et al. used Q-Exactive 
Orbitrap MS at 35,000 FWHM to do untargeted metabolomics, however there was 
no reasons provided for choosing that specific resolution (Raro, Ibanez et al. 2015). 
Thomas et al. acquired full scan data at 70,000 FWHM in polarity switching mode 
for doping control (Thomas, Geyer et al. 2012). 
Polarity switching mode is a practical feature of the Q-Exactive, which is a positive 
and negative ionization scan-to-scan alternating mode, and both spectra can be 
obtained in one injection. Thanks to this feature the analysis time will be cut into 
half and it is especially helpful when sample volume is limited, which is ideal for 
large-scale metabolomics analysis. However operating in polarity switching mode 
will also reduce the scan speed to half. In order to determine the best resolution for 
untargeted metabolomics and to build a standard protocol for our laboratory, 
different resolutions of 140,000, 70,000, 35,000, and 17,500 FWHM in polarity 
switching mode were tested on a urine sample and a pilot study was performed on 
5 urine samples in resolutions of 140,000, 70,000 and 17,500 FWHM. The TIC 
chromatograms in Figure 3-3 illustrated the good reproducibility of the 





observed. Figure 3-4 demonstrated the selectivity of the 4 different resolutions. It 
can be observed that an increased mass resolution is associated with a higher mass 






Figure 3-3 TIC of 4 different resolutions of 17,500, 35,000, 70,000 and 140,000 FWHM. There were 3 repeated injections in 







Figure 3-4 Combined mass spectrum during 4.04-4.27 min from m/z range 240.0550 to 240.1850 at 4 different resolutions of 





However the higher resolution is achieved by longer scan time, and in order to 
optimize the mass spectrometric resolution for metabolomics, a compromise between 
selectivity and sensitivity has to be made (Vanhaecke, Van Meulebroek et al. 2013). 
Figure 3-5 showed the MS spectra of a single molecule, salbutamol, in stick view at 
different MS resolutions. There were approximately 10, 12, 14 and 14 scans for 
salbutamol over the 0.2-min retention time range at the resolutions of 140,000, 70,000, 
35,000 and 17,500 FWHM, respectively. The calculated corresponding scan rates were 
0.62, 0.87, 1.06 and 1.11 Hz. For qualitative analysis, a peak composed of more than 3 
scans can be considered valid; however for quantification usually at least 12-15 scans 
points per peak are needed. In untargeted metabolomics, semi-quantification is 
normally used and strict quantitation rules are not applied; however the discovery of 
potential biomarkers relies on the relative concentrations of metabolites in different 
groups. With fewer scans the accuracy of quantification will drop and furthermore, the 
slow scan speed could miss some low intensity features that quickly pass the detector. 
For this work, HRMS was the instrument of choice for our metabolomics study 
because of the advantages of high mass accuracy, which is essential for identification 
in untargeted metabolomics. Considering the balance between the selectivity and 
sensitivity, from this stage, the resolution of 70,000 was considered to be a plausible 








Figure 3-5 MS spectra of salbutamol (in stick view, m/z = 240.1594) at different 
resolutions of 140,000, 70,000, 35,000 and 17,500 FWHM. There were 
approximately 10, 12, 14 and 14 scans for salbutamol over the 0.2-min retention time 
range at the resolutions of 140,000, 70,000, 35,000 and 17,500 FWHM, respectively. 
The calculated corresponding scan rates were 0.62, 0.87, 1.06 and 1.11 Hz. 
  
In the following sections, the data treatment stages would determine if the resolution 
of 70,000 could provide the amount of information needed for metabolomics. 
One possible drawback when comparing this new protocol with the laboratory’s 
established metabolomics protocol was that previous research in our group using 





However, in this study we found that adding fragmentation would further reduce the 
scan speed. Thus it was proposed that full mass scan would be used and then 
fragmentation mode could be run on selected samples. Hence after data analysis, 
selected features can be fragmented and compared with the pure standards when 
possible. 
3.3.2 Data pre-processing 
Before statistical analysis, the raw data obtained from LC-MS need to be subjected to 
pre-processing to change from 3-D format to 2-D matrix (Figure 3-1). This process 
includes data format converting and XCMS pre-processing. XCMS can only recognise 
several data formats for processing, such as .CDF, .NetCDF, and .mzXML etc, which 
are not the raw data format obtained from LC-MS instruments, so an additional 
conversion is needed.  Whilst the raw data generated from Waters Masslynx (.raw) can 
be converted into .NetCDF format using the Databridge package in Masslynx, the raw 
files from Thermo Xcalibur (.RAW) can be converted by Proteomic Wizard 
into .mzXML format.   
The converted data then can be processed in XCMS in R or XCMS Online. XCMS is a 
powerful untargeted metabolomics processing tool and it is operated in programming 
software R. XCMS Online is an alternative: it is a web-based version of XCMS 
software that allows users to easily upload and process data without bioinformatic 
and/or software programming expertise. LC/GC-MS data, and results can be browsed 
in an interactive, customizable window online showing statistics, chromatograms, and 





major drawback of XCMS Online is the time-consuming data uploading, which was 
not ideal for our research laboratory. In addition, it is also lack of normalization, 
transformation and scaling steps. Therefore, it was suggested that data pre-processing 
in XCMS in R would be more practical, followed by normalization in Microsoft Excel, 
before importing into statistical software such as SIMCA, SPSS or packages in R. This 
protocol shows multivariate analysis utilising SIMCA which is more user-friendly, to 
do data transformation, scaling and multivariate analysis. 
Several peak-picking, grouping and alignment parameters in XCMS were chosen and 
tested according to the instrument capacity and settings, raw chromatograms and MS 
spectrum. Finally, the parameters were set as follows: for peak picking, 
method='centWave', ppm=4, peakwidth=c (6, 30), prefilter=c (10, 5000) were used; 
for peak grouping, bw = 5, mzwid = 0.05 were used; for peak alignment, “obiwarp” 
method was used to correct minor retention time variation. Matrices with time-aligned 
detected features were exported with their retention time, m/z and peak area in each 
sample. There were 1,946, 3,315 and 1,337 features detected in the resolutions of 
140,000, 70,000 and 17,500 FWHM respectively across the 5 test samples, which 
indicated that the largest amount of information was obtained from 70,000 FWHM. 
3.3.3 Normalization method 
Since metabolite concentrations across urine samples can vary more than 15 times due 
to variable water content (Warrack, Hnatyshyn et al. 2009), a good normalization 
method is needed. Some authors use creatinine as the normalization standard (Zheng, 





since creatinine levels may be affected by protein and creatine intake, as well as 
catabolic state of the athlete. Other methods such as using internal standard, total peak 
area, quantile and median-fold change were also described (Kultima, Nilsson et al. 
2009, Veselkov, Vingara et al. 2011, Dai, Yin et al. 2014). In doping control, specific 
gravity is the standard normalization method recommended by World Anti-Doping 
Agency (WADA) (WADA 2014), hence specific gravity was applied as the 
normalization method for this urine metabolomic study.  
3.3.4 Multivariate analysis 
The cloud plots (Figure 3-6, A-C) visually showed the discriminant features 
separating the DET and NON-DET groups, with p-value ≤ 0.01 and fold change ≥ 1.5 
in 3 different resolutions. It is observed that there were 96 distinct features in the 
resolution of 70,000 with p-value ≤ 0.01 and fold change ≥ 1.5, more than the number 
of 77 in the resolution of 140,000 and 20 in the resolution of 17,500, which further 
indicated the potential of finding more candidate biomarkers in the resolution of 
70,000.  
According to the results showed and discussed above, resolution 70,000 was initially 
chosen for our metabolomic study. To further prove its feasibility, the matrix generated 
from XCMS in the resolution of 70,000 were imported into SIMCA and subjected to 
multivariate analysis. The PCA score plot (Figure3-6, D) showed the clear separation 







Figure 3-6 Multivariate analysis showing in cloud plots and PCA score plot. A-C, 
cloud plots of the data from the resolutions of 140000, 70000 and 17500 FWHM, 
respectively. Green: up-regulated (intensity increased in DET samples) features. Red: 
down-regulated (intensity decreased in DET samples) features. p-value is represented 
by color intensity (more intense means lower p-value). Fold change is represented by 
the radius of each feature. Retention time is represented by position on the x-axis. 
Mass-to-Charge Ratio (m/z) is represented by position on y-axis. D, PCA score plot of 
2 NON-DET (yellow) and 3 DET (blue) samples in the resolution of 70,000. 
 
3.3.5 Reproducibility test on the proposed protocol 
To assess the feasibility of the protocol with a bigger number of samples and QC 
samples, 91 urine samples and 10 QCs were analysed using the proposed protocol with 
the chosen experimental and data processing parameters. Multivariate analysis results 





of observations and their relationships. The “pooled” quality control (QC) urine 
samples were used to provide a representative mean sample that should be identical or 
very similar. The QCs clustered together in the PCA score plot, with the distribution 
measured as 4.4% and 11.9% (at t[1] and t[2] directions, respectively) of the entire 
sample cohort distribution. Considering the large number of variables in these data (ca. 
3,000), the quality of the data corresponding to the method applied was deemed 
acceptable.  
 
Figure 3-7 PCA score plot of 101 urine samples. Red circles signifies a repeat 
extraction of a urine pool used as a quality control (QC) (n = 10). The QCs cluster in 







This study developed a protocol for UHPLC-Q-ExactiveTM Orbitrap-MS based on 
non-targeted metabolomics, including instrument resolution optimization and a data 
mining workflow. Resolutions of 140,000, 70,000, 35,000 and 17,500 FWHM were 
tested. Two groups (DET and NON-DET) were created according to whether or not 
containing salbutamol and analysed in the resolutions of 140,000, 70,000 and 17,500 
FWHM. For data processing, parameters tailored to high resolution Orbitrap-MS data 
in XCMS were chosen and specific gravity was used as the normalization method. 
The result showed that fingerprinting using this protocol measured more than 3K 
features in urine at the resolution of 70,000, giving more features compared to the 
other two resolutions. Multivariate analysis also revealed that the largest quantity of 
discriminant features (96) was obtained at the resolution of 70,000. Therefore 70,000 
was initially chosen as the MS resolution in our protocol and PCA plot showed a clear 
separation of DET and NON-DET using this protocol.  
The protocol was then applied to 91 urine samples and 10 QCs. Multivariate PCA 
analysis showed overall analytical stability of the protocol across 101 samples, with 
the distribution of QC samples taking 4.4 % and 11.9 % of the entire sample cohort 
range at t[1] and t[2], respectively. It is ready for further analysis of data interpretation, 
including OPLS-DA and S-plot to find the discriminant features, feature annotation 





In the next chapter, this protocol will be combined with the previously developed spots 
IVE method in Chapter 2, and to compare it with the conventional sampling method as 
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Chapter 4  Evaluation of dried urine spots using 
salbutamol as a model non-endogenous metabolite —  
a metabolomic approach 
 







Chapter 2 demonstrated the potential of in-vial extraction (IVE) of dried biofluid spots 
as a viable alternative to the use of small volumes of neat biofluids in animal 
metabolomics studies. In this chapter, IVE of dried urine spot will be further evaluated 
utilizing the analytical and data-mining protocols developed in Chapter 3.  
DBS represent an attractive option for global metabolomics studies as stated in 
Chapter 1, due to the potential advantages such as using smaller sample volumes, ease 
of collection, simplified transportation and storage requirements and cheaper overall 
costs. 
Urine is regarded as an ideal biofluid in metabolomics studies, as it captures and 
concentrates a wide range of metabolites and dynamic processes occurring throughout 
the body (Emwas, Luchinat et al. 2015). Urine generally is prone to changes induced 
by genetic and environmental challenges reflecting cells and enzyme activity (Walsh, 
Brennan et al. 2006, Walsh, Brennan et al. 2007, Fardet, Llorach et al. 2008, Scalbert, 
Brennan et al. 2009). Compared with plasma and cerebrospinal fluid, urine is non-
invasive to collect and requires less sample pre-treatment as the matrix contains 
relatively low protein levels.  
Sample preparation is considered a limiting step in metabolomics as ideally samples 
should be kept in their original physiological state.  In urine metabolomics, the 
preferred preparation method is dilution and direct injection of urine into an LC-MS 





2010). However, as the inherent complexity of urine containing abundant metabolites 
with distinct chemical characters and a high dynamic range, sample preparation is a 
vital step to ensure reproducible, accurate and reliable results in any metabolomics 
study. More recently, dried paper spots represent a potential sampling method (Deglon, 
Thomas et al. 2012), which as mentioned previously have many apparent advantages 
over conventional methods such as small volume of samples (typically less than 15 
µL), easy sample storage and transport. Paper spots can also lack reproducibility and 
coverage, but it has been demonstrated in Chapter 2 that the potential of in-vial 
extraction (IVE) of dried biofluid spots as a viable alternative to the use of small 
(10−15 µL) volumes of neat biofluids in animal studies to generate reproducible 
metabolic “fingerprints”, with sufficient feature coverage for high-throughput 
metabolomics experiments (Sen, Wang et al. 2013). 
The feasibility of IVE dried urine paper spots compared to conventional urine liquid 
method has not been reported, neither has the comparison conducted in a 
metabolomics doping test application. Thus one of the aims of this study is to evaluate 
these two sampling procedures mainly by using untargeted metabolomics, to 
investigate the IVE paper-spot method in terms of precision and whether or not it leads 
to information loss.  
Several studies have demonstrated the stability of dried biofuid spots during short and 
long term sampling. Kong et al. showed that 10 metabolites randomly selected across 
the analysis appeared to be stable in dried blood spots (DBS) for up to 48 h at both -20 





plasma and found increased concentrations of long-chain acylcarnitines and a decrease 
of arginine concentrations in DBS at room temperature or 5 °C, however, storage at -
80°C for 3 months revealed no significant change (Brauer, Leichtle et al. 2011). 
Mitropoulos et.al suggested that long-term DBS sample stability is limited unless the 
cards are stored at, at least, -20 °C and preferably at -80 °C (Michopoulos, Theodoridis 
et al. 2011). Regarding IVE paper-spot method reproducibility, whilst the intra-batch 
reproducibly of IVE paper-spot was assessed in Chapter 2, the inter-batch storage 
stability during one week will be evaluated in this study. 
In the present chapter, high-resolution UHPLC-Q-ExactiveTM Orbitrap-MS analysis 
was performed to investigate 61 urine samples from sports which were prepared by a 
conventional method and IVE dried paper-spot method. Salbutamol, a prohibited 
substance in sports (when in excess of 1000 ng/mL in urine) was used as a model drug 
for the evaluation of dried urine spots. Then the paper spots stability after a one-week 
freeze-thaw cycle was assessed. Univariate and multivariate statistics were 
implemented to interpret the data output obtained from the UHPLC-MS. The workflow 
of this study is shown in Figure 4-1.  
The aims of this chapter are: 1) To compare of paper-spot method with conventional 
liquid urine sampling method; 2) To appraise the paper-spot method for metabolomics 
discrimination of salbutamol “users” and “non-users”; 3) To evaluate the short-term 







Figure 4-1 Metabolomics strategy workflow of this chapter. Firstly the comparison 
was conducted between conventional and paper-spot methods, the data analysis 
focused on three areas of interest: 1) Data quality test using internal standard (IS); 2) 
Feature number comparison after peak picking and alignment; 3) multivariate analysis 
after normalization. Secondly, 30 samples from the paper-spot method were randomly 
chosen and stored in -80°C for one week and were defrosted. Data acquired before and 
after the freeze-thaw cycle (F/T) (Batch 1 and Batch 2 respectively) were compared 







4.2.1 Chemicals and materials 
All solvents used were HPLC grade. Acetonitrile and methanol were obtained from 
Fisher Scientific (Loughborough, UK). Formic acid (99–100 %) was purchased from 
VWR (Leicestershire, UK). Ultrapure water (18 MΩ · cm) was obtained from an ultra-
pure water system (Elga, UK).  
4.2.2 Urine samples  
The samples from antidoping tests were acquired after professional sport competition 
and came from diverse demographics at random times of the day. A total of 61 urine 
samples were obtained from 61 different athletes, who had indicated their consent for 
research on their samples, with 30 salbutamol detectable samples (DET, 10 -
1000 ng/mL, 19 males and 11 females) and 31 salbutamol non-detectable samples 
(NON-DET, less than 10 ng/mL, 20 males and 11 females). The numbers of samples 
for endurance sports were matched in both DET and NON-DET groups. The specific 
gravity was measured by a calibrated DM40 densitometer (Mettler-Toledo 
International, Switzerland).  All urine samples were aliquoted and stored in 
polypropylene tubes at -20 °C for at least three months and anonymised prior to 
analysis to comply with the ethical requirements of the World Anti-Doping Agency 
(WADA). 





A pooled sample from 20 urine samples with an equal number of DET and NON-DET 
was used as a quality control (QC).  
In the conventional method, all the urine samples were centrifuged at 6,000 r.c.f for 15 
minutes to remove any particles. An aliquot of 50 µL of supernatant was diluted with 
200 µL ultrapure water previously spiked with internal standard (IS) containing D3-
salbutamol at 500 ng/mL. The solution obtained was pipetted into amber HPLC vials 
with inserts.  
In the paper-spot method, an aliquot of 2µL urine sample was spotted on each sample 
paper card (WhatmanTM protein saver 903) resulting in the diameter of the urine spot 
less than 6 mm, and dried in ambient temperature for half an hour. These procedures 
were then repeated 4 times. A total volume of 10 µL urine was spotted on the same 
position of each paper. Spots with a diameter of 6 mm were punched out of the paper 
cards and introduced into amber HPLC vials. A volume of 50 µL 50 % methanol in 
ultrapure water containing 500 ng/mL IS was added to each vial containing the urine 
spots. All the vials were vortexed for 10 minutes before being centrifuged at 6,000 
r.c.f. for 15 minutes. Then a volume of 10 µL sample in each vial was injected into the 
LC-MS system. All the samples were randomized and QCs were inserted after every 9 
samples throughout the whole run. 
4.2.4 Inter-batch stability 
To make a Batch 2, 30 paper-spot samples (15 DET and 15 NON-DET) and 7 QCs 





sample vials were then defrosted and analysed using the same conditions stated in 
section 4.2.3. 
4.2.5 UHPLC–HRMS analysis 
For a detailed description of chromatographic separation, refer to section 3.2.4. 
Detection was performed by means of a Q-ExactiveTM Quadrupole-Orbitrap mass 
spectrometer (Thermo Fisher Scientific, San Jose, USA) equipped with a heated 
electrospray (HESI-II) ion source, operated in polarity switching mode. The instrument 
was calibrated before each batch of samples. Source conditions were as follows: sheath 
gas flow rate, auxiliary gas flow rate and sweep gas flow rate: 70, 10 and 0 arbitrary 
units respectively; capillary temperature: 320 °C; heater temperature: 350 °C; spray 
voltage: +3.75 kV (positive ionisation mode) and −3.00 kV (negative ionisation 
mode); lock mass: off. Nitrogen was used as both the source and the collision (HCD) 
gas. Data acquisition was performed at 70,000 resolution (FWHM). Each acquisition 
cycle included a full-scan acquisition in positive ionisation mode and a full-scan 
acquisition in negative ionisation mode. The AGC target was set to 1e6 and the scan 
range was m/z 100–1000 for all acquisition events. The resulting scan rate was 1.2 s. 
4.2.6 Data processing and analysis 
All raw data were collected using Thermo Xcalibur software. Internal standard (IS) 
peak area of each sample was calculated to process data quality test. Then relative 





All data were processed within XCMS in R and exported into SIMCA version 14 
(MKS Umetrics AB, Sweden) for multivariate analysis. Data files (.RAW) collected in 
Xcalibur were converted by Proteomic Wizard to .MZXML format, before importing 
into freely available XCMS software. For a detailed description of XCMS settings, 
refer to section 3.2.5. The resulting tables were readily exported to Microsoft Excel 
and feature numbers of both methods were obtained. Then the data collected from both 
positive and negative ionisation modes were normalized by the specific gravity (SG) 
of each sample prior to multivariate analysis. For a detailed description of calculation 
of normalization, refer to section 3.2.5. 
The data from both positive and negative ionisation mode were then normalized by the 
specific gravity of each sample, before importing into SIMCA 14, where it was 
subjected to multivariate data modelling, including pareto-scaled principal component 
analysis (PCA) and log-transformed orthogonal partial least-squares discriminant 
analysis (OPLS-DA) with corresponding S-plot analysis. Graphical outputs were 
prepared in SIMCA.  
 
4.3 Results and discussion 





4.3.1.1 Overview of the chromatograms 
As can be seen from the positive Base Peak Intensity (BPI) chromatogram of urine 
shown in Figure 4-2, the largest base peak intensity was reduced approximately by 30 
% from conventional method to paper-spot method, and more significant reductions 






Figure 4-2 Representative BPI chromatograms in positive ionisation mode. The 
chromatograms were normalized to the largest peaks and y-axis is relative abundance 
level. A, conventional sample; B, dried urine spots. NL, normalized level, represents 







For negative mode, around 20 % reduction of the intensity of the largest peak is 
observed after spotting, and more noticeable decreases are observed at time points 
such as 1.96, 2.91, and 6.14 min, etc. (Figure 4-3).  
 
 
Figure 4-3 Representative BPI chromatograms in negative ionisation mode. The 
chromatograms were normalized to the largest peaks and y-axis is relative abundance 
level.  A, conventional sample; B, dried urine spot. NL, normalized level, represents 






4.3.1.2 Comparison of feature numbers 
Pre-processing steps were applied in parallel to both sampling methods (N=61 in each 
method) and the features pertaining to each were extracted. The following table shows 
the total numbers for comparison (Table 4-1): 
Table 4-1 Number of features generated in R: XCMS of two methods in two 
ionisation modes (N = 61 in each method) 
 Conventional method Paper-spot method 
Negative mode 2,205 2,054 
Positive mode 2,758 2,262 
 
The data were processed in R: XCMS and a total of 4,963 and 4,316 features acquired 
in the conventional and paper-spot methods were extracted, respectively. It can be 
observed in Table 4-1 that the positive ionisation mode yielded more features 
compared to the negative ionisation mode, and the conventional method generated 
more features than the paper-spot method. The procedure of spotting urine samples on 
a paper and extraction before injecting into MS could have led to feature intensity 
reduction and even loss. In the sample-spotting step, some metabolites with lower 
boiling points could evaporate and, in the extraction step, some metabolites might stick 
on the sampling paper.  
After spotting, there was a 7 % feature number reduction for the negative ionisation 
mode, compared to the 18 % reduction in positive mode, and this is consistent with the 





Michopoulos et al. showed a significant reduction in feature number for spotted 
samples in negative ionisation mode, with only 30 % of the features from liquid 
samples were detected in the spotted samples (Michopoulos, Theodoridis et al. 2010). 
These contradict results were not surprising, probably being caused by: 1) The 
different sample preparation and extraction methods:  in this study IVE method was 
used on the entire sample spot to preserve the metabolites; while in their study, 
multiple sample cores were extracted using 20 % aqueous methanol, and the extraction 
supernatants were evaporated in 40 °C and resuspended, which could probably cause 
loss of volatile metabolites;  2) Different detector: in our method, a Q-ExactiveTM 
Quadrupole-Orbitrap mass spectrometer was used, while their experiments were 
conducted using Q-TOF Micro mass spectrometer. The different resolution and 
sensitivity of the instrument could possibly lead to different feature numbers as in 
paper-spot method some ion intensity could dramatically be reduced. 3) Other 
experimental differences may also account for the different outcomes, such as column, 
UHPLC instrument and method, data pre-processing method, etc. 
4.3.1.3 Data quality test 
Data quality test was carried out to assess the variance caused by sample handling and 
analytical instruments, via the descriptive statistics of the IS peak areas in the raw data 






Table 4-2 Descriptive parameters calculated from the peak areas of IS in the two 
methods (N = 61 in each method) 
 Conventional method peak area 
Paper-spot method 
peak area 
MEAN 2.23e9 2.71 e9 
SD 5.14 e8 4.79 e8 
% RSD 23.0 17.7 
 
It can be observed from Table 4-2 that the paper-spot method showed higher precision 
in the quality test as the RSD of the IS in paper-spot method was lower than that in the 
conventional method. Peak signal stability is influenced by factors such as the type of 
molecule being detected, absolute concentrations, matrix effects (Ellison and Williams 
2012) and systematic errors introduced during the analysis, and the lower RSD in the 
paper spots might have resulted from the paper-spot samples being cleaner, since some 
molecules that affect analysis, such as remaining proteins might have stayed on the 
paper. The features that could cause the higher bias (e.g. volatile, unstable analytes) 
were not studied in this analysis, salbutamol is a relatively easy molecule to analyse, 
and its behavior cannot be extrapolated to other metabolites.  
If we compare these data with FDA quantitation standards (FDA 2013) the RSD 
should be lower than 15 % so at the moment neither sampling method would pass the 
criteria for quantification. When sample volume is limited or near LOD (limit of 
detection) the criteria can be extended to 20 % variation, considering that our samples 
were only 10 µL with no pre-concentration and clean-up step. In a metabolomic study, 








Figure 4-4 PCA score scatter plots of conventional method (A) and paper-spot 
method (B). Data were from positive ionisation mode. 
 
Multivariate analysis results are shown in Figure 4-4, 4-5 and 4-6. PCA score plot is 
an overview of the entire multivariate data showing observations and their 
relationships. The “pooled” quality control (QC) urine samples were used to provide a 
representative mean sample. By detecting the distribution of QC samples in PCA plots, 
the quality of the data corresponding to the metabolomics method applied can be 
assessed. PCA plots of both conventional and paper-spot methods (Figure 4-4) show 
that the QC groups cluster together, which indicate good overall data reproducibilities 





OPLS-DA was performed to distinguish two classes of interest among 30 DET and 31 
NON-DET samples. After log-transformation, removal of outliers and excluding 
variables with VIP (variable importance for the projection) value <1, final OPLS-DA 
models were rebuilt (Figure 4-5). Both OPLS-DA modelling can demonstrate DET 
isolation from NON-DET.  
 
Figure 4-5 OPLS-DA score plots depicting the discrimination of DET and NON-
DET samples. A, conventional method; B, paper-spot method. Blue, DET; Purple, 





Figure 4-5 B is a plot of OPLS-DA modelling of all urine samples in the paper-spot 
method, as analysed by UHPLC-Q-Exactive MS in the positive ionisation mode. The 
R2X, R2Y, Q2 and CV-ANOVA values of each model are shown in Table 4-3.  The 
algorithm was able to clearly discriminate the urine samples into 2 groups 
corresponding to DET and non-DET samples in the paper-spot method showing a CV-
ANOVA p-value = 2E-4. It also shows a clear separation and a significant model when 
such analysis was performed in the conventional method (Figure 4-5 A, Table 4-3), 
although not as discriminating as in paper-spot method. The paper-spot method model 
explains more of x-variables (R2X = 0.483) and have a better model fit (R2Y = 0.697) 
and prediction (Q2 = 0.385) than the conventional method, which might have resulted 
from the paper-spot samples being cleaner as mentioned in section 4.3.1.3. These 
indicate that the paper-spot method could possibly work better in metabolomics for the 
prediction of some doping substances such as salbutamol.  
Table 4-3  Some parameters for the OPLS-DA models of the two methods 
 Conventional method Paper-spot method 
R2X 0.314 0.483 
R2Y 0.582 0.697 
Q2 0.266 0.385 
CV-ANOVA (p-value) 1.7E -3 2E -4 
 
Metabolic correlations between all the discriminating metabolites were constructed in 





paper-spot methods show that the most significant feature with the largest correlation 
value to DET group is salbutamol. This is an expected result provided that the LC-MS 
analysis was appropriate to detect salbutamol and that the data pre-processing and 
modelling steps were built correctly. The P correlation value (p (corr)) of the 
conventional method (p (corr) = 0.75) is in the same range as that in the paper-spot 
method (p (corr) = 0.73). These indicate that both methods were adequate to 
discriminate our model drug or a potential biomarker of similar characteristics using 
urine metabolomics. 
The sensitivity of paper spots can decrease according to Figure 4-2, yet it is sufficient 
to detect salbutamol with a wide concentration range from 10 – 1000 ng/mL. However, 
we also concern about the sensitivity of the endogenous compounds altered upon 
salbutamol administration as well as other prohibited drug with lower decision limits, 







Figure 4-6  S-plot depicting salbutamol (marked in red) as the most significant 
feature of in conventional method. A, salbutamol p(corr) = 0.75 in conventional 






4.3.2 Paper-spot inter-batch reproducibility after a F/T cycle 
4.3.2.1 Comparison of feature numbers 
Thirty samples were randomly selected and subjected to UHPLC-MS analysis for a 
second time after a single one-week -80 °C freeze-thaw cycle. The two raw data 
batches were processed separately in XCMS using the parameters aforementioned in 
the method section 4.2.6. The results showed high similarity in feature numbers 
between the two batches, with slightly less features in positive ionisation mode for 
Batch 2 (Table 4-4). This indicated that there was good stability in metabolite 
numbers between batches. The non-significant reduction of the feature number could 
be due to the freezing, storage and defrosting procedures, or merely system variability.  
Table 4-4 Number of features generated in R: XCMS of two batches in two 
ionisation modes (N = 30 in each batch) 
 Batch 1 Batch 2 (after F/T) 
Negative mode 2,081 2,070 
Positive mode 2,132 2,053 
 
4.3.2.2  Data quality test 
The peak area of internal standard was quantified in the raw data in both paper-spot 






Table 4-5 Descriptive parameters calculated from the peak area of IS in the two 
methods (N = 30 in each batch) 
 Batch 1 Batch 2 (after F/T) 
MEAN 2.99 e9 2.85 e9 
SD 5.10e8 3.00 e8 
% RSD 17.0 10.5 
 
The IS of the two batches showed similar intensity as we can expected. T-test showed 
there is no significant difference between Batch 1 and Batch 2 (p >0.05). D3-
salbutamol is a relatively stable compound, and its behaviour cannot be extrapolated to 
other metabolites. However the RSD of 10.5 % shows good overall system stability for 
Batch 2.  
4.3.2.3 Multivariate analysis  
The two batches of raw data were processed together in XCMS, before exporting to 
SIMCA to perform PCA analysis. The PCA score plot in Figure 4-7 shows two 
batches of samples evenly spread in the plot, which indicates that there was no 
significant difference caused by a one-week freeze-thaw cycle. The QCs of two 
batches cluster and mix together in the centre, showing an acceptable intra-batch and 
inter-batch data stability. Moreover, the two batches are closely paired together, and 
noticeably two batches of the outliers, S11 (from DET group) and N22 (from NON-





 Here we studied the stability during a one-week freeze-thaw cycle but longer term 
stability of IVE paper-spot should be thoroughly investigated, and the metabolomics 
strategy proposed here is also applicable. In addition, the stability of different types of 
substances including various categories of drugs and endogenous compounds should 
be assessed when using the IVE paper-spot sampling method. More and more 
metabolomics projects use sample numbers in the 1000s, and that would translate to 
months of storage which in turn could bring some unexpected stability effects. 
 
Figure 4-7 PCA score scatter plots of 2 batches of 30 samples and 7 QCs. Samples 
with names started with “S” were from DET group, while samples with names started 
with “N” were from NON-DET group. The QCs of two batches cluster and mix 









Urine metabolomics analysis of 61 urine samples was performed to evaluate 
conventional urine liquid sampling and IVE of dried paper spots using UHPLC-Q-
ExactiveTM Orbitrap-MS. Two groups (DET and NON-DET) were created in each 
sampling procedure according to whether they contained salbutamol, which was used 
as a model non-endogenous drug metabolite.  
For the comparison between the two sampling methods, there were slightly less 
features in paper spots than that with conventional urine samples, despite the base peak 
intensity dropped by more than 30 % in positive ionisation mode and 20 % in negative 
ionisation mode consequentially after spotting and extraction. However, lower 
variation (17.7 % versus 23.0 %) was found in the paper-spot method showing higher 
precision. Furthermore, OPLS-DA models showed better discrimination capacity of 
variables for DET and NON-DET groups in the paper spots than using the 
conventional method (CV-ANOVA p-value = 2E -4 versus 1.7E -3). The S-plot of both 
methods indicated both methods were adequate to discover the main discriminating 
feature salbutamol (with correlation values of 0.73 and 0.75 for the positive group) in 
urine using metabolomic analysis.  
For the evaluation of IVE paper-spot inter-batch reproducibility, two batches of LC-
MS data were accessed and compared. The results showed good inter-batch stability 
and little information loss after a one-week -80 °C freeze-thaw cycle, and multivariate 





To summarize, IVE paper-spot sampling can cause some information loss but it proved 
to be robust and very similar to conventional sampling when used for urine 
metabolomics, and it could be a good alternative when sample volumes are limited, 
such as in studies when many “omics” analyses are required from one sample.  
However the long-term reproducibility of spots still need to be evaluated, especially 
when bearing with other doping agents or endogenous metabolites that are not as 
stable as salbutamol. 
In the next chapter, we will apply the metabolomics strategy to anti-doping 
application. As the paper-spot method risks a loss of sensitivity and there are sufficient 
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Chapter 5  Metabolic phenotyping of urine samples to 







A small molecule phenotyping strategy for HRMS-based metabolomics was developed 
in Chapters 2-4, using both conventional and paper-spot sampling methods. In this and 
the next chapters, the strategy will be applied to the anti-doping field using 
endogenous and exogenous model compounds, respectively, to finally test the general 
hypothesis. Since the paper-spot method risks a loss of sensitivity and there are 
sufficient sample volumes at this time, conventional liquid samples will still be used. 
One of the main challenges in anti-doping control is the ever increasing number of 
endogenous and exogenous compounds to be screened routinely. New drugs appear on 
the market every day and athletes quickly switch to new substances to avoid being 
caught. As stated in Chapter 1, anti-doping laboratories in recent years have started 
modifying their screening approach from targeted data acquisition (e.g. SRM) to total 
data capture using high resolution mass spectrometry instruments(Virus, Sobolevsky et 
al. 2008, Peters, Oosterink et al. 2010, Vonaparti, Lyris et al. 2010, Musenga and 
Cowan 2013, Thevis, Kuuranne et al. 2014). This permits total data capture and 
eliminates the requirement for a priori selection of the compounds to be targeted. 
Though this adds tremendous flexibility to the methods and enables retrospective 
analysis of samples, the data processing step still depends on a targeted approach, 






Biomarker screening from metabolomic profiling is an alternative that has the potential 
of spotting both up- and down-regulation of metabolites and creating predictive 
models for individual or group case studies. Approaches that do not target the doping 
compound would be very valuable; surrogate markers could be identified and 
quantified where necessary. Depending on the surrogate’s specificity this could lead to, 
for example, a prolonged detection time, or improved detectability for substances at 
very low concentrations and/or which present challenges being detected. At present, 
the metabolomic biomarker strategy has been applied in a variety of fields, including 
diagnostics, patient stratification, drug development and clinical chemistry (Lindon, 
Holmes et al. 2007, Nicholson and Lindon 2008, Patti, Yanes et al. 2012, Sen, Wang et 
al. 2013, Jung, Jung et al. 2014, Lindon and Nicholson 2014, Mathe, Patterson et al. 
2014). It is of particular interest in areas like doping control, as new approaches are 
needed to fight the ongoing development of performance-enhancing methods 
(Riedmaier, Becker et al. 2009, Teale, Barton et al. 2009, Guha, Erotokritou-Mulligan 
et al. 2014). So far, the biomarker approach of the combined detection of  insulin-like 
growth factor-I (IGF-I) and procollagen type III amino-terminal propeptide (P-III-
NP)  for testing growth hormone (GH) misuse has been approved by the WADA and 
has led to the detection of a number of athletes misusing GH (Powrie, Bassett et al. 
2007, Holt 2013). 
In this chapter, the previously-developed metabolomic strategy is applied to samples 
from a clinical trial for GHB administration, with the aim of finding the biomarker of 






Gamma-hydroxybutyrate (gamma-hydroxybutyric acid, GHB, molecular structure 
showed in Figure 5-1), an endogenous, naturally occurring compound in mammals, 
has gained increased public attention for its illicit use, including recreational use and 
drug-facilitated sexual assaults (DFSA). It can be used alone or mixed with other 
substances in beverages due to its colourless and odourless liquid state (Freese, Miotto 
et al. 2002, Kintz, Cirimele et al. 2003, Castro, Tarelho et al. 2016). 
 
Figure 5-1  The molecular structure of GHB. 
 
 
GHB was initially used in Europe as a general anesthetic and sleep aid, but usage was 
ceased because of its insufficient anesthetic potency and unpredictable duration of 
action (Tunstall 1968, Margulis, Andreyev et al. 1975). It was also once marketed in 
health food stores in the U.S., as a growth hormone releasing agent to stimulate muscle 
growth. Again, it was taken off the shelves and has been banned since the late 1990s in 
most countries. Today it is only allowed for the treatment of narcolepsy and rare 
alcoholism (Mayer 2012, Keating 2014, Caputo, Mirijello et al. 2015). However, GHB 
as well as Gamma-butyrolactone (GBL) became popular substances of abuse because 
of the euphoria and hallucinogenic effects, branding these molecules with the name 
“liquid ecstasy”. Moreover, it is also used as a doping agent by sports athletes due to a 





Chiodera et al. 1997). In addition to that, strong sedative and amnesic properties of the 
drug further propel the abuse of GHB by criminals in DFSA: it can be spiked in drinks 
of unsuspecting victims and its sedative effect is exploited for “date-rape” criminal 
offenses.  
From the forensic perspective, however, to prove the ingestion of GHB, surreptitious 
or deliberate, is rather difficult due to its endogenous nature and rapid metabolic 
elimination rate (plasma t1/2 = 20 - 40 minutes), which leads to levels of GHB in urine 
back to basal concentration during 4-12 h after ingestion and even shorter time in 
blood (Brenneisen, Elsohly et al. 2004, Abanades, Farre et al. 2006, Brailsford, Cowan 
et al. 2012, Liechti, Quednow et al. 2016). This brief window makes proof 
of administration problematic in most rape cases. 
Urine is the most used specimen matrix currently for GHB testing, the cut-off value of 
10 mg/L in human urine is typically considered to distinguish between endogenous 
concentration and any concentration consistent with administration (Shima, Miki et al. 
2005, LeBeau, Montgomery et al. 2006, Brailsford, Cowan et al. 2010, De Paoli, 
Walker et al. 2011). Hair (Jagerdeo, Montgomery et al. 2015, Vaiano, Serpelloni et al. 
2016) and saliva (De Paoli, Walker et al. 2011, Mazina, Saar-Reismaa et al. 2015) 
specimen analysis using GC-MS, LC-MS/MS and CE have been reported by research 
groups. 
The metabolism of GHB occurs via GHB dehydrogenase to succinic semialdehyde 
(SSA) and then subsequently to succinic acid and gamma-Aminobutyric acid (GABA) 





sulfonated (Hanisch, Stachel et al. 2016) metabolites of GHB were reported. Although 
the mechanism of action of GHB is still not fully elucidated, it is generally accepted 
that GHB affects the balance of neurotransmitters (Drasbek, Christensen et al. 2006). 
To extend the detection window, some studies focused on the discovery of surrogate 
markers of GHB. Larson et al. found that epiregulin and Pea-15 protein levels 
increased in a GHB dosed mouse model by means of transcriptomic and proteomic 
approaches, and suggested that these two proteins could be used as surrogate markers 
in the indirect detection of GHB that may extent the detection window from 12 to 48 
hours (Larson, Putnam et al. 2007). Using metabolomics, Nasrallah et al. incubated 
guinea pig cortical tissue slices with GHB and observed various metabolic responses 
on different concentrations of GHB, and suggested potential target receptors for further 
investigation (Nasrallah, Maher et al. 2010). However, no study has been reported on 
untargeted metabolomic approach to find biomarkers of GHB using human samples so 
far. 
The objective of this chapter is to find a biomarker of GHB administration in human 
urine samples using an untargeted metabolomic strategy in order to aid the short 
detection window of GHB. The samples from volunteers were obtained from a small 
clinical trial that looked into the pharmacokinetics of GHB (Brailsford, Cowan et al. 
2012). Potential biomarkers of GHB were mined by questioning the data in different 
ways accompanied by a relevant statistical data processing tool.  








Figure 5-2 Data treatment workflow for longitudinal study of GHB 
administration. PCA: principal component analysis; PERMANOVA: permutational 
multivariate analysis of variance; OPLS (-DA): orthogonal partial least-squares 
(discriminant analysis); PLS-DA: partial least-squares discriminant analysis; ROC: 
Receiver Operating Characteristic; QC: quality control; admin.: administration. 
 
5.2 Methods 
5.2.1 Chemicals and materials  
GHB (sodium salt, Lot analysis = 99.7% purity), deuterated GHB-d6 (4-hydroxy-
2,2,3,3,4,4-hexadeuterobutyric acid sodium salt) supplied as 1 mg/mL stock solution in 





(Poole, U.K.). LC−MS grade water and acetonitrile were purchased from VWR 
International (Fontenay-sous-Bois, France). All sample extractions were performed in 
2mL microcentrifuge tubes (from Eppendorf, Hamburg, Germany). Amber glass 
HPLC vials with fixed 0.3 mL inserts were from Chromacol (Welwyn Garden City, 
U.K.). 
5.2.2 Volunteers and urine samples  
Samples were from a previous GHB pharmacokinetics study (Brailsford, Cowan et al. 
2012) taken from 12 healthy volunteers  (6 females and  6 males), see Figure 5-3.  
Volunteer recruitment 
Ethical approval for the GHB administration study was obtained from our institutional 
research ethics committee (approval number CREC/06/07-30). Written informed 
consent was obtained from the volunteers (six men and six women). Males had a mean 
age of 25 years (21–36 years) and a mean body mass index (BMI) of 23.7 kg/m2 
(21.7– 27.1 kg/m2). Females had a mean age of 26 years (22– 32 years) and BMI of 
23.0 kg/ m2 (19.5– 25.9 kg/m2). Prior to the study, volunteers were assessed to be in 
good health. Exclusion criteria included a history of liver disease, succinic semi-
aldehyde dehydrogenase deficiency, and currently breast feeding. All volunteers tested 
negative for the current use of sedatives, recreational drugs, and pregnancy (females 







On the day of study, volunteers were asked to finish a light breakfast by 7:30 a.m. 
before arriving at the secure study suite. At 10:00 a.m., a single dose (25 mg/kg body 
weight) of GHB was administrated in the form of the pharmaceutical preparation 
Xyremw (sodium oxybate, 500 mg/L). The mean dose was 1.8 g (as the sodium salt) 
and ranged from 1.4 to 2.6 g (equivalent to 1.2 –2.1 g GHB). The preparation was 
diluted with 60 mL water prior to administration as directed by the manufacturer. 
Urine samples were taken for 13 time points at –10 min, 1, 2, 4, 6, 8, 10, 12, 14, 16, 
20, 24, and 30 h. The time point numbers and their corresponding time are shown in 
Table 5-1. 
Table 5-1 The time point numbers and their corresponding time of urine samples. 
Time point 
No. 
T1 T2 T3 T4 T5 T6 T7 
Time -1 week 
-10 min 
(0 h) 
1 h 2 h 4 h 6 h 8 h 
Time point 
No. 
T8 T9 T10 T11 T12 T13 T14 
Time 10 h 12 h 14 h 16 h 20 h 24 h 30 h 
 
Sample storage 
The volunteers were asked not to void any urine at times other than those specified up 
to 30 h post-administration, during which time they were monitored. Samples were 





5.2.3 Sample preparation 
A pooled sample was used as a quality control (QC). All the urine samples were 
centrifuged at 6,000 r.c.f for 10 minutes to remove any particles. An aliquot of 100 µL 
of supernatant pipetted into amber HPLC vials with inserts. GHB-d6 stock solution 
was diluted by LC-MS grade water to 20 µg/ mL to make an IS solution and 80 µL of 
the IS solution was added into each vial. The QCs were inserted after every 10 samples 
throughout the whole run. 
5.2.4 Analytical Setup 
For a detailed description of LC-MS instrument and column, refer to section 2.2.4. 
Urine extract (5 µL) was injected into the LC-MS system. Separation was performed at 
25 °C with a flow-rate of 0.2 mL/min, solvent A composed of 0.1% formic acid in 
water, and solvent B composed of 0.1% formic acid in acetonitrile. Metabolites were 
eluted using the following gradient elution method: from 0.5 % B at 0 min to 50 % B 
in 8 min, increasing to 100% B in 11 min, returning to initial conditions in 0.5 min, 
maintained at initial conditions for 2 min. MS analysis was completed in separate 
positive and negative mode experiments. In both modes, all analyses were acquired in 
LockSpray mode to ensure accuracy and reproducibility; leucine-enkephalin was used 
as a lock mass (m/z 556.2771) at a concentration of 500 ng/mL and a flow rate of 10 
µL/min. Data were collected in the centroid mode over the m/z range of 80−1000 with 
an acquisition time of 0.1 s a scan. In positive ion mode, the XEVO® QTOF was 
operated with a capillary voltage of 3.2 kV and a cone voltage of 35 V. The extraction 





°C. The source temperature was 120 °C, and the cone gas was set to 50 L/h. In 
negative ionization mode, the XEVO® QTOF was operated with a capillary voltage of 
−2.6 kV and a cone voltage of 45 V. The extraction cone was set to 2.0 V. The 
desolvation gas flow was 800 L/h and maintained at 350 °C. The source temperature 
was 120 °C. All data were collected using Waters MSe technology, at two constantly 
interchanging energies.  For a detailed description of MSe technology, refer to section 
2.2.4. 
5.2.5 Data preprocessing  
Data files (.RAW) collected in MassLynx were converted by Databridge to .CDF for-
mat before importing into freely available XCMS package in R. For peak picking, the 
following parameters were used: method = “matchedFilter”, fwhm = 10, snthresh = 9, 
mzdiff = -0.001. For peak grouping, bw = 10, mzwid = 0.05 were used. After peak 
alignment to allow minor retention time variation and filling missing peaks, an output 
table of time-aligned detected features was exported with their retention time, mass to 
charge ratio (m/z), and intensity in each sample. A feature is any m/z signal 
maximizing at a specific retention time. The resulting tables were readily exported to 
Microsoft Excel and feature numbers were obtained in the Excel output tables.  
5.2.5 Statistical analysis  
The data from both positive and negative ionization mode were then normalized by the 
total void volume of each volunteer at each time point, before further analysis. The 





and log-transformed, before being subjected to orthogonal partial least-squares 
analysis (OPLS) with corresponding S-plot analysis in SIMCA 14 (UMetrics, Umeå, 
Sweden).  PLS-DA and PERMANOVA were performed in mixOmics package in R. In 
stepwise analysis, orthogonal partial least-squares discriminant analyses (OPLS-DA) 
were used on grouped datasets in SIMCA 14. Volcano plot, ROC curve and boxplots 
were prepared in MetaboAnalyst (www.metaboanalyst.ca/) (Xia, Sinelnikov et al. 
2015). Other graphical outputs were prepared in SPSS (IBM SPSS statistics, version 
22).   
5.2.6 Putative metabolite identification 
The features that were observed to influence models the most were preliminarily 
identified using the human metabolome database (HMDB) (www.hmdb.ca/) (Wishart, 
Tzur et al. 2007, Wishart, Knox et al. 2009, Wishart, Jewison et al. 2013) and the 
equivalent METLIN (METaboliteLINk) database (https://metlin.scripps.edu/) (Smith, 
O'Maille et al. 2005). 
Due to the high number of database hits generally returned by a database search, a 
number of rules were enforced in the identification database search in order to be as 
consistent as possible. These rules are listed and explained below: 
• 30 ppm error 
            The mass error of the search on the database searches was set to 30 ppm, as this 







            The feature in each instance must realistically ionize in the polarity being ob-
served. For example, GHB is generally only observed in positive ionization 
mass spectrometry.  
• Human biology 
            Features in the search must be possible metabolites in human urine. HMDB 
lists instances where the molecules have been extracted from human tissue or 
biofluids and previously reported in the literature. 
• Retention Time 
            Retention time and the matching chemical properties such as partition-
coefficient (P) of each feature are considered, for example molecules with a 
similar polarity often elute in the same region of the chromatogram and 
metabolites with small or even negative log (P) elute early in the reverse phase 
chromatogram.  
• MS2 fragmentation 
            As mentioned in section 5.2.4, accurate mass fragmentation data (MS2) can be 
collected simultaneously with accurate mass precursor ion data. The 
identification will be more accurate if the fragment spectrum of the candidate 





All of these rules were taken into consideration step-wise when completing the initial 
database search. 
5.3 Results and discussion 
A total of 5135 features were extracted after data pre-processing in XCMS, including 
2399 features from the positive ionization mode and 2736 features from the negative 
mode. 
5.3.1 Possible metabolites of GHB 
It is overserved that urinary GHB reached highest concentration (Cmax) at 1h post-
administration and back to basal level in 4 h from the previous pharmacokinetic study 
(Figure 5-3, data not shown after 10 h post-administration).   
All known metabolites of GHB were first checked in the raw data, including succinic 
semialdehyde (SSA), succinic acid, GABA, glucuronide and sulfonated GHB; 
however, none were detected in the chromatogram using fingerprinting. Therefore, the 
whole dataset after pre-processing were subjected to a battery of untargeted statistical 







Figure 5-3 Urinary GHB behaviour in 12 volunteers following a 25 mg/kg oral 
dose for 10 h post-administration. A, Urinary GHB concentrations for 10 h post-
administration. The dashed line represents 10 mg/L (discriminant limit). B, Total 
urinary GHB elimination for 10 h post-administration. Mean for 12 volunteers =  ; 
profile for maximum Cmax = ; and profile for minimum Cmax = . Figure obtained 
from (Brailsford, Cowan et al. 2012) 
 
5.3.2 Data overview 
5.3.2.1 Data quality (PCA) 
At the beginning of the untargeted statistical analysis workflow, the data quality was 
inspected by the variation of QCs in the PCA score plot (Figure 5-4). The distribution 
of QC samples (N=17) was measured as 3.7 % and 4.4 % (at t[1] and t[2] directions, 









Figure 5-4 PCA score plot of all urine samples (N =168) and 17 QCs. Data were 




Permutational multivariate analysis of variance (PERMANOVA) was conducted using 
the Euclidean distance. PERMANOVA is analogous to multivariate analysis of 
variance (MANOVA), which allows partitioning the variability of the data according 
to a complex design or model, and provides F-ratios that are analogous to Fisher's F-
ratio in MANOVA (McArdle and Anderson 2001). PERMANOVA was used to detect 
possible significant differences in data between time and treatment (pre- and post-
GHB administration), which were treated as fixed factors, and individuals as random 
factor. The PERMANOVA test result is shown in Table 5-2, which indicated 






Table 5-2 PERMANOVA test of the whole dataset 
PERMANOVAa STRATA Individuals b 
 Df Sums Of Sqs Mean Sqs F.Model p 
Treatment 1 3257 3257.3 3.65 0.002 
Timec 1 7793 7793.2 8.73 <0.001 
Residuals 150 133887 892.6 0.92  
Total 152 144937 1   
 
a. Data were log-transformed before PERMANOVA test. 
b. Calculation excluded the individual difference among the volunteers. 
c. Excluded time point 1, i.e. one week before GHB administration. 
 
5.3.3 OPLS analysis 
In order to search for the features with similar metabolism pattern as GHB, OPLS 
model was built using GHB as the Y-variable. The corresponding S-plot (Figure 5-5) 
indicated the features that the most positively correlated to GHB metabolism (top right 
in the S-plot), and 10 of them with largest p (corr) value were selected. However, most 
of the selected features showed random fluctuation along the time when univariate 
analysis was performed. That could be expected as there were significant GHB 
elevations only in 2 time points out of total 12 post-administration time points (see 
Figure 5-3 and 5-6), hence the model could be easily driven by the rest 10 time 
points. The feature at m/z 209.9830 showed a similar pattern with GHB (Figure 5-6), 
with significant correlation (r = 0.517, p < 0.001, Spearman’s Correlation). Such 





GHB administration, however, if it were a metabolic change after GHB administration, 
it could help finding other metabolic paths for this drug. This feature was increased 
greatly at 24 and 30 hours which would have made it an ideal biomarker if it was 
causally related. However it was not possible to elucidate the structure of this small 
molecule and this feature remained unidentified. Additionally the lack of a direct 
control group (or diet control) in the experimental design of this clinical study meant 
that the biological origin of the feature was also unknown. 
 
Figure 5-5 S-plot from OPLS model where GHB was set as Y-variable. The circles 
represent the features. X-axis represents covariate while y-axis represents correlation 
to GHB. The S-plot showed a straight line instead of “S” since the data were 
univariate-scaled. Features in the top right positively correlated to GHB, and 10 
features with biggest p (corr) value were selected as features of interest and marked in 








Figure 5-6 Concentration changes (Mean ± SEM) of GHB and feature at m/z 
209.9830 during the pre- and 30 h post-administration. Left, GHB. Right, feature at 
m/z 209.9830. Y-axis represents the peak area normalized by total urine volume. 
Feature at m/z 209.9830 significantly correlated to GHB post-administration with r = 
0.517, p < 0.001 (N=153, Spearman’s Correlation).  
 
5.3.4 PLS-DA analysis 
To extract overall changes during the time, a PLS-DA plot covering all the time points 







Figure 5-7 PLS-DA score plot showing a trend of the longitudinal moving. The 
numbers represent the time points, and each coloured circle represents the mean 
position (± SD) of the each time point. Group A and B: time points 7-11; Group C: 
time points 12-14. 
 
PLS-DA using the whole “fingerprints” showed a trend of time points being driven 
away and then back towards the initial position. The time points were later divided into 
groups based on the clustering position to perform OPLS-DA analysis stepwise. It is 
also of practical use if biomarkers of different time periods can be found, as victims 
can go to test their urine in a wide range of time frame after being drugged. The group 





Table 5-3 Group assignments of stepwise analysis 
 Group A Group B Group C 
Time point No. T7, T8, T9 T9, T10, T11 T12, T13, T14 
Time (h) 8-12 12-16 20-30 
 
 
5.3.5 Stepwise OPLS-DA analysis 
Based on the group assignments in section 5.3.4, stepwise analysis using OPLS-DA 
was performed between T2 (0 h) vs. Group A, T2 vs. Group B, and T2 vs. Group C, to 
find biomarkers of different time periods post-administration. Figure 5-8 showed the 
OPLS-DA model of T2 vs. Group B. The score plot showed the separation of the two 
groups. To find the features of interest, initially 5 features in the S-plot with the 
highest p (corr) values were selected and then checked in the raw chromatograms to 
exclude noise features. Also, correlation tests were performed among those features 
provided they shared the same retention time. If the correlation coefficient was > 0.9, 
one or some of the features could be considered fragments or isotopes and excluded. 
Then another feature with the highest p (corr) value will be added in and checked as 
the procedure mentioned above, until a total of 5 features of interest were chosen. The 
concentration levels of those features were then plotted over the time from pre- to 30 h 
post-administration (Figure 5-9). The putative annotations and their possible origins 







Figure 5-8 OPLS-DA model of T2 (pre-administration) vs Group B (T9, T10 
and T11). A, OPLS-DA score plots in the predictive (x-axis) and orthogonal (y-
axis) components of LC-MS data of urine samples, where dark red circles 
represent samples at T2, blue circle represent samples of Group B. B, 
Corresponding S-plot. Data include features from both positive and negative 
ionization modes, and were univariate-scaled and log-transformed. Model fit:  R2Y 






Figure 5-9 Concentration change of GHB in urine and the top 5 features selected 
via the S-plot of T2 vs Group B (T9, T10 and T11, 12- 16 h) during pre- and 30h 
post-administration. Data were presented in mean ± SEM. The x-axis represents time 






Table 5-4 Annotated putative metabolites of top significant features in stepwise 
analysis. (Bold font indicates that the feature appears in more than one group) 
Feature (m/z) Putative metabolites Origin 
T2 vs. Group A 
192.1612 (+)a Unidentified _ 
277.0907 (+) Biotin sulfone Endogenous/Food 
434.6143 (-) Unidentified _ 
414.1053 (-) Unidentified _ 
399.1276 (+) Riboflavin  Endogenous 
T2 vs. Group B 
430.1802 (+) Garcimangosone C Food 
379.1803 (-) Deacetylisovaltrate Food 
192.1612 (+) Unidentified _ 
399.1276 (+) Riboflavin  Endogenous 
411.0826 (-) Patientoside A Food 
T2 vs. Group C 
192.1612 (+) Unidentified _ 
525.1493 (-) Dihydroxychalcone Food 
430.1802 (+) Garcimangosone C Food 
195.0285 (+) Unidentified _ 
392.0804 (-) Isoorientin 2''-[feruloyl-(->6)-glucoside Food 
a. (+) : Feature detected in positive ionization mode. 
(-) : Feature detected in negative ionization mode. 
 
 
It can be observed in Table 5-4 that the features at m/z 192.1612, m/z 399.1276 and 





192.1612 which appears in the top list of all the 3 groups. However the only identified 
endogenous compounds are m/z 399.1276 as riboflavin and m/z 277.0907 as biotin 
sulfone, despite most of the features were putatively identified as compounds from 
food or remained as unidentified. The putative identifications were based on the rules 
mentioned in section 5.2.6. For instance, m/z 192.1612 was first checked in databases, 
with no hits of +H and +Na adducts. There were several hits of +NH4 adducts, 
nonetheless. After confirming the endogenous origin and reasonable log(p), the 
candidate molecules were then inspected in raw data for fragmentation. However, the 
fragments of these candidates were not found in the sample MS or MS/MS spectrum, 
in particular the molecular ions (without +NH4). Thus m/z 192.1612 remains 
unidentified. Final confirmations with standards for putatively identified compounds 
are still needed, however more experiments with a control group will determine if a 
feature is worth confirming with standards.  
5.3.6 Metabolic change between pre- and 24 h post-administration 
In addition to the metabolic changes caused by GHB, circadian rhythm also plays a 
role in the urine metabolome changes (Giskeodegard, Davies et al. 2015). By 
comparing the profiles of pre-administration (0 h) and 24 h post-administration, and 
selecting features which do not return to basal concentrations in 24 h, the effect of 
features that follow circadian rhythm can be somewhat avoided. Features that increase 
greatly at 24h after GHB administration could be in turn related to GHB. 
 It is observed in Figure 5-7 that the time points of pre- and 24 h post-administration 





after a 24 h cycle. A volcano plot can be used to quickly identify the most meaningful 
changes in a large matrix (Cui and Churchill 2003). It plots significance (p-value) and 
fold-change (FC) on the y and x axes respectively. In Figure 5-10, the feature at m/z 
192.1612 gives the highest fold-change (FC=12) and lowest p-value (p = 2.31E-08). 
This is the feature with the greatest change 24 hours after administration of GHB. 
 
Figure 5-10 Volcano plot of pre- vs. 24h post-administration. X-axis represents the 
fold-change (FC) in log2 (FC), and y-axis represents the p-value in –log10 (p). The pink 
dots are the features with p < 0.01 and FC > 2, and it is observed that they were all 
upregulated after 24 h post-administration. The feature at m/z 192.1612 in the top right 
corner gives the highest fold-change of 12 and lowest p-value of 2.31E-08.  
 
To test the capacity of the feature at m/z 192.1612 to predict the GHB administration at 
24 h, Receiver Operating Characteristic (ROC) analysis was performed. The curve is 





false positive rate (FPR, also known as specificity) at various threshold settings, and it 
is able to test predictive properties on selected candidate. ROC curve gives an AUC of 
0.986 for the feature at m/z 192.1612 (Figure 5-11), which is considered an excellent 
prediction for a potential marker. Yet our model might be over-fitted because the 
samples were not divided into training set and test set due to the limited sample size 
and further validation study is necessary to test biomarker capacity. The box plot of 
m/z 192.1612 showed significant concentration elevation at 24 h post-administration (p 
< 0.001, paired t-test). This feature also appeared in the top discriminant features list in 
stepwise analysis in each group (Table 5-4). 
 
Figure 5-11 Receiver operating characteristic (ROC) curve (N=26) and box plots 
of the feature at m/z 192.1612. Data were univariate-scaled and log-transformed 
before analysis. The ROC curve returns an AUC of 0.986, 95% CI [0.931, 1]. The box 
plot for m/z 192.1612 in the pre- and 24 h post-administration groups shows the 75th 
and 25th percentiles and the median value. The whiskers represent the highest and 
lowest values that are not outliers. Outliers (values that are more than 1.5 the 
interquartile range) are represented by circles beyond the whiskers. The box plot 
demonstrated significant elevation of the feature at m/z 192.1612 at 24 h post- 






Ideally, the major difference between pre- and 24 h post-administration should be 
driven by GHB and not by the circadian rhythm effects. However there was no control 
of the food intake for volunteers in this study, as a result the difference could be 
caused not only by GHB, but also by diet. This is likely the reason why some of the 
putative biomarkers in Table 5-4 are originated from food. During an acute 
longitudinal monitoring period such as one or two days, the urine metabolic profile can 
be largely affected by food intake, thus the food control is essential. The possibility 
cannot be excluded that the feature at m/z 192.1612 and other features (p < 0.01 and 
FC > 2) in the volcano plot were originated from food provided that all the volunteers 
had similar food intake before or during the trial.  
5.3.7 Limitations of this study 
A limitation of this chapter is that linear mixed-effects models could have been a more 
appropriate statistical tool in longitudinal studies. However in this study, GHB was 
administrated in the same dose (25 mg/kg body weight) for all the volunteers. It is 
proposed that in a further study or other longitudinal study design, a multiple level of 
dosage could be given to build a linear mixed- effects model and visualize the 
predictive trend of potential markers. 
As commented previously the biggest shortcoming of this study design was the lack of 
placebo group, i.e. control group of non-GHB administration. If there are samples 
taken from non-GHB administration group, the metabolic profile of each time point 





The environmental factors were not controlled and these could not be excluded. This is 
a big limitation of metabolomics in general as diet and xenobiotics will affect 
outcomes. The design could have taken into account biomarker specificity by 
employing volunteers from both GHB administrated group and non-administrated 
group with cross-over design, together with controlled food intake. These studies 
however demand a lot of resources, such as a metabolic facility where volunteers can 
be monitored continuously in-house. 
5.4 Conclusions 
In this chapter, a longitudinal phenotyping approach for discovering surrogate markers 
of administration of an endogenous compound GHB was developed. A total of 168 
urine samples were analysed by UPLC®-QTOF MS and a total of 5,135 features were 
extracted by XCMS. QCs clustered in the centre of the PCA showing a good overall 
reproducibility of the experiment. PERMANOVA proved the metabolic profile change 
after GHB administration, and OPLS analysis found a feature at m/z 209.9830 
significantly correlated to GHB. PLS-DA showed a trend of the time points 
longitudinally moving away and back towards the initial position in 30 h. Stepwise 
OPLS-DA analysis revealed the 5 most elevated features in each of the three different 
time period (8-12 h, 12-16 h and 20-30 h) post administration, in which riboflavin and 
biotin sulfone were putatively identified among the most discriminant features in 8-16 
h and 8-12 h periods respectively. The unidentified feature at m/z 192.1612 showed 
significant changes in all the three periods. Further analysis of pre- and 24 h post-





FC=12 and the smallest p-value of 2.31E-08. ROC curve of this feature returned a 
prediction capacity of 98.6%. These results suggest that the feature at m/z 192.1612 
alone or together with other significant features found in stepwise analysis such as 
riboflavin and biotin sulfone, can be potential surrogate markers of GHB.  
This preliminary research provides a general strategy for longitudinal metabolomics, it 
could be applied to a study which is food-intake controlled and a cross-over designed 
clinical trial. In the next chapter, a study design will be drafted taking into account 
some of the shortcomings, such as the lack of a control group, and an additional group 
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Chapter 6 LC-MS based metabolomics discovers 
purine endogenous associations with low dose 







The importance and necessity of biomarkers in doping control have been demonstrated 
in Chapter 1 and Chapter 5. In short, biomarkers have the potential to facilitate the 
discovery of new doping agents with biological activities similar to related named 
prohibited substances, as well as improving the sensitivity and prolonging the 
detection time window. 
The identification of a metabolomic biomarker requires access to samples obtained 
from individuals who have administered the substance under investigation. This could 
be challenging when dealing with sport samples. Indeed, sport samples can be utilised 
for research only if the appropriate research consent has been agreed by the athlete and 
only after the required storage period of three months has expired. Further to this, 
samples that generated adverse analytical (positive) findings must be stored sealed for 
several years in case further analyses are requested. This makes positive samples not 
readily accessible for research purposes. 
On the other side, according to WADA regulations, the presence of “threshold” 
substances (such as salbutamol, ephedrines, morphine and a few others) in urine 
constitutes a doping violation only if their concentration is determined to be above a 
certain threshold (WADA 2014). Samples that show the presence of these substances 
below the threshold are negative for the purpose of doping control, but represent an 





Following these considerations, we selected salbutamol as the model exogenous 
compound, based also on the availability and accessibility of samples in our laboratory. 
Salbutamol (albuterol), [2-(tert-butylamino)-1-(4-hydroxy-3-hydroxy methylphenyl) 
ethanol] (Figure 6-1), is a relatively selective β2-adrenergic bronchodilator commonly 
used as an aerosol for relieving the acute symptoms of asthma (Zhang, Teng et al. 
2012). The list of prohibited substances in sport published by WADA specifies that the 
use of salbutamol is only permitted by inhalation of therapeutic doses (WADA 2016). 
Administration by oral or parenteral routes and administration of very large inhaled 
doses (greater than 1,600 µg in any 24 hours) are prohibited due to a strong adrenergic 
stimulatory effect and anabolic-like effect (Martineau, Horan et al. 1992, Caruso, 
Signorile et al. 1995). By contrast, administration of therapeutic inhaled doses has no 
observable ergogenic effect (Meeuwisse, McKenzie et al. 1992). A urinary 
concentration of salbutamol in excess of 1,000 ng/mL is considered a doping violation, 
unless an appropriate pharmacokinetic study can prove that this is the result of 
abnormal metabolism when the compound is taken according to the permitted 
administration. The threshold concentration is based on the sum of the glucuronide 
conjugate and free drug concentrations according to currently effective WADA 
technical documents (WADA 2014). In a previous study, salbutamol glucuronide was 
found in urine at less than 3% compared with unconjugated salbutamol after oral 
administration and less than 1% in authentic doping control urine samples (Mareck, 







Figure 6-1 The molecular structure of salbutamol. 
 
Several studies have used metabolomics to find the biochemical paths implicated with 
doping substances. Boccard et al. discovered several metabolites relevant to the 
detection of testosterone intake, and suggest both glucuronide and sulphate steroid 
conjugates can be include in the Athlete Biological Passport (ABP) (Boccard, Badoud 
et al. 2011); Raro et al. also found 1-cyclopentenoylglycine as a potential marker for 
testosterone ester misuse (Raro, Ibanez et al. 2015); for salbutamol Kiss et al. found 
increased pantothenic acid (vitamin B5 ) in a salbutamol positive group (Kiss, Lucio et 
al. 2013).  
Detection of salbutamol is not particularly challenging, but this substance can be used 
as the model compound to demonstrate the feasibility of an approach that can later be 
extended to a much larger cohort of substances. 
The main purpose of this chapter is to find surrogate markers induced by the intake of 







6.2.1 Chemicals and materials 
 All solvents used were HPLC grade. Acetonitrile and methanol were obtained from 
Fisher Scientific (Loughborough, UK). Formic acid (99–100 %) was purchased from 
VWR (Leicestershire, UK). Ultrapure water (18 MΩ · cm) was obtained from an ultra-
pure water system (Elga, UK).  
6.2.2 Urine samples  
The samples from antidoping tests were acquired after professional sport competition 
and came from diverse demographics at random times of the day. A total of 91 urine 
samples were obtained from 91 different athletes, who had indicated their consent for 
research on their samples, with 30 salbutamol detectable samples (DET, 10 -
1000 ng/mL,19 males and 11 females) and 61 salbutamol non-detectable samples 
(NON-DET, less than 10 ng/mL, 40 males and 21 females). Samples were obtained 
from a total of 18 sports, 11 of which were classified as endurance sports. The number 
of samples for endurance sports were matched in both groups: the DET and NON-DET 
groups. The Specific gravity was measured by a calibrated DM40 densitometer 
(Mettler-Toledo International, Switzerland).  All urine samples were aliquoted and 
stored in polypropylene tubes at -20 °C for at least three months and anonymised prior 
to analysis to comply with the ethical requirements of the World Anti-Doping Agency. 
6.2.3 Sample preparation 
 To make a spiked (SPI) group, 30 independent samples (19 male and 11 female) from 





100, 200, 500 and 1000 ng/mL. A pooled sample from 20 urine samples with an equal 
number of DET and NON-DET was used as a quality control (QC). All the urine 
samples were centrifuged at 11,000 rpm for 15 minutes to remove any particles. An 
aliquot of 50 µL of supernatant was diluted with 200 µL ultrapure water previously 
spiked with internal standard mix (IS) containing mefruside and D3-salbutamol both at 
500 ng/mL. The solution obtained was pipetted into amber HPLC vials with inserts. 
Additional samples containing pure hypoxanthine standard obtained from Sigma-
Aldrich (St. Louis, MO, USA) were prepared for compound identification. 
6.2.4 UHPLC–HRMS analysis 
For a detailed description of chromatographic separation and mass spectrometer 
methods, refer to section 4.2.5. 
6.2.5 Data processing and analysis 
For a detailed description of data conversion and XCMS settings, refer to section 3.2.5. 
The data from both positive and negative ionization mode were then normalized by the 
specific gravity of each sample, before importing into SIMCA (UMetrics, Umeå, 
Sweden), where it was subjected to multivariate data modelling, including pareto-
scaled principal component analysis (PCA) (Figure not shown) and log-transformed 
orthogonal partial least-squares discriminant analysis (OPLS-DA) with corresponding 
S-Plot analysis. The features with p(corr) >0.25 or <0.45 were selected and re-
evaluated using OPLS-DA again. The OPLS-DA model was cross validated 7-fold and 





To test predictive properties, the receiver operating characteristic (ROC) was used. 
ROC curves with area under the curve (AUC) statistic and 95 % confidence intervals 
(CI) for salbutamol, a chosen feature and creatinine were recorded. Mann–Whitney U 
test was used on the features in DET and NON-DET and Spearman’s correlation were 
calculated between selected features and salbutamol. Box and whisker plot to 
demonstrate the data distribution were calculated using raw data measured as area 
under the peak and then normalized to IS and specific gravity of the feature was used. 
Analyses were performed using SPSS (IBM SPSS statistics, version 22). Features were 
investigated for fragmentation, m/z and retention time for identification purposes and 
Post-hoc analysis for statistical power using G*power (http://www.gpower.hhu.de/) 
was conducted (two tails, α=0.05, Normal distribution was assumed). Figure 6-2 








Figure 6-2 Experiments overview. (DET, salbutamol detectable samples; NON-DET, 
salbutamol non-detectable samples; SPI, NON-DET samples spiked with salbutamol 
reference standard).  n= 91 samples were injected into UHPLC-MS in polarity-
switching mode, data were processed in XCMS before multivariate analysis:  DET 






6.3 Results and discussion 
6.3.1 Normalisation method 
As mentioned in Chapter 3, specific gravity is the standard normalization method in 
doping control recommended by WADA, hence specific gravity was applied as the 
normalization method for this metabolomic study on salbutamol.  
6.3.2 Surrogate marker screening 
 A total of 3895 (+, acquired in the positive mode) and 3159 (-, acquired in the 
negative mode) distinct features were observed. PCA modelling showed a repeat 
extraction of a urine pool indicating the good reproducibility (figure not shown). 
OPLS-DA modelling demonstrated DET isolation from NON-DET. The corresponding 
correlation S-Plot was used to generate a list of features of interest that were of 
importance to the discriminatory model and increased in DET, which could contain 
candidate surrogate markers. To enhance the specificity of the model, in the initial S-
Plot of salbutamol DET versus NONDET (figure not shown), features with p 
(corr) >0.25 or <-0.45 were selected to build another OPLS-DA model (Figure 6-3A), 
with a p-value = 6.8e-7. Figure 6-3 illustrates the models using data from the positive 
ionization mode.  Figure 6-3A showed that the two groups can be clearly separated. 
The same protocol was applied to SPI vs. NON-DET model. In the two models, 
surrogate markers account for the difference between DET and NON-DET in addition 





 However, as confounding effects due to the analytical workflow and the diversity and 
individual differences of human urine occur, a third group was created to assess for 
“random markers”. Thus, a group of samples spiked with salbutamol (SPI) was set to 
eliminate possible confounding effects. Two S-Plots from DET versus NON-DET and 
SPI versus NON-DET groups can help directly visualize the result (Figure6-3B and 6-
2C). Features with p (corr) >0.5 in Figure 6-3B were highly correlated to salbutamol 
and were considered features of interest. The model in Figure 6-3C was constructed 
with urine samples that were controls spiked with salbutamol (SPI) versus control 
urine (NON-DET), in this figure the features that are highly correlated to SPI group 
were regarded as false positives. Feature at m/z 381.0792 seen in NON-DET versus 
DET (crossed square in Figure 6-3B) was considered a false positive as it was also 
mined in Figure 6-3C and correlated to the salbutamol spiked group. It was hence 
considered as not associated to salbutamol metabolism and excluded from further 
consideration.  The same protocol was applied to the negative ionization data, the 
figure for the negative ionization OPLS-DA was added in the supplementary 






Figure 6-3 OPLS-DA Models in positive ionization mode. A, Score plot of the 
OPLS-DA model from DET vs. NOT-DET. Blue, DET; Yellow, NON-DET. B, S-Plot 
from A. C, S-Plot of an OPLS-DA model from SPI vs. NON-DET. Features of interest 
were marked in red in B. Salbutamol, solid red boxed; a “false positive” marker, m/z at 
381.0792, solid black boxed and crossed.  
 
6.3.3 Exploration results 
 Two features of interest with distinct mass and retention time from both ionization 
modes were selected after the procedures mentioned above. The feature at m/z 
137.0458 (in positive ionization mode) was identified as hypoxanthine against a pure 
reference standard (Figure 6-4). The feature at m/z 336.1134 (in negative ionization 






Figure 6-4 A chromatogram of a urine sample and the MS spectra of 
hypoxanthine. A, An example chromatogram of a typical urine sample. B and C, 
High resolution tandem MS/MS spectra of the feature at m/z 137.0458 at retention 
time 3.80 min obtained from and a urine sample (B) and hypoxanthine reference 
standard (C). Mass accuracy< 3ppm. 
 
A ROC curve for hypoxanthine, salbutamol and creatinine from the fingerprinting data 
was performed. The curve is created by plotting the true positive rate (TPR, also 
known as sensitivity) against the false positive rate (FPR, also known as specificity) at 
various threshold settings, and it is able to test predictive properties of selected 
candidate. Salbutamol was chosen as positive reference and creatinine is a waste 
product of muscle-building processes and reflects muscle turn-over, the latter was used 
as a reference to compare the specificity of hypoxanthine and salbutamol. Salbutamol, 
hypoxanthine and creatinine gave the area under the curve of 0.983 (p <0.001), 0.790 





and specificity of each compound are shown in Table 6-1. Samples in SPI contain 
salbutamol but are negative for surrogate markers, thus these independent samples 
were combined with the NON-DET group in ROC test for hypoxanthine and creatinine 
(n=91). Only DET and NON-DET groups were used for ROC test of salbutamol 
(n=61). 
 
Figure 6-5 Receiver operating characteristic (ROC) curve of salbutamol (n=61), 







Table 6-1 Descriptive parameters for the ROC analysis 
 AUC Accuracy Sensitivity Specificity 
Salbutamola 0.983 0.984 0.967 0.967 
Hypoxanthineb 0.790 0.769 0.633 0.836 
Creatinineb 0.542 0.670 0.900 0.180 
a, Calculations were based on 61 samples.  
b, Calculations were based on 91 samples. 
 
The ROC curve of hypoxanthine suggested a predictive potential of near 80%, which 
is currently regarded as a minimum requirement for biomarkers (Report 1998, Whiley, 
Sen et al. 2014). In the meanwhile, creatinine showed a predictive potential of 54%, 
which was considered as poor predictor. This proved hypoxanthine is more 
“salbutamol-specific”. Yet our model might be over-fitted because the samples were 
not divided into training set and test set due to the limited sample size and further 
validation study is necessary to test biomarker capacity. Univariate analysis after semi-
quantitation showed a significant increase of hypoxanthine in DET (Figure 6-6). Post-
hoc analysis yielded a statistical power of 90 % for the effect size of hypoxanthine in 
this study. Spearman’s correlation showed the correlation coefficient of hypoxanthine 






Figure 6-6 The box plot for hypoxanthine in the DET and NON-DET groups 
shows the 75th and 25th percentiles and the median value. The whiskers represent 
the highest and lowest values that are not outliers. Outliers (values that are more than 
1.5 the interquartile range) are represented by circles beyond the whiskers. *** p 
<0.001, Mann–Whitney U test. 
 
The metabolite identified here as being correlated with salbutamol is an energy-
derived metabolite that indicates high (adenosine triphosphate) ATP turnover (Hellsten, 
Sjodin et al. 1998, Stathis, Zhao et al. 1999). Hypoxanthine is a purine derivative and 
it is one of the end points of purine metabolism in humans. The level of hypoxanthine 
in plasma is a marker of adenine nucleotide metabolism (Figure 6-7) and its rise in 
plasma reflects greater efflux from the muscle following exercise (Sahlin, Tonkonogi 
et al. 1999). Urinary hypoxanthine excretion indirectly represents a net loss of ATP 
from the muscle, chiefly because of the metabolic stress of intense activity (Stathis, 
Zhao et al. 1999, Gerber, Borg et al. 2014). Hence in our study, the higher 





The next step was to investigate hypoxanthine up- and down-stream metabolites. A 
strong correlation was observed with its direct downstream metabolite xanthine 
(Spearman´s correlation 0.706, p < 0.001). Similar yet weaker correlations to 
hypoxantine were observed for the purine metabolites: urate, inosine and 
methyladenosine. Interestingly, xanthine also showed significant correlation with 
salbutamol (Spearman´s correlation 0.358, p < 0.01) and had a p (corr) value in S-plots 
in OPLS-DA model just under our threshold p (corr) > 0.4. Table S6-6 in 
Supplementary Information shows these data. 
 
Figure 6-7 A general scheme with molecular structures of ATP depletion pathway 
to Hypoxanthine (Hx) and finally Xanthine and Uric acid. 
Interestingly, Zieliński et al. found that hypoxanthine was a strong indicator of 
performance in highly trained athletes and its prediction ability was quite good 
regardless of sport disciplines (Zielinski, Krasinska et al. 2013). As stated above, 
salbutamol is a drug that can improve respiratory adaptation (Goubault, Perault et al. 





the athletes were well mixed in each group in this study to exclude the effect the 
endurance sports may cause, our finding provides a possible link between endogenous 
compounds and salbutamol, indicating the combined detection of salbutamol and some 
endogenous molecules. The follow up to this pilot study is to understand hypoxanthine 
increase in relation to the administration of salbutamol. To this end experiments using 
controlled athletes will be performed to study if salbutamol administration has a 
measurable effect on hypoxanthine in urine. Indeed, though the samples in the DET 
group contained salbutamol below the WADA threshold, we cannot exclude the 
scenario where these athletes had been taken larger doses of salbutamol for a long 
period and reduced or stopped the dose before being tested. 
6.4 Conclusions 
A small molecule phenotyping approach for discovering a surrogate marker of 
salbutamol administration was developed. A total of 91 sport urine samples were 
analysed by UHPLC-Q Exactive MS. Three groups (DET, NON-DET and SPI) were 
created and two models were built. Hypoxanthine was identified as a potential 
surrogate marker of salbutamol, with the ROC curve returning a positive actual state 
prediction of 79 %, and showed a significantly increased trend in the salbutamol-
containing group, but not in the negative and spiked groups.  
This metabolomics approach to screen biomarkers of drug misuse should be applied to 
a larger cohort of doping substances in controlled longitudinal experiments. 





urine samples that tested negative using conventional screening methods. This strategy 
could be used as an intelligence-based complementary approach for targeting of 
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6.6 Supplementary Information 




Figure S6-8 Models in negative ionization mode. A, OPLS-DA model. Blue, DET; 
Yellow, NON-DET. B, S-Plot from A. C, S-Plot of an OPLS-DA model from SPI vs. 
NON-DET. Feature of interest was marked in red, and it was not appeared in C. The 
feature m/z 336.1134  in negative ionization mode was most correlated to DET group 








Table S6-2 Correlation coefficients for purine metabolites with salbutamol (SB) 
and hypoxanthine (Hx) 
 
p(corr) in S-
plot of M1a 
p(corr) in S-







Salbutamol 0.588 0.806 NA NA 
Hypoxanthine 0.629 0.511 0.415*** NA 
Xanthine 0.382 0.253 0.358** 0.706*** 
Uric acid -0.220 NA 0.303* 0.300** 
Inosine -0.002 NA -0.062 0.252* 
N1-Methyladenosine 0.112 NA -0.113 0.282** 
 
a, M1, the initial OPLS-DA model  
b, M2, the OPLS-DA model built on selected features with p(corr) > 0.25 or < -0.45 in 
M1 
c, Calculations were based on 61 samples.  
d, Calculations were based on 91 samples. 






Chapter 7  Final conclusions and future directions 





7.1 Final conclusions 
Traditional anti-doping analytical methods in sport are mainly tailored to the targeting 
of known drugs and endogenous molecules, which cause difficulties in rapidly reacting 
to emerging threats, such as designer drugs, biological therapeutic agents and new 
technologies. These threats require radically different approaches, among which the 
use of metabolomics to find biomarkers is considered a promising strategy.  
To this end a number of studies were designed and undertaken, and the results were 
presented and discussed in the previous chapters of this thesis. 
In chapter 2, the study aimed at improving the amount of information obtained by 
using untargeted analysis in dried spots, which at the same time show advantages in 
sample collection, transport and storage. In-vial extraction (IVE), in-vial dual 
extraction (IVDE) and UHPLC-MS analysis were employed for metabolic 
fingerprinting. Firstly, an analytical method for dried biofluid spot metabolomics was 
designed and tested using samples from rat serum and RPMI cell nutrient medium. 
Univariate analysis of selected metabolites and multivariate analysis of the whole 
dataset showed acceptable reproducibility for the method. Secondly, the application of 
the IVDE method to different dried biofluid spots from rats and mice resulted in 
reproducible metabolic fingerprints, with sufficient feature coverage for high-
throughput metabolomics experiments. The small sample sizes (10-15 µL) required for 
the spots, and the low transfer losses associated with the IVDE method, suggested that 





studies. However the possibility of loss of sensitivity due to the spotting and extraction 
procedure might be a risk that should be tested versus liquid samples. 
In Chapter 3, a protocol for the UHPLC-Q-ExactiveTM Orbitrap-MS was designed in 
order to obtain high mass accuracy in non-targeted metabolomics. One of the 
bottlenecks of metabolomics is identification of metabolites and high mass resolution 
can greatly improve it. The study was based on finding the best instrument resolution 
and producing a data mining workflow. By using conventional liquid samples, the 
results showed that fingerprinting using this protocol measured more than 3K features 
in urine at the resolution of 70,000 FWHM, giving more features compared to the 
resolutions of 140,000 and 17,500 FWHM. Multivariate analysis also revealed that the 
largest number of discriminant features (96) was obtained at the resolution of 70,000. 
Therefore it was initially chosen as the MS resolution in our protocol and PCA plot 
showed a clear separation in a pilot study using 91 real urine samples and 10 QCs. 
Multivariate PCA analysis showed overall analytical stability of the protocol across the 
101 samples. Hence the protocol was deemed of good quality and ready for practical 
applications with further analysis of data interpretation. 
Chapter 4 brought the work performed in chapters 2 and 3 together, by evaluating IVE 
of dried urine spot metabolomics and comparing it with conventional urine liquid 
sampling. Additionally spots were assessed for one-week freeze-thaw stability in terms 
of a data quality test, feature numbers and multivariate analysis. The protocol 
developed in chapter 2 was applied and results showed IVE paper-spot sampling can 





conventional sampling when used for urine metabolomics. Paper spots also showed 
good reproducibility after a one-week freeze-thaw circle. All of these suggested paper 
spots could be a good alternative when sample volumes are limited, such as in studies 
when many “omic” analyses are required from one sample.   
In chapter 5, the metabolomics strategy was applied to the samples remaining from a 
clinical trial, hence applying the metabolomics approach for discovering surrogate 
markers of the administration of an endogenous compound, GHB. The focus was to 
find metabolites that were related to GHB and had a longer detection time than GHB. 
A total of 168 urine samples were analysed by UPLC®-QTOF-MS. A battery of 
multivariate statistical tools was chosen to mine the data and understand the effects of 
GHB with time in the urine fingerprints. The results suggested that the feature at m/z 
192.1612 alone or together with other significant features found in stepwise analysis 
such as riboflavin and biotin sulfone, might be potential surrogate markers of GHB. 
These preliminary results provide a general strategy for longitudinal metabolomics 
despite several shortcomings in the study design. Findings were limited by the lack of 
a placebo and diet control. In the future the statistical workflow could be applied to a 
study which is food-intake controlled and cross-over designed, in this way maximizing 
the chance of discovering biomarkers. 
In chapter 6, a metabolomics approach for discovering a surrogate marker of 
salbutamol, an exogenous doping substance, was attempted. A total of 91 sport urine 
samples were analysed by UHPLC-Q Exactive MS. Three groups (positive, negative 





potential surrogate marker of salbutamol use, with the ROC curve returning a positive 
“doping” prediction of 79 %, and showed a significantly increased trend in the 
salbutamol-containing group, but not in the negative and spiked groups. These findings 
need further validation but meanwhile the strategy could be used as an intelligence-
based complementary approach for targeting of athletes for further testing. 
In summary, Chapter 2, 3 and 4 supported the general hypothesis in methodological 
aspect, addressing the practical possibilities of HRMS for small sample volume 
fingerprinting. In chapter 5 and 6, the metabolomics strategy was applied to actual 
doping samples to validate the hypothesis.  This thesis has shown that, following the 
protocols and strategies developed herein, LC-MS based metabolomics can provide 
novel information in the doping field and that metabolomics, as an untargeted 
discovery tool, can contribute in addressing emerging threats in sports. Endogenous 
metabolite alterations such as hypoxanthine could aid the preliminary screening of 
urine samples that tested negative using conventional screening methods.  
7.2 Future directions 
Further validation of hypoxanthine as a marker and biological interpretation 
Hypoxanthine was found as a novel potential biomarker of salbutamol in the last 
chapter using samples from anti-doping tests. To be accepted and utilized in anti-
doping tests, the markers should be further validated and it would ideally be specific to 
salbutamol or the same category of β2-agonist. Therefore the primary interest for the 





salbutamol administrated in different doses. By comparing the urine and plasma 
concentrations of hypoxanthine with different single dosing and multiple dosing of 
salbutamol administration, it is hoped that a direct or clearer relationship could be 
established between the two compounds. 
As an example, alternative future work direction would be to investigate the actual 
biochemical pathways and imbalances behind the concentration variations of 
hypoxanthine and other purine metabolites. For this, other different analytical 
techniques can be introduced to better detect the up- and down- stream metabolites of 
hypoxanthine such as using HILIC and measuring AMP and ATP.  An approach such 
as this could identify novel pathway targets of salbutamol or β2-agonist and help 
improve the understanding of the mechanism of β2-agonist, leading to novel detection 
targets. 
Applications in other doping compounds or technologies 
Another inspiring further work pathway would be to apply the protocol established in 
this thesis to investigate some untraceable doping compounds or technologies such as 
hGH, EPO and autologous blood doping. Although there have already been some 
preliminary findings on the biomarker of these doping substances and technologies, 
metabolomics can still provide complementary paths and possibly more biomarkers to 
be added in the Athlete Biological Passport (ABP) to enhance the specificity.  
Moreover, in the future, substances that are pathway related could be grouped and the 





of great value to help screen for the so-called “designer drugs”. By monitoring the 
biomarker as a function enhancer group, the use of a designer drug with minor 
structure modifications could be possibly pinpointed assuming similar biological 
activities achieved with known substances. 
Sample sharing system across anti-doping laboratories using paper spots 
Although a paper-spot metabolomic method was developed and validated in this 
thesis, it has not been applied in anti-doping practice yet. For the last two chapters of 
anti-doping applications, paper-spot method was not used because we had access to the 
neat urine samples in the same building, and we wanted to acquire as much 
information as possible. However, it is indeed difficult to find a large number of urine 
samples positive to one drug to carry out a metabolomic study in one WADA 
accredited laboratory. Since positive urine samples will be stored for a long period, it 
would be of significant value to make use of these samples first instead of expensive 
clinical trials and complicated approval procedures. Herein it is proposed to establish a 
sample sharing system across different anti-doping labs in the world using dried urine 
spots, which would be more cost-effective and efficient than urine liquid samples for 
discovery of emerging threats. 
Future outlook for biomarkers in anti-doping control 
Biomarker approaches have the potential to largely simplify the screening method, and 
continued innovation in this field is making it more difficult for people to cheat. We 





and the practice of ABP. There is little doubt that the use of biomarkers will play a 
pivotal and even irreplaceable role in anti-doping test in the future. Research into the 
use of metabolomics is still in its infancy but has great potential to significantly 
expand, and more and more studies are using metabolomics as a tool to identify new 
biomarkers for doping.   
 
